var title_f6_42_6816="Onchocerca volvulus microfilariae";
var content_f6_42_6816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Onchocerca volvulus microfilariae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microfilariae of O. volvulus from a skin nodule of a patient from Zambia, stained with H&amp;E. Image taken at 1000x oil magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention, Diagnostic Findings. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/frames/a-f/filariasis/body_Filariasis_mic1.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/frames/a-f/filariasis/body_Filariasis_mic1.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6816=[""].join("\n");
var outline_f6_42_6816=null;
var title_f6_42_6817="Melitracen: International drug information";
var content_f6_42_6817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Melitracen: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dixeran (AT, BE, CH);",
"     </li>",
"     <li>",
"      Thymeol (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Melitracen Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 25 mg 2-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as hydrochloride: 25 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10414 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.80.101-607E99995B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6817=[""].join("\n");
var outline_f6_42_6817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304026\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979500\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979502\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979505\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979501\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821123\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979504\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_42_6818="Patient information: Anesthesia (The Basics)";
var content_f6_42_6818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33873\">",
"         Patient information: Managing pain during labor and delivery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/52/30530\">",
"         Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anesthesia (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H85389675\">",
"      <span class=\"h1\">",
"       What is anesthesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anesthesia is a term that doctors use for different types of medicine they give people before surgery or another procedure. These medicines work by making sure that you do not:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel pain",
"       </li>",
"       <li>",
"        Move during the surgery or procedure",
"       </li>",
"       <li>",
"        Remember the surgery or procedure",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85389690\">",
"      <span class=\"h1\">",
"       What are the different types of anesthesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 3 main types of anesthesia:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Local &ndash; This type of anesthesia uses medicine to numb a small part of your body so you don&rsquo;t feel pain. It can be given as a cream, gel, or spray on the skin. It can also be given by an injection (shot) into the skin. You might be awake when you get local anesthesia.",
"        <br/>",
"        <br/>",
"        Doctors give local anesthesia before minor surgery, such as a skin or breast biopsy. A biopsy is when a doctor takes a tiny sample of tissue using a needle. You might also have local anesthesia sprayed into your mouth before a doctor or nurse puts a tube down your throat.",
"       </li>",
"       <li>",
"        Regional &ndash; This type of anesthesia blocks pain in a large area of your body, such as an arm, leg, or the lower half of your body. One type is called a &ldquo;spinal block.&rdquo; The doctor puts a small needle in your lower back. The needle goes into the fluid around your spinal cord, which is the bundle of nerves that runs down your back. He or she then injects medicines that block pain and relax your muscles so you do not move. It can be used for surgery done on your legs or inside your belly.",
"        <br/>",
"        <br/>",
"        Another type is an &ldquo;epidural.&rdquo; The doctor uses a needle to put a small tube (called a &ldquo;catheter&rdquo;) into your lower back, near the nerves around the spinal cord. Some women get epidurals during childbirth. Other people get them to control pain after surgery.",
"        <br/>",
"        <br/>",
"        If you get regional anesthesia, you might be awake. Or you might get a medicine to make you relax and feel sleepy, called a &ldquo;sedative.&rdquo; Sedatives can be taken as pills or through a small tube put into a vein, called an &ldquo;IV.&rdquo;",
"       </li>",
"       <li>",
"        General &ndash; This type of anesthesia makes you unconscious so you can&rsquo;t feel, see, or hear anything during surgery. Some of the medicines are given through an IV. Others are gases that you breathe through a mask that is placed over your mouth and nose. You might also get a breathing tube, which is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing. A special doctor called an &ldquo;anesthesiologist&rdquo; gives general anesthesia.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85389707\">",
"      <span class=\"h1\">",
"       What does an anesthesiologist do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An anesthesiologist will meet with you before your surgery and ask you many questions, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do you have any health problems?",
"       </li>",
"       <li>",
"        Do you have any dental problems, such as loose teeth or false teeth?",
"       </li>",
"       <li>",
"        What medicines do you take, including over-the-counter medicines and supplements?",
"       </li>",
"       <li>",
"        Do you smoke, drink alcohol, or use any illegal drugs?",
"       </li>",
"       <li>",
"        Do you have any allergies to foods or medicines?",
"       </li>",
"       <li>",
"        Have you or any of your relatives ever had a reaction to anesthesia medicines?",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The type of anesthesia you get depends on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your answers to the questions above",
"       </li>",
"       <li>",
"        The type of surgery or procedure you are having",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, your surgeon might want to use a certain type of anesthesia. And in some cases, you might have a choice between different types of anesthesia.",
"     </p>",
"     <p>",
"      Your anesthesiologist will also tell you how your anesthesia will be given and answer any questions you have. He or she will carefully check your breathing, blood pressure, and heart rate during the procedure to make sure you stay pain free. If you have general anesthesia, your anesthesiologist also makes sure you stay unconscious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85389724\">",
"      <span class=\"h1\">",
"       Can I wake up during general anesthesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is rare to wake up during general anesthesia. Your anesthesiologist checks on your reactions during the surgery and adjusts the medicines to keep you from waking up.",
"     </p>",
"     <p>",
"      But it is impossible to guess exactly how every different person will react to anesthesia medicines. Some people are more likely to wake up during general anesthesia. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Children",
"       </li>",
"       <li>",
"        People who drink large amounts of alcohol",
"       </li>",
"       <li>",
"        People who take medicines to treat anxiety, called &ldquo;benzodiazepines&rdquo; or certain medicines to treat pain, called &ldquo;opioids&rdquo;",
"       </li>",
"       <li>",
"        People who get certain types of surgeries",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85389741\">",
"      <span class=\"h1\">",
"       Are there any side effects from anesthesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each type of anesthesia has side effects. If you have a spinal block or epidural, you might feel numb for a short time after the surgery or procedure. You also might have trouble urinating. In rare cases, people bleed or get an infection where the needle went into their body. These problems usually go away within a few days.",
"     </p>",
"     <p>",
"      When you wake up from general anesthesia, you will likely feel a little groggy or confused. Other side effects can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling sick to your stomach (nausea) and throwing up (vomiting) &ndash; Your doctor can give you medicines for this problem.",
"       </li>",
"       <li>",
"        A sore throat &ndash; This can happen if you had a breathing tube. It usually gets better soon.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, people have trouble breathing during surgery and general anesthesia. If this happens, you might need a procedure called a &ldquo;tracheostomy.&rdquo; For this procedure, the surgeon cuts a hole in your neck and inserts a tube into your throat to help you breathe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85389758\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33873?source=see_link\">",
"       Patient information: Managing pain during labor and delivery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/52/30530?source=see_link\">",
"       Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/42/6818?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16246 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6818=[""].join("\n");
var outline_f6_42_6818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85389675\">",
"      What is anesthesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85389690\">",
"      What are the different types of anesthesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85389707\">",
"      What does an anesthesiologist do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85389724\">",
"      Can I wake up during general anesthesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85389741\">",
"      Are there any side effects from anesthesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85389758\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33873?source=related_link\">",
"      Patient information: Managing pain during labor and delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/52/30530?source=related_link\">",
"      Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_42_6819="GB cholesterolosis US";
var content_f6_42_6819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholesterolosis and multiple cholesterol gallbladder polyps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACilAycDrWslnDHbI00bEldzc5/LH9aAMiitKXTlYj7NLkkfdfr+dUZoZIW2yoVPvQBHRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUoBY4AJPoKAEoq/Bpksi7pSIk9W6/lVxrSyihAAMsnGSW6/lQBiUVbumtwSscDIw7l81UoAKKKKACiiigAooooAKKKKACiiigDqfhzOw8QSWMUavLqlpNpqM7bRG0yFA5wDwM9KKp+Br2DTvGGj3l2xSCG5R3YAnAB9BRQBhUUUUAFFFFABRRRQAUUUUAFFFFABV0anc/ZxDvGB0bHzAemahjWLywzk5Jx9KW4WLIMO4Z6KeaAJLe7COGkTJwfmXhjWnDewoVKzBosEFXj6f41iRMFbDKpU9SR0qUMHYJCu0A++CPegDaNjZXC5CFAy8PGcjcP0/wD11C/h6V+bSQOD0DDB/SqsmmT4WS2Ush4BQ5x6+4qSNdSt4WJaWNAQMMp5/HtQBBNo97EzgxbtmM7WB6+3WqUkbxsVkVkYdmGDWuus3du7JNGhUtyMdfXrVttdWSdi+Y0IxtdAVI6EYH+eKAOaorodumSjcyW6gZBG8o2fpSLYWE28pjHRRHLn8TQBz9Fb7aLDn5HlYAnPK9MVH/ZdqU+WRy23J+cAfyoAxKK3BpMBXIeQ8Z+8Of0qSHSrRZSJC77chl3jNAHP0oBPTmuiNppsG0SbPMIIw8nQ88+nalW6srVcQbQ3cw9T6c/WgDHt9NvLj/VW74xnLfKD+Jq2mh3G5BPJFEGGSM5I/p+tacuqb2aO2WaaQY+78oz/ADqktzeuzbrUsOi8ZK9wKAJBo9rCDvmaZwOgGAc/T/GnFobWJ1Ef2fPyjeQCSO/c02Gyv5pCk8hjQ8kdP169e1WLfQLYzILieWWVj/qkXJ/OgDNfUQj/ALomZtwPIwDx6flU1vpd9ep50qmO3Odz/dwffNdZa+GUitXeWGC2hDAHLb5SO3y/Wl1YWdvDJDby3Mk6OAd5wq47gd80AczDpUcSFyd0f/PXB+U46Vjalai1nCoysjDKkHPFej6V4V1zxKp+wQeZEnAAGFcjqBnqQOaqeMfB5tLG4capY3E9p8zwxKd47FcY696APOKKKKACiiigAooooAKKKKACiiigCeyYJeW7EgBZFOT0HNFQUUAFFFFABRRRQAUUUUAFFFFABRRRQAVPblSygkqefm9Bj9O9QUUAasNjG0XnQsHQ5GZOAD71o21r5NwkXnLHOV/eGQcHtwR26Vh2dz9n7uOc/Kev4Guo8K6jpMNzI2q2739u4wYXbbx6ZoArXOm3VncbFnVMcSbeRg+4qXN9C3nSyMURgp3LkY9eP88V1ulWXh65vWlt5ZZdOYbmi34kiH930b6in21ppt9qb29msbW/m7IprhyrAHs3Hbnk9aAOMTURK8izxxPCp4k2ct9eKfNBp180ZaMxgjYrA+g/TvXr3/Ct9GvzeQ6JrlrJc2du00puEZE3Ancq4HzGsR/hFf3N9HHbGN7eSMOsquFLgjIIAyAO3NAHAW/haznEUralFDHKpIXYWxjpkioZ9EtoplYyhgvDKI8AgcZFd3d/BvxJpt6kN2iW/wBpG6NvPVgFx/Oq+p/DXxFYi2tEsJp5Jssvlrv3LnHGKAONGiWt1KYxNCkhUMGdm4X1OPaoYPD0U7bYbm23DIO58cj612P/AAgOus0lobKRJFGWzHjaMcnOOB61Db+CNburnyY9PluNybl8tNwIwcMvqDQByf8Awj8Yck3EMgJ6ISMUP4bCMcX9shAyVbJ49uPavSdO+E3iG+tBdw28Xlo/ksC3lsrcfKQR61YvPgd4rs2V7jTXmiKHdJFIJdh9GxyCKAPLYNEsoFVr29jcSA7DHyAfwNWrqz0iFE+zXMk0eRuUIEOfrmvQvDXwrudS1w2l/mCMp5iy7tgx3HI547Cux0/4I6FLFdT3WsTAQh90aW5y4HO5fTjFAHgiwh5HjitGDA8MXII96vWsF5cIIgsUUTj5WkblQOcmvb4fh9pomeHToIbyeELiG5keNypIwwOMdPWvSIPCXgyO1v5NOvbS1ubRhOLiRlc27KPnQr/Fjk9O4oA+WINLuZ4PMtIGurbzNjzAfKH/ALpP61vv4b1e2tUuzYvEihdky4A98kHtmvZ1+KPhHRbq50qeVdRsJlLSS2OmJEbhyOrdMfXFYOqfFPwxb6RPp3hnwzGkRwEa5n/j+h6fh1oAzfD/AMJvEmvNazeJzFplrIyhLlvvSAgY4XufU4rt4fhT4X8F6ml/4pnhvLJATHGyklsAnnnsea8R8TfFDxbqU5WfVbu3hKBRaQtiIAdANvHaucvdR1HU7lNQv7+cs64O6RmJI7c8DpQB7R8RfizoqRfZPDYWKGOTDQQ2wCMnruJ69AQK8a1PxTqUnmRW0MFtDNuzGFBL5HXcRn9azprZ3KyLKPs/qB84Pcn1FVbp33q8bMyRqQJHXbuHtQBzMsbRSMjjDDqM5plTXMbK7MR8pPBqGgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqa1aJJczruQjBFaKxW88B27So43fxKP84oAyKKsTW5U5RHCk/LuFRGN842k9+OaAFjUMD8yqwOfmPBFaTWdq0Ecgl8rPDrnI+tVBYyuiGLDsw5UcEe2D1pIpJYWOVVSFIw6/pQBYWdkhAiy7Hj5MjC9e3TtU1vdzQlQkswUfMAB39DjpUcN1Z+Vma1YSn5TIjYx7gVJZmCJCjyq5JLZC5P6dO1AHZeH9f8T6PYyz2txJZrc8EhQzSfiecU//AISzWxZp5U8tu0Xy+Zbs6NJ3JGD9c1zto75EI815AMp5hxsGe34VcghN3BMy74iv3dwzgD09RQB3ug/F3xdp9isTtb3MccaxQvdxrIYVH8S7uST71Na/G3xTaNG4kXMUxJmMK8j+JcAADt0x0615jtncgwwssYkCmRjg5+lWoZJI5rn7aF5GGQpuUdhyKAO81n4veL9XjjN5NCgWZpI5fLCBlPRTjgj271Z0r4z+LLLw9LaxW8EpeVSJpIfmUDgqpBGBx+H4153KyBYlM2VjUlY2QnAOfuiqbW062an98gLEkkE8dvx4oA9X0745+J4Z2iuJVS2l/dm2jQZUY6gkE55POe1U2+KerSiaKe5kJaVDujbYygHnJxwT615w8n2WUSM6MwwqmMAfqaR7jz5nOxim35psjg0Aez678b7nUwq6dY2i6gqqr3N2wkDKB/COAD6+tcf4g+KHiW7EFrcXUKWu0RCOCEKFz1wy8/nXBrHtTy5Y1YckEcEelWIQYyqSRKisfmdz+gJ70AbF94q1eYCIa1fm2UgPbiZ3UEdO/QUy51KXV1WS5e73HKgFsM7ev86zfs7h1ltDszgbDwMd/wD9dTRwtcosMbM4JB3yDGSOoB4xQBMbRmtvMvLmKKNcIzE/OcdM45pXFvJcNFOiqqpiKRuhOe/pRKEsrl5IpVZzgKWTcVHqauf2Xd3UAia2xnB3BuSe2PrQBRt4khnk82JJ5WGS7LhDjoOO9bV/Fc3dnAJLWK1jCbt4HDH3B/nWppVvd2BS3m0ZJHLczToVZeeg7H8as6va3Npqyy6rd/adPkwESJ1Zk9VZV7fSgDi4HiuWEdorXExOWyPlTHcGrr+D9SULquoxmHT5DkTEZCcZGRnAyOfetSfW9HDSx2FlDZzYYCaMkHPqAeoz2Nc5q3izVpLM2EkkiQB95RgAGbGM/l27UAUtbTTEURTbGcZAmQ8N/hXGnGTg5HrW0sTTXUyzxNIrN/CpOOO1Z11brCMo7Mc8goRj8aAKtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVa0yOOW9jWc/u88+9AFWpIlDnAba+ePSug1rRYIojNasQP4Rxgj/IrnSpDbepzjjmgC1AklwHVpAAOSp61fi0+aMKdyxDna7twOnaqNulzasJUTK/zrq/DniVbWeNza28kbZWaKYAqy9xj+ooAzVffBKXgVph0kQ5I9DiqU5aeBnmZpFU4w2Sc+1e/eGfGvw1vbS1ttf8H6ZAYDlGs5HDFSOT6ufYnitLX9I+Guqx2jeFb5bRmlH2gX8bxxxJ6B2Xhgcf3sj6UAfNC6ezFmiXcmcbXG0ip7e1uYo8RW7mQdWU4B9s19TX3wI0DU76wfwhqjyWNzkz3cjrcoCOqqy45x2NefeLPhHrmhtdqtop8m4KRPHKp8yL+GTbnPPp270AeQwGezdTPCI5kHysxLEf7ODxWnpGofaFYhTFODn5jhfw/Wu01b4TeOLCwiu73w1d3CPyEiYSsg9XVCSB9a5S88OavoFxbHWtMnsnuVMkJljKZXpuAPbmgCS01mJ7hjOqu8ZKySZwFB74pYrm1vPOV0Vgj/ACFPk3+ufwrPFhc3smTazuMnLInQetQrDPG2+JWaMMcs2QQf6daANe7ntC3kWqsXiHMjkFR/u+1QyahElpGJXMjHKlIxtD8dayYFldBCQ0ly+WWIpnjPtWtLYzWdr5N1bzJIgWQhgVIHuCM4IoAnij0iewJlfyLgHgkZTj1qTTbXTnmiXz2ADD5GjyH5q3Y+JNKtDHH/AMIdaSuRuEzzuzFwO4zjHes+81261O4N79igtURtzLDFtBI9+1AF66tbNNVnZbaRFL/JEMlj79KzntrmUyKsTg8MN/Gzng8/54p83ijVXkG6edQ5yEdeD6ncajnvJboKZmlltBk+YThQeuAf8aAOpg8FytpUGp3eo2cau4XMk2WXP8RQdqzoE0WxW4QX019MH2lIiRHNg+p5H1rJgsNV1OOcaPp95cwgfvDEjMIwPUjgfjV7T/CfiPWLWcadpyulu3ly7mCsCeckdfxoAnm1SzRQ9paIoclWZ5C4X2B6D6VDb+JdYsTI9o0GHGw7gCUx2BPArStvh9qk9rDbm8sIJ0zi2lnUGRsdh7HPXFd/4e+E3hWO0sF8XeLoY5bgkSWtuwVoWxnazHOB2yQBzx60AeYxxX2o6dLeO+ozxjLspO5UPUnP9KxUudlxEWdSxJConynB78d/rX2F4U+C/g7S5jdw3F/qFtNHkpJcg2zj1woGfzxW4Pht4VunMV34T02G3T51eJvv/XGCPX+tAHxnpei69q0yxaZatc3MjFFQICxP0616J8PP2fvEGuzSz+JA2jxKSA80e+VmH91M9Mjqce2a+lL/AMWeFvDNx/ZaSxQXMcQHl28YOxQOAT0/AmuC8UfGPR7S8hhvkvjaRqC2NitIcfeODgD2oAs6F8IbHQdL1C3m0xNYklRV2qRD5jDkPvLZB7EDisb4qxeFbrwRqfh/X7DRtM8QG3M1mtovCuoygMgA5OMEHjHrXn3xC+POuahD/ZuhzRWlnIvls8cWHZT2ySccemK8T1LVZ/MSOOeZ3zlg/A/PrQBzUqNHI6OMMpKn6imVPeSrPcPKoYbuTu9agoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClBwcjrSUUAWob6eJSu/eD2fmq7OWxu7U2nK2FIwpB9RQBoWd9+78icMynoy8n8qSBzI7x7hvGcOeePwqzoekzXkoAuFtScfNIMDr1roZPBmoW6SSXKukS4AulKmNsnj6UAYcUI3CRZITcj5hhcA/iOlaT6teyQxwpK8agDGwbtxHYevvXR6r8OPEujWdub3TpV85PNidFDqy9mJXOKqjwjqcU9qNa028tFlBYSEfwj+MKOccjnFAFLTvE+sWtqIYLyWONJC+QxXBxyTz1rqdL+KnisSof7auXMB+UzsJVPGCMNkf5zUUvwr8RXVvFdWmmXeoWhIC+Qu50Bzh9pGccGubvfDkr3TacbO8+3wOFcOmzafpxQB6B4a+NniHw/Lf/6Xby3d4/nP9stycnnoQRj6dK6rwf8AGzVLuO7u9dm0W/uYo2NubqHy2iPXACrk+nb614sui6gWKy2V1JcWh+eL7O5JUdyccf8A1qL9bQTCYWrQSkY2nOCenT68UAe92f7RGqR+V9r8PadcWSjbILZnQspxnaDkAY7HNR6p8b9AmsDHp3g+xtZWuUkV5UjdcA5LFQowxAx+PWvAVi2qHBlkmVMlUB2ow6EsOlLbO9yyxBPIiOd7kHLnPP0oA+hdQ+NXh3ULO4k1HwvDbX6KWt7qMLIwwMbvugj0xnoawdd+Oja/pFm134f0U6pC4IuJV85cc5CqRlc/7xFeQXwtVkSZpJjHENrFo859vpVAywJC8sL7QcYTZjgn0oA9it/jH5VvHG3hzwu97C3yO9sFLD/aHr75FJJ8c9eSYGDRfDSwgqyw/ZCIwcdT82SQOnIryOw0oyb5RbvMS4XzAh3DPTjFdEvgrUJLYSWFrPcw+Xnds3DI6g46cUAdz4k+Mur6tYGGfSvDF5D0VJrEuIzjkICxIPvXLzeO9SvvDSaPJaaabJDvZ0j2yBs8DGORVZPht4xvLd510uWBIoBMFKctHkAFfX6fWu48AfBi317QI9U1rXF0x3P7ndErhh68sCPoaAOYj8ea5pfhdbHTr5bS2GQ8Vt8pk3ddwx6VmQa3qflKlvdeQoQqXj+VgD6+telR/DHwZoOr3kfjHxtDcwxwhkjtzsl3k8HA3Zx7c+vFW9T+JHw78J2sEen6TP4mljRFDXSRpEijjIO0/N+H9aAOE8KeEZ9YUxRwXd+0rsjywRt8pAyMY6+pr0Sz+F3hLS4V1rxV4rh+wRJslgjb95v/ALrHJbIzgrtzXnvi/wCOOpXkjHwxGdFtc79tqdhAx0yAK80l1S51G5lnvZjLJKxfeX5dj1J9c+tAH0/4h+L3hPS/CmnWHhWya/EWF8ifzIoQuOd2PvknHHP9K8i8Z/F7WNfhube7nK27EFbS2k2RIBwFA6/ma87AZY4njmMxBwcHGz8KQqkBdiqFmB+U87/pQBuX2vnULLy7cyqiKAVkOAGI7YrBlfy42mk2zbwPkLZwfT61VdU+0wtMCiFshYgSR/h/9arBtwpGFJc/OoLZOaAIp1mngR2CQ2/8K+/rmoPs6srG6ifYcbXJxg+1ahnSSVRdvBDhSBEee1Y91fTKxj8xUA4HGRj1FAFW/wBhyEmVgmMKEAx+PeqNPkxuJDbs8k0ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACnIVDZZdw9M4ptFAGlFqEgdApwmQGLcgVo2usajZpItrMxhflcNlc/j3rn4i4cGP730q7asElUyAhh/ARhW7UAdtZ/FbxdbeHxoraxdyWPK+TvDED03fe2+2cCneHfip4p0FUt7K5jW1jOcvbJIy55PzEZ/DNc48FjKhkLhZcAgBQMH+tSWOjTPCJ4pGKNknB2k/h0oA9Msfj14xtrq7ure6inlm2lzMqkDbx90DA/Cumi/aZ1ybSZEm0vTp52+Xe0bBR0wcZwa+fm054rouAxiBwSOT+NTiNUhGELQscbVGF9/egD6Ftv2k9VbSpC2lad/aPlhWuk3LkjvsOc/n69KpeG/jXpVvfTXmr+FNKvr643PPcphZJGxxgMpA7cCvCYnigZTNC5I+6c449/zpZBBKsLuhSFs7SBkD3oA+nbP43eCdZ0O+0vWfDNvYaZdoY5Yo5BtkPUA7UUjnuOR1Fchf+O/A5LSWfhDSra4tiVit1h3xXK55Lvwcjtxnnr0rxGWQPC8KqAoOQ6AHipIb+JImDL8ygANjJPrkUAevf8LO8NW8tnd6X4E0q0uLdCs6sokilUrjlCM8Hv1rD174mabqN9bXNr4Z0Kx2k7/s1qBvBHQ5z+QrzGQI9w04nXZt24HBOe1KITJEoRGGWzuJoA9AuPGyreT3ln5Ns0hyI4I0XZ+nPSrVv8bvF8Fk1pBru20kJBVbWFGyf9pVz+XNeU3CRnzFkeTcp7DKilj/ANGk3xrkf3TkgH+dAHotp4+8S20O608QaiioMJCJjhV56KeK5+41V5pRPql690C27KA7g/qKwUikmk80S5Crk8DaT6CpXRkI3wqflwCpPX3oAXU7p1V8HaSwHzMTkVVxu2sy7MjBXzeT9BT0tQsxiZM5YFgafeyRAMJoY2IbC4OOP8aAIBLK1ssKIWwxHzjqM/n3qwgeTZGkohI+UqOx9M9u1UxdybowpjQRrxzkkemak86WaFQkioCSSOCf89KAJLaVopWjmJSQfdOOG+tXm1CVYkfYiqPlyBz/AIg1jxRxyDiQlyCOWxmphMLImBokLg8jG49PXvQBY1DUpJ8eYu1F6he//wBasyKVncpljuPXOCKlI33Jx8jYyRwR9KQxQysArFXJxzk9+poAPKRYWLODKOep496rwxGeTAYA9Tmtt9KkhjBSRXAwC68lR6e9XLOKyhEgvLYzSLykjNhR6cflQBzsdjcSI7RxlgpwahkRFHyuSe4K4xWzqkkKRM8U+ZpP4V+6MVjvIzou8ZxkZPegCKiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKUYzyCR7UATrJHgKYmEgGAVbBz9MUs11JIoVwuV46dvpV22BntmV5ImwB0XJx796me1kURRIqgEZQoQd1AFSKUW5K3asRj5SgFWo5JTb+XbzMSXwwPBx1pP7Ou7hInMu5WPysRwCO1SpFJHJ5c0J2nk5U/oaALIv5I0BfcXBILdc47Y/OpVu0QCQ7SQvAIwc+uKq22kzXpMiRu20D5VPP6dKhaxmguWhvBJBtHKsOvPqaAJp9TluYgzRRoo45XBxnvVqOdCTmNVAA5zhSv496qzWEp2q+9ohg7yT/P1qtNaEsA8zyIBtVM5P4j8uaAOi0+z0m+l3OlxDFjPBzVK7TRYA8VtJKZV7kYHPGOtZ5kVYxBCJQSOcMVAx+lVJLaQ8hY3ReT8244oA2L220j7LGVgeOXGTtJ5P4/WolubJZYFDsp2/61jtBFUzJbxkNcKSZBjBPHp+H0q29tFFbRA3MMivlljkXp/nNACf2raeWYvICuf+WhX745560S3KWxjMShnAB5QHH5VnlYyzLMSyjkjIGPxpjRRiDcvzlTtAK5P+etAFlbiQo7Kyq7/eHlgD8aZZGRnYLIrJKMH5en0qKCSTeJBIioowMLgGprKaTaMH5FOeSFLUAWLsIuVt4muCFGHDYx9aimsG8oS3ckAyMKiY3H64qeF4QTJKw3kYwD7deOh/8Ar1kyN57zqmdzsMIetACzWiLyJhnHCYyfoPWoozIjBVVVJyAWGCanjRY2bzoHxjDd2z6imvG0r4QHbswgYZAH19aAH21tC23zlZRjB9zTo5Ig0h2BnZvlwwJx/kVE6FXIl+fHAUE7sfSnSIzf6uKNAeGAOQfegCe12Ro00sByx2tj+lSRJnf9lbYzNvAJPPtiqtv5vnGNioKD72Sea2tGt42ZpJiqqgyDtyW/CgCrcSOpwxw2P4G46+naqE0MjQFySccEliAR7VuThBLLKtshh6fe68+nrWdKdsbAEiNh/q2Bzj6UAZZZ4kOxE2MOo5/Wo1kDKElztHI21JBEJt+Syj+Edu9NcJtUFVV+Qec9O/FADGjcIJGHyseuepqOnO7O2XOTTaACiiigAooooAKKKKACiiigAooooAKKKKACiiigApRjI3Zx3xTo3aNw6HDDkGrDSy3snzlCVHQ8UANjkkjuCISULHoePwrStLm4xsZ1aNTkqpyR9B+f51WhsvNYv80iknGDx+dImm3Ebbi6xup6k9PxoAupcl7tpA7iPIO3ZgLWimu+TuiMccivwcqCWH9PqKyIZZYPmYguDkkN1/GmFJEZijoY3yckhiCc9KAOi03VDFeIzF7YZwpjGVPHqfWkdlvZ3l1GZlXOScluPXFY9hPHGqQtDJLKp2lckAj6VdjaWyuTKECRgcB13LnI7UAbWmWtje3ggtdTjtIR82+SNtrAdQOOvSpJ/C6nVI4zqNrPIwJDxNlV/wB49RVKPxDbSRfZbnTLdASWYxIQ3Xse3f8AOo5dUtGhK21ssW1w7MG+ZgO3IxQA46E8Jltlu1klXJzFll69j6VVsNFkmeTfcW7SkHcC2M45/wAipG1gRyBljDtnG0HAYeg4xnpSLOl7cq406WI7vm8kj6ggfhQBI/huOFFa7uVlD5EZVeh9MHvWx/wr7V5LeKS1topTKCwC3CZ2jvtJz/OsW92SzBGkvG3HIc5XYPr/AIVvLbXMcFrcaVdxXE8JCoizkyAnrx19KAM298Ga1pVusuo28EMZAJlZwVIPTgdawHjRZiEK7mYKq4Oc/wBR1rv5/GevXaGw8QwQT20Z+ZjDhoz0PI59abqz6JLHDDokKX4xuMmxhKremCenvQBzWmaJ9p1COJVMu4/c3hRk+hPFT6n4ftILiWInMsOchSJNp7jK8f8A6qfaaX9puzbGOZGbL7Qc49QDXo/gbS/D3h+yutX1i31CfULdGI0ye12xy4HBaQ8Y9vagDx6PS5PmOGZTnb0yfb61BPHaw3flsJo2GC44ypr0jxD8Q9NudOdE8HeHLTzckyhHd1Pscg15v59pcagZTaKGJ3Fd2Pl9aAG3Nwn2cRrC7g5Cu2Nw/Gqtvsnf5VKIOVONxJ71c+zpLdSglooj0Qc4981nQTQQ7VyUZW5yM9+tADZTIxIjZQq9W6cimW9uZY9oR9rdW25wavXttHtVUlklLnIKpt/DGKZZ28sm7yZWiVSM8k8dKAHWKGS9jgiiyAQDgZGPX+dd9D4MF3E/2K8hjkGCwx+YA9an+GvhG28S6tJbw/bZLiBfMY26GQn1zjtX0f4C8Baj4Tme/u49NHQxSzSM8qZHZduM47ZoA+T7vRNQhEmbSYGFiGYxtjHrWRJaPJJlZFjUfeyfmb2r6u+LvxSjsra50m0WKK/dlV7qHa7OnPylWXjP1OK+edSaGSZp5lESyZk2OnLnuQaAOKvrCaBd7OfLduE7/rWa21pHCxlEH3lVvTvzXUzWV1rFyxsI32R4JDdD7CsPUoZrXAulXkYVQOn1PrQBmybMjy92P9qmVPHbu6K4UsnfHao3ADsBkAdj1oAZRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU4NjbwDj2ptW7W0ubmFzbqHRGyRkDHHvQBZtbwBgI8wuOMqc8fy/wAiuu0XXGtYBZvb2txMz7gbhP0yDjFcNGqCTE4w2eAMc+2BWvDpd1dD7RZyRRk/LtLYJNAHcSXOmXE/2nWtPEkKoVEUH7td5PUMO3Wsu80jSJbhJtNVIbYqSRM+NjegI61U0JLyG8WPXtOvnt1ypdUIxgdcng9a7bV7PwjqWkA6XZXVtfKQpEtyDGxxywUjK/TnrxQBw9vqUtvO8FtZ2dwijbloycDpnPrRc2czwh4JF8/OfL3AgAdgD+FdDL4NurXTVvbeaIWs4+UwowwfTLD5vwpllperx2rXK2sRjyFMrxl8Y9+2B3oAwXt3li3w2szSqhDALt2n19+lZwR4pW+0275bIypIz7c9K6STT7qK6llmvD5ZI4iOce/uKqtoQe6ke3uJLi234BZG578+lAGBMsZuUVnUQrk46kVbt7CbURvEkfynACDacev1q/Z2C2s7ySIJLYjYY35BPYevWpVEcltLF5Kpc5yu1TnHHGaAMZbdVk8tBPljjeT1/HNWriKe3aOVgnmnjKyglR+FWzClyBGouIUTlwpwfyNV5pLa2nhuVkKsnyuiJlh9fWgCa1M6xSvJciaI9UYkAH19+tNtL5miItEWObPD7ev0pjy2kURmtop5C3QY+XJ6/wD6qbpYEmoLIbQ3OTk24k2kHtg0AdD4b1XV9LvhqVvdRSXEfzFvNw0Z9hwSazPFXiXUtT1R59VupZRLy4ByxH4VPaNFNqzLqunSWsQGzzISoYHHTk4zVTXDp9ncBtMlkk3AZaZwzfXA49eKAM6KCzVXnuS75OVEmMj8BVBmgmYNFsYgYYjjAz1rTa2WdVeRg25uPXJqC902Ka7McapE38QOcn8qAKlndOHeCLBjVucnJx7flSSRxRz77RRIrnG1h93pzVrT9PjjuBHOxLj5iGPX86beW+1DEgi45+STJbrQA1LS8LwiF13DILAHn/Z59qmW3aC8UXbmJN3L8nd+FWrC7ks2UKgdRxyB6c96rz6g810+5l2Ywu9en+HX9KAPpr4E2nhnT9Bn1C+8VC3uclGgjm+zFQehJ6ydOMcD09PQNSi8Ma1Zxg+LGW1Vt4F3cncWH8SGQg9Cema+I7dnF2RO8gTnYwJ2g/Sp9Tn1CKF4JZpMdUMn9054Gf50Ael/EYaFp3iS5tNAu1vrcEESSnnd/vHGea841fVJLu8ja9KvIgKqpONo6dRXOz39zhfPAYHIAbk4+tTaeizlpHVkReQ+cnv0HagDdsp7q3tZQLudYj0hQ/KT7mnano91/ZZvbqBlDLuXzMLkf1qjZXjXrsEdkjAALMQOeOfrUUtv58MjXV/cOUfHllsrigDJaGa4+bZIFPQY4qvNLuVYwpVV7H1rSuZYXI+zTPGv3WQHcSPb86zZlLONsbLk4G7vQBDRTmUqcHGe/tTaACiiigAooooAKKKKACiiigAooooAKKKKACrFsLhTutyQTxwRVendAGDDPp3FAFh/PLBpVZWdsbyuDWnpqvLbsmZRIjEhiDgjt+tRabeywuBMFLYJBl5z7c966DRta0rzJRe26SK65+UbNp96AL9v4m1ma1jsZ9cuGtoyN0O87cehB4IqE6hDiaWeBiJMqMJhV7DAqxout6emqCCTRba5ib+LPOPYnipPE81pbXQ8mBoY5V3okhzkH6UAUW12+fTVsrue5gtFYsoHO30OD/SmLLfQyfZ31G5mtJDnCs2D74zUFjCbuTZNGXIcZcHp6V2VjpryRqk2pXNmxBVENuQr+24c0AczZ2F9BdeRZzbLdgCCx7+nPavY7fS9D1rwba32m6ozf2aP9PibajKfUAYyC3GfavM9ag1S2ULczXUiKf8AVI+EC+pxn/Oa6vSteuNH8NtHZf8ACOQwXIAlmuYR9pzzwpIOfyFAGXYP4bjtJxrsOoR38jNtjif5QezEH8+K561+3Tw3a6NvdSpOUT5wo75+ma74n4f2+gxtP9u1XXpMs5kl8tIj1wCv4YrM1D4fX50aPxDpWp2kdjdqJFiWf9+vqrLjGePyoA870uOKTU1bUNWitHZgvmTg4z/tEZx9a3ZtNs2muIoJoLi8jLKstrL5kcqgHkZxx/8AXrF1nwprd3bPqBsJvsy5Bl3rtLfhWD4clurLVoWUSBeVYKcEA8GgDfeG6tYSA7OT8xgLDBH060n2p1njmsFaGf7odDnaRXWSS6fZWDpc28aS8qsqLmQZ9Sfr2qhompxabdSfbCs1sw/dokSncc98/WgDGtdPv7yaWK4smk8zDGVicj3B6VZnuLbTreOzgVJ3PBZkO9T6A46V2T+PbS5sPsotYInQEKWJXK56DHSuP1nWGutka28UR3bQ64Yj6nsKAMq5AcrLsCODgqDzyO4/WrJ055LF5lkKBeSYzu4/p+dXGS3mhWUOpkUBSCCc/wBKmsbVv7JlnZG8pSQI4+VOO5HpQBx6xSXLhWI27v3YY/N9fetSK0d0jVZYxzsTeu3n/a7itBBZ3BW3jhNvH1aSTqB7MPSpmlsra7NtaBL9AAHdVZwT6/59KAO/+EHhrwtcatPb+LNUgSWZCER2XYp9y3QVwHinTdPs9cv47I/a4LeRoxJEgwwB6j26c1JJCrhryFJZZYxhUAACj+provCumxajZXlzqOraXpCpHkJdA+Y7eiheSaAPNftL2EhlgV2VjyG6nnqO9R3csl7Iz3s7JI3QZywH+RWtqdlGs88clys7tkrKoIGPrjNZT3EdqCVgBAGDvOMjp6UAZd+VO3BbPoRxT9Km8qVtwO3HLA8L7026haWUyRDIY5wOwxVMjBwetAF+6uI1ZxC5cnvtwAe9QyXk00flE5Bx165qBXKlSMfL04qdGNxKCMrLycqvGKANbT9MeKEzNNDGwGc7gTipprS4EDP9sR0bgYUDH1rMkaRHMabVdhyHHP4elSrY32xiPnh6kvwPTgUAZc6GOVlLq5z1BzUdTTQmE4LAtyMY7VFjjPagBKKKKACiiigAooooAKKKKACiiigAopcfpUiRq6fK4D/3T3+lAEVPjdozlTg00AsQB1NTrBOh3IhyvPHNAFi2KuqtLdBRu+ZSvP51daSBF2RopO7ndwW+lVkhS/VW3kSDqAMCtGK3uXiWNbVZFQ/eALen40AQRbvtMbLcM2W+VWxlf1rdj/tLUryKElbtU4Crx1rnrq6kWdvOtuV+VwVA/KtHSFiuLqFrQShiAT32n04oA9b8M2Gi+Fb0Dxjot2ZpFV4Etb04l9mA5wenHetrXI7q8e+u7Ky1zwxphARo7uOV4sHphiuQf8a4eG9i05Cb9Z5bhOMkgiLuGHt7Vu+JvilrOrJFpUfiBJ7EJ+8a5QBpP94Dr6560AeUeKNRvbG8kt4NQE0OQQw6k+o4rIi128IVbmXzlX7ocA0zxFcNPqkwMyTIrEKyDA/CsugD0TSdVtLm6txHHAkhXBSPqxrvdA1a+0m2v4/Dum27LcxbbmW7CykAA5wG4XAPb1rwKF2jkRkbYQQQwHSvZWs9EsPDWmTDxVfXlxeqGurGK3CeQSOQST83OO1AHa6RrsN3DFP4j8NWy6WqfuodJZY1QjILsmc5PrXHQ6po9lJcvqvg7TLmO4ZjBJK80UkS5wCcHDHp/jXM3FxNZagx0O6uYmicHz94VtvtjvXtXwZuNF8XLrUXi+aW61VbfME18fN2p0O1TyxBwcc0AeV3PiGSy0qTTbO1tAj8tLNErzqD2VvQVhWtnaFszypcqx3bC5Rj9e1db4ptHttcu4dTjW3ukyIooowqkdBuGARxzWdpGmWdiJJtZs5F3A7ZWO6IfRaAMuzeGYQ+fbQm3U4Lj/WKmcZ9639R0LQ7e0lnsdSuJL3cFitWhVPl7lm3VyUdsTctcWQeXYCCB8vFSghoZGM0jngbC5Yn8BQBdvI5IgLiNIVeNNoLMCslZEeqz2ksjzuI0k+Xy4Dww9hmprbTJ9QZIYraSeTruL/d9yPSuwHhDUrWGF5TostuYtxYyhnH14yD7UAXfAvgLX/G1pcTaFbqbRCEe5kcR/ORnHzcn3wO/vWBrej6z4bFzYXdibOeNykjldhkPb6j0resPiLr3hvTJdI0C6NtbqS7fZ8HDHgnJz146Vx15qd9rmpm/wBXmmlMr5fzXLeY3cn06UAPm1XUodHAe6Z0U7jGq4UH61DPaS3UcTW5lIY5+VdzFvYda3bHQk1i9t2ju0srV5ArSP8AKqjuTnNe8LqPww8P6fLYQ2zS3sVuX+1KfMO8DgBw3HPYDFAHzxoPg7XPFd5LaaLa3Fxcw4eWLZsK9sndgDnHWuxHgvTfC8skPxFSa0vAu+NIXSTIxwSQSPbFZV18QNdm1G48vUJEhlwW8sBWOOgyMH171X8d6z4X1jTbBbRb5dZXd9sknmaQSntjJ4oAytfmstWupDplhFb28KYHyg7gM4Y+hNec3odJGUjC5z071vPqdza2skMjkQtn5QQC35Vzcz+Y5bJznge1ACRyNG25etOimkjcsjYY8Z6YpittOQAeO4zTaALsd0sVxHMVE0i8kkkA/hV+fVrzUFO8bYwNoAGF9xmsaMqpy67h6ZxWzZ3U/kgRqiwkgeVj196AIoNN85VkUOTnJVcNj611WleD72+tzFDarKJYyyHGMcU63tZbOyheQxIzHd5SDLZ9+w/GtC6+Juqw6eunl4liQcMUXzAPYjpQB5ldQPbXMsEqlZI2KsCMHIqGtLxBdfbtSkuy+95gGdi2ST05/Ks2gAooooAKKKKACiiigAooooAXP61c0dY21CIS7dueN3TNUqkKoVyjktkDaRyaAPRPEHh62TThfPpV3HM3SaNg0LfQf/XrjZxcodyK0YwMcY3VBM2owxI0r3Cx5+XLHFXLLVN8YS8mZWB4cru4oAdHdb9OJE0UZX72Ewc+x71paVqE32YTMY0SNT99tpb0rPjt7ZVmeFnlfPIKECqckJIYXSyJ82FwO30oAt6neCaWVgjsj9Np4Jx39aueHXFncRPbyLnOWZsjA781zisFlQLIzKDjgYr1n4fR6LLZvHf6detc4/cmORQmexOfw4oAs+PFFzoMRtzZOkyj99DIGlY9s/xY+teMygrIwbqDz9a+yfh/o+l61o2qaPM1qsnlFZ7u3iy1rkfK27GO3rXyZ4u04aX4gvbZZGlRJWUSN1fBxmgDGooooAKvwajOJrdpCr+Uw27h0qhUtvC08oRBk9euKAPZbPxPFq+hJpt7pWjblkDLdtFscDH95e1afwys4bb4kaSF1WxSJ5MszXGU9kPfk8dq828KSeIrW/8AI0yKeZGG1kaISAjPoR/Kuru9OtUn36hF9lvsfujaBUVm9XB5GP50AfRHxZ0n+0vD+iDVLdNP8RykxkQyFk8sMfl3twSMqRzkZNeGeK9AHh/VZbWS7a9jVd378f6ontw2D2r6P+F/xKsPFPh6O312a1i1uBQk6OMRykdHXPH1HrnHauB+Kfg6a6hvryxuPDd5qZcNLY26oJAMnkFiSTQB8/XkP2hI4JAUyQECMAGz2xWxYeDIZ7R549Qs4WjXBSWXa4zwRxxXeaL8E/FniLSLXVI30OESKdqOzBmA452qQD1FQXnwU8WaOs01wumwWoXJm+15UsT90AjI7dqAOCsornw9dvK88DLb5G6KXJP4iqmteIJ72JwsUYWVi2xF+YN6k+9dj4b8P6NqF89p4tfVgqAjNhBG6gg925z9celV5/h/eRX0otNG1aOzBJtbi5s2UEE8ZcfLQBk+EvAWveIrad3W5S0Rd7OYSVx9R+NbWsjwh4ftbe0sLHUJ9VVcSPcyARFxjkAAYGa6e90Lx9onh6OPURa6da2q7UKSANJn+8B94fWuFTSZr69iTXJRauMhJWOFbnpkdOO5oA9Q8LaFp/jHRpJfFXii30qGEr5MVukUW3jnLkc+mK4X4geHf7Aj8q21my1CBi3kvA7bpUycFuwPqMn6mumuvgtdnSVv7XVdLvIwm4x2VyWZiecA4wTWFrnwz1ywt4JrozQSPgJFMQwb2HT/ACaAPNpI4YYWnKCRwvJbnBzXI3N7LLcGQOQc8Gu+1zwvcG1nN5by27ROAQCOOem3PH1rir7Rby1yxhcxZ4agDNLsc7jnPrzTan+zndgugI67sjFa0mlw/YQYpMynrxmgDDIpyxlvu4Y4yQO1X7bSbiVmGwnAzx9M1b06wRbjZIm116sxBA9qAIbK0Rky6DsW39QPatyCzgkERk2xx9fMU8n0psI0yNjsmleV1K/d+UH29qSKxW6k2pcqVfgADA60Aa1zBI9kYtPmkYyLg7F3k+3rXEapYT6fL5c4ZS3JB6g+hr0uxvF0LTxBEFg3cvNGQJOnTPf/AOtXNrZSeJNb+x6ZbyT5OdzDLEk0AcUKSvcdS+Ed1pnh2O/1UWdnbscL58gR2Yc4VTXkPiHT107UpIo2DQn5kYEHI/D3zQBmjr60UlFABRRRQAuDjPYcUlWXaJ02iPbIOBzj9arUAFKBk8kD60lFAE0bC3lzhJCB9RVia+WXbuto/l9O9VUk2qRsQ+5GTSxI77iqBh37UAdXpHi5YNPezvdOiuLcfdOcGPPcVTaxtNSfzNORYSBu2E/KevHNZi2bhGeF43Xo6jPH1qWCB2dQ5JRBnbG3sPWgCd4r+2cMYEXHG8uDj05zTdUS5e3MtyxJVsqQMD8KvJpuIxe2rNIq4byGbkn8PrUd5eW91Ew1K38udeE8ocMfegDn7dQ86gMFOfl3dM+9esfB/SrTVvFVlBql5Da2kuVka4OVbjjrwK8zZYAyiNRtbGNy5J9fpXonwb07S7zxVbR6/fPZ6cclpCpYbh0z7e9AH07pl3Z/C2aLSIYZL5dRIe3jt0BDDpndknqfSvC/2ofDsNl4xlubNLG3+0RLI9vFJko5HzZUdD3r2v4h+E9M06w07UdD1ue1vbdtiNFIpDIeTjGMHOOSe9VLTw9pvjDwvqMk9vY32syrshE9zGZ94HGSQcHOO+KAPiGiug8aaBqWga5c2mq2MlpcI2GjK42/j0PHccVgEYAPHPvQAlb3hjU47F5Ua2ikd1IV2OMVg0UAfWHwU0lpdPN6l9Dptwy4juxOjsnHZCDWF8XvD2oaUs1/q+oWetb23i6tmLuMcEycAA/Suf8AhR8YLXwTpk1va2ZuLydcD7SQEVumc9fwqn4/+MOq63pUthO1vvuExK8MCAHn2/z70AWNFukN/a3Hh2SO/s4oxJKLyAoYmAyenXB712+h654N1HxDJqviCzvptQUK0DWhEWx++PmGfYk49q+cNK16+0mTfYXMqbh+8Q/df2I9K6jQ/iM+majBeyaRp908O3ZHLFmMEe2aAPa/Evjm8gWW30LxZefZ5JTItvHHtnTP951HPbOO9cFfa5q+q26xajr1/fMhK7Hmc7B75P1rk9U+Jt/qeoXV7JYWlvd3LZaa2zGVHoMdBWM/jbV2A3m2eQf8tWiBc/U96AO6sJUjCtcqZLK2yB5NzsaQ5557mug0Txb4oj1Cabw3eQWVqoGYXumYBfcSHk/hXhUuqXkiFGmIUsWwABzURuJFQbJCAcg88/nQB9E6z451fWrHyr6GVmiyXvBLujxjkBegrgNM1CO31WQ2zSbGXDB2DLjk98jvXm5v7vyPJ+0yiL+4GIBqWz1K4tyQkpAbuRu/SgD17Qtdk0bXba+i8u5MLb4zDKY3RvbsQPQivWbr4wWPi7SJtI1PQZ7ohQwmhmVJFkHQ7SOCPUHv0r5s0vVraU77pEaQ/cWOPlvU108JuvsjyC5dox2SHbtHue9AHSTeGbzVNPn1G1dYZYsl3uJQznGegzk8Drirb6P4cm8Ffa9SvL681Js4ihjyc+h5HH1qj4W8Q/2IEkhe2lkzyWOdy+gFeyfCUaN4jkvItWks1eU7ksEIQSZ/iOOp9gaAPlGSztwJAgK4bASQfN19a6TQLLT4wiXUQkdSCQhwD7E13Hxk8DR+FvFk/l2O2wvFZ7doVLrGAf4s8g1j+BvAGv8Ai91h0yAJAp+a7YlUi55+v0FAHJ+Iru0hmcWsMEA+Y7IpCxH1z3+lcndXzBt8cWXzwcZr1X4ifDfSPCsjyHxFYavfr/y6xgAKB13HnnPavK2nQFmECq3pnIH4UAJbxm6c+bKBJnJVR1rcsZbaxhPnsiZzhU+Zj/SuWe8kbMca8D72evHvUU07q5KhAD3BzQB0d7fx3058iU8HBRwOffir1nr1v4fKy24d7xV4ZHAUH6Y5/OuLM7hWDH5zxnH9Qar0AdR4o8b634jgt4NT1C6uYrcloVmlLeXnrtHQVzTyM4AY5x0plKwxxnn2oASiiigAooooAKKKKACnBflLZHHbPNOEYK5MiDjOKRl2gcgg9xQBNa2xuM/Ng9APWle1ljOTHgjnB70lq8sJ8yNSR7VsrPDdKBfhmC8Zxz+dACQizuUiWKCSAnkkH8zV6KCPJitpLjeuSGVduR71WEkdkY/sMJeI+o3c/XqMVo3WrTMI0mt2hIH3ojwB3yD+FAEMNwtvfD7XG6kdTwpYg+tQ6h/pEyzxQFFYYy5BHtVwzxXMTSynftHI2EqO/Pr71itDHMQ7uRCT8uGP+RQAQ2pE2TIu8HAVRz69/wDCu/8ADNsY44ZJrJ54n6h3Ef44HWuMs3ksWKma3ePlS2cgd+DXomjaDqV/Yb286a2U/wCutZVeNAfXuD1/KgD6k+GF9o/iXwc+lNp1ksFsRHJYgGVAvBBbdwSTk9T0qp488H6pPIsHhm1soNPeLkQwxxyxyD+FW4wrDHrgj6Vo/BG2Nr8PrKNUT7PvdoZAMNIpP3mHrnIz7Cu9oA8U1v4VQeJ/CEceovc2Wr28ZRhLtumYqOApByQR6f0r4w8WaDd+HtYl0+/tZraeMkFJUKn64PNfpkILe2aW4SFEcjLsifMR+HJr54+L3hnUfiFfzyWngma22gJDqMgKTzY7MoyNp7bueB9KAPj54zGPn4b09qjrpvFHhy80XU59OuYWilgfa64z83esOa1ZFyA2AMncMZ9xQBVopQDgkA4HU0lABRUnlSYJ2MABnkYqOgB8bmNwwxketMoooAKKKKACpVhdiMAYPGQcj9KZtOQOpPTHNXLaxMoB37GB57/yoAghaSOQrCRv7EY/nXUaXruq6dZNbmZ2s5uJYnPWs+bS5LArPuyx5+YcHvSTXJkthwyygg/L2oA6iN4X01vsrKpIy0YUls49fzrs/gzqkOj+K9PdmLMnztGPvD35/rXAaRBMbWIzsoQguGVTk/Wt7w9dW+m6pb3aQO0Zf967f3c84oA+g/jJrb6vozWdrbWUt3lZZJo2ZlEYOMZIHPavCI/+Ei0nznW4aytGUMUWUjf1GcDmvQNY8fR3bQQaNJHp8TAo2Yid4PQbjn8q8/8AF8l3NcGG43PePhD5cYUj0wO9AHFXF1FJJMjySEsSSW4BrnJPJjmZ4GYBTgFecelev2Xwf8Wanpss9pBEMLuVJpVjkkGOiqeTXPp8MdTjEjalA1hMvVZzjPrx3+lAHnEkjPKZGOWJznpVm3sLi6fdHGXUkEsMDrXU6poem2H7tXeaYcFlO0Z/3cdKlhurezjVUV0V14RUBAP+FAGHb6CyMzXLDaORgjn61XntliLfu1Kj+LbgVqXGpRy7ikQDNjlh0/Kqs18ZIdvlrnkZTAzQBiu0ZUk7S3QBRgD3qCrZtZJJCz/IrHgtzSNZykjyomIwMkdM+1AFWirb2MytgKSD3IxRQBUooooAUd+lPiG2RS+VHUHH5GmAFiAOpqeJ26NEJAvHI6fjQBK0cRhywz/00UYA/ChIEILCdEQn+IZFLZwxujNI21D154FEMKSSYQx4Ud+c/X8qALJ0+aVl+zzFxjqpzj8vrWjp7zRl42ZHGflHUg+oqjYyyx4WOcqik4X7q1q2unxy3gLSz+Z/sMAP50AQoNQ3Sy+ftQZbaygMR04Brb0K5upoSkloJ1P/AD0Xj8PSrF9A0Gleaz+ZznJQNIMVS0q/M0ckDWFyxOQhgGM/73r9KAG373IzCirZsx/1WDtPsDWNPG0ClGAUs3IXk49q6u1kxdJHdWjxQFd26U7SSOB2rubvTNL8VeHY/wCydLt7V7Hb9pnik8yQqe5U4IBNAHjllbRtNHFbmTnnBONp967TTf7Xs2SweB1gfCiPO2Nu+Ccisy+t7G0uSLZLlypz83BPbnAq1d6iFtg0TTLIP3ZSU5UD6Y5oA+u/gxquqXWlGz1R4XjhjQW626ApCgGNrODjPoDzxXpNfMXwU+J9poWj3VhLpU1wyESSXEBHPHA2gdv8a9I8OfGOx1S9aO7sktbfOFkW53v+KFQfrQB6rTJhIYm8kqJMfKXGRn3qpZavYXsZe3uo2UHBJ+Xn8cVeoA+Z/iN8MPE+va9qGs/ZrWadHJMYuAeOxCjnBHY8/wBPDPFfh+40uHZcK6NvO2OQ4UMDyBjmv0ClsYJb6C8ZMXMIKrIDg7T1U+orzv40+GNP8V2Fvp32eNtYz5sEzYRY16Hex7HsBzkUAfCSadK0PCum/nYMc+uKUaSVchGcSgHAC5z+del+OfAWo+EpmTUYrdi/+reGXKn3rkrON7e4RpbjZASAecY/rmgDl5V8tiJ3OP7vUD8R9aoEYzg5A7iui16GFdUkDYlz3TIz3HTp2rKMsKyeWqyeWuc7T0/GgCkdpHGQfSm1pzNazH/RvkfGBletQwEO8hYAY6kH5TQBTAycDrXReF9PsLiQyapbzvFGfmVZRHuH1NUtG043cxCTRIcHaX6fWvof4WfBeHXNAub6582Y4CxgSKuXzzgZ6Yx1oA4JfB9lqLAeG9BkZwcMHuw7D6A9+RUereEdb0fTBdz6YdPtBIVPnAKxYfX5sfpXb+Kvhp4z0BlXSLOKOy3ExR/bUMpxjnqM/hWDYeNte8JWd7ZahoNheS3YxKNWczDGMApg8cZ6UAeYzNNcXBMqgoOwJx9R71OhtbJyzw+arLhWI4B9fWqWs6hK8rzIIlDNkInIQc8A/jWTNcXDMDO7juvcfTFAHax61CQ8EUabGTO5R0+lT2Zjg2gqSAeucEVyVvdmNgFCyL3Abp71v6IJZI3VXDmXACJkkH060Ae2fDe90u/u49Ki0Jb2SQqzCTLOnPYhf8Kf8Z9FbS/E8VxPeLFbGNWW3jUmSEduc8dO9RfDzwj4vvJbMaXtso5Bk3Uq4KgdfmHP4Zr2fVPhfa6sludY1aW7uYsGRpl3Bh6YyCB+NAHz7J46vrF/smkXck+MhJpZHDZPUY5FYGq2ms3U0kmpvvZvmaSKUvtGOMdh16V9O+IfAun60sGlaRHZWTWQVxNDaMgCnoA/Ic/ifeuL8bfDiPSbN521VY4ApYRMpDMAO4UY/LFAHzi8LRKVQMnpITluP51nJaXDB5QCyg/xAAj/ADmt7UbyOK6BjBkkXhiI9u/3xnOOlZE+pmNn3Y2Bh8mOR9O1ADLXSkkiIdGjY/MX8rgfnTbjTmhYeUEbPIYADirBv7i6ikSd2WI42EgY/wD11Ta9maJivlbAMBmyp+vvQAySyWMMY1R+5LY+U+mKz5POBU+dlCMIqrjNPub53lKFgzDo6jAwKrFZnZXeVmToAxH86AL9tZASNIXkeTrgdPyop0cpOzypVRl4IUcGigDlwMnA60pUgZIOM46d6ReCDkj3FaFjqJt32SqJoOcgjk+9AFAcYY9M1ah2SKEUEZJJUngn0zW2+nWV7CDYZSQgAxluM+3rWRdWz2sohkjZMsGBU5I4/wD10AWIreNXPybSRncp3BeKv2MdszAP8x6Zxx17+lZZ2MyozMH4Jxxn8atYjcARyPGoB3bj39vWgDoPNg8hoUtFeLHUJ3qxd+DfEUHh5dcg0u5j0VcN9sK5VQT1J7c8Z9TWRp9mqRmW1u5CzAbgPX0wa7TwT8RfEvg+XyINSe601gd2n3sJkt3B68Z+X8CKAOTtZY7aHztVL3MLDlEO3j+tdLa6TDqmjzaj4f1SKDYSDay5WZc+nqKx/H/iCbxR4nuNQmsrWzEgUmCxTYikLj9cc+5rkoGm+2E25YADH38c/wD6qAN/Uv7Qt4mS/U3SjlZGYsoH1/Lio7a+FuPPjmcSthSkR25/CprS6RbH7M9w3mMSzwuMpuPU5qpIfJuiI7aIlhgFcDPegDa026jupzcmRhLGRiNiQo9qsalc3l+zGS4iAAwR7D0qvoVlfaqzW9lZKbonhR1P6/5zVnVtC1fSoVe+gkAPVdmceoJHSgA8NXF5pt7FdWTqt5G5KMxBz+B/rXrHgHTPE+ttf38RiOeMmOMjd+WMYrzHwtbabe3scOq6hJo9vI3/AB8rCZfL/Ac12OpaINL1NbHwvrN1q1lKgeSRQ0QcYzgAH8aAPVLi/wD+Ef0yK33Wep3jSb7y3jRpGVADhlGNufpxXe/DXX7vVtPklv8AU7C9idz5TI+2aL/pnIuBz/nJ4rlfC1na6j4SsZdC8KB7jGyeSWYoyHuRuI3+uM4qfRrPUL7UV0jxF4aM+jRbmguls1iKN1IA7A9/XjrQB65RXM6XoEHh26eexlkttMWIvLCCCrMAf4duRgc8HnpXQWV1FeWsdxbsWikGVJUqfyOCKAOf8YeFbTxCsBnTcY25Ro0dGB6khv6HNfP3jz4HmOG/utD1CS/khYtJbIgj2d8Dnn8OTmvqeoJLeMv5iQw+buBLMnPXnn1xmgD80dQiura/kjuVdGRiPLlTay/UH+tV5LZ5WKrJGobn5efwr7Y+J3wSi8a67Nqo1VYJ5QAfOt/MKgdgQw49PbivBPiJ8Fdd8KahCsMb6jZuu5bq0iYBTk/Kw5we/WgDxg2qxP8ANIGHqDjn29aaNhuAFLKuOo4yTzya19R08wuwnz5gO1o5AdwNVIojGR5qsqf3QOlAHW/DfR5dY1hbCwaNL24/dQCRfkLnoD2H1r7r+Hfhs+F/CtlYTmF75UH2iWJcB3/rjOK+FvAlrbza7pUh1c2B+0KpkIJ8rH8WP1xX3x/bNnaLY2st/FdXk+yNNrLulOOWwOB3PpQAnibw7pniXTmstXtlmi52t0ZD6qe1fNXxj+Dlh4bs5NTttTiSwPCJc/NMX7KvZuO/H0r6pmDtE6xOEkKkKxXcFPY4714z4/8AB3jjxJol1Br19oMtpArPHJbQyCfHU4yMDoOnpQB8carbxQ5G1pwf4t2M+n0rJt4XluSwTAH98ngetdHrNnOJPs65lCHAbsMetYsNtMjNHIwXzB/Cc4/yaALEEMZOEKOScnAI/I969C0XT7fTbZL1IwkhHBBJJyP0ri/DWh3V/qUVtbuofeAm+vUU8CXMl9BbR6haNI+AV887R67vSgD0Twv8Z4tM0m1sbGxs4oIxsQzl9xbH3jjpVPWvjdqq30c1vaWbXYUKJLWTcirnJBBzn/69cP8AFHQLbwxLG8c1rOzIBshbcfrivM5r64yfJJgUHocAH6+n0oA9+tfjvc22qi5k0i3VG+YsgYE9c5ycD8KzviJ8U7jxTIVt5mtrMIUMSjGT656/lXhV1dzuI2LZY9QDnd/kUy5vJHlAdxwOpGQfbj/PFAGpqd75aL8xEoyVB7jnqa5+W+MrCZRFgcYPAFMmkEpIh5l3fMX4FNWy2/Ll0AOcnpn+VACzXSXJ2+cUIxhV6Gq8Nw7qyliQMbQPxqSW2QJ5ahR/tKc5FQQxMjcMrMMggEHYfWgCVfJMuQVLk+uaWR8BvLUnucsBgfjUUkSks+9UI4PcnPeq79kBKx9RuH+FAFo3Pk70WMBmGWOeQfaiq4ZSCqRl2xjcef0ooAgp6BSPmIXnr+faljCMVDEKBkk+tPQK7NlgsY5IHXH1oAeizwghQRk9V5I9xTnuncKkjO20dsg59DUlp5QBkZiE6EnrxUzCHh7eM4xxwAaALFjdQmIboX34JDKP61ftp4Jo1WeBHOepB4/xNYNo6R3ClBLuPr/FzW61rMbYlImjRTg7uh9qANJLK1kBAmW3GAQCw4rS05rnRr6HzFjvrYMD8gzlfQ/hXO6dHPcny/mwwyGMeQD9a3dDs76MPFapuuFXcHIJDepwaAO88deLfAfiWyFtH4NfSdRChY76zkVSv1XADA+p596414dEjsngRJM7QFcyKHb8OcdaZPNNfSLb6uI3dWwXKeWV9Oag8QaVDYBLi2ltiEA+cOHzQBlvHvYpIJOONyrz+PvT9PQxt+9tlltV5XKkZH1A6moYrq6uGVoGIB++CflPv1rSeZ7e1ZLS6lkUn5lyRg9KAPV/hvN4LEVxca9oFugjUOslq8iTIfqWAYYz059q53xvrWkjxLJe6Be3QtYuIY5mJ3jHOVPv61ztsk+paeiFZHMY2hsDKn8ufxq5o2jTuZIZbm1imH3RJIgBOe+TQB00dpoN7o73yzQG9kQbkllVBG/r0960/hp4g0TwjqMkupYvN0ZdLa2gLRhvXec5/LvWN4a0vV7LXWgsdFe6uidjLcQiSBvcZGD9a9o8OaNp8kcsGuFtC1HaRJBY+WkBX2OCfqBjpQBd8F/EhfFWsSCCXTrAnC2sN2zKzjjKjkBmPr29DXeNq96n2SK4sBHNNL5cpgnEqwD1Y7R1+leZ+IvAWl619mvP7LmKp+5DaeI2VgMYeQK3X1xzXpWkNBpEmm6HY2LRQG337yuwDA6Yxy3qM0Aat1Db6jDJA0pZRw4jfkd+cVhjQBpcpvdLv75/sysWspbjdDKdvAbIJBGQRj24rpwAOnFY+u6Ra3lndtdpLOrJkxm4aJcD0IIx9TQBl6d4k1G61aKCXTokhaLcRFK0jh8ZxnaFH4+tdTG7P96J4/8AeI/oTXOyabeHSBDp0kMlsYvkikuJHzxkYkByfxqp4R1DxDqFujax/Z1mqMBsjLPIyj1JOOfUUAdhRRRQB5B8S/gfpPiy9k1HTZ/7N1GeRpJ3IMiyk85wT8pz6ccnivnfxX8Lta8JNLPrFq4tUcpHcblKt9AD/Ovuesu90DTL+9a51Cziu5CuwLcDzEUeyngUAfnktkPO3LnyWOQFBBH4V9W/s4eGdPFiNbe9upNWhzFJas/7uEEcHHckZ5+vFWPHvwRsZbG+vfCCSRarJJ5q28koEXJ5C5Hy/ia2vhDe67ptsNE8Q+GZdPZMk3sUfySv6uRxnHGc9hQB6lTZZEhieSV1SNAWZ2OAoHUk9hTY54pCBHLG5POFYGvm79oLx7Kdau9CsbyX7FHEiyLDINrv1YHHpwPqDQByv7Qfjay1nxA1v4eu4Z7BVCuyRgBpMncQcAke57g14j5jSTbUI3E8ll7f59a6C28L6zfQteWmm30lghw9wYGKKe/zYxXrfwW+D9jr90t3r0epi1gXhWgMUcp9N569unpQByfwi0mz1TXVttbN0LXYWMkC/MGHbPNfUngPwnoFnprXkGlxHzd224umEskkfq2Rx9Oa37DwnoVhbwxWul2ieVja4jG/I77utaGq2EOqafNZ3JlEMylWMblGx7EUAfJnx2m0NPF902kzRSQbAjLEP3aOBzhumM56fhXjBWWWZmaSEDPBB4PBxXqvxf8ACw8Na/PZtdefZEblZeGHPQ15q1tshYwZZcjGVGDQBkxQmWRneYJsOMsM9KaIkSd90xaXI2jbxmrkowG2kLggL5nGTjkDH+eaSbMdusrqm8jAIwM+1AGfcW5jk+0FvNZRyoHtVcJKUMu4xrJnCZz9OKsfvbgKu4E5z0PH1oKiBtrTHPeQjlRjpQBXAQA7otxY8knIBppRM7gSpzzjjNW3iSKRMy5BwSVHIFObBmCwyFgx++VBYH8aAKChI2A8sjnAI5zRLIqtzuP8JUDg1beR8ssj8JzlgCCab5kc0I8t9h5IBBKk9KAM0NEs4OxlC9j1zRWh9ikwrLKkbN1GcgmigDNaUs46EA/LupN6MfmBC9flAzmpo7cPLtlYjGBkf59MVdl0eXcPJXcmMbhz+n/6qAK1kMXG5cEjgAc96lv4zIY95PmNzhhjj/IqpLA0alDvbnIAH55rT08m4Hl3CMPL79sf59+1AEml6f8AaLna0e3B/iGCR9a7WwW5tIdslkzREYPG7cPXP4Vy6afMkJkgRZOmDnp9eafb3t5ZzLPZySI3Qru4I/zxQBuXHkXLlLO3KuSMKjbQCf4aXUf7b0pI01O2ubF9oMU0sRVSP97HP/169L+GHxtGjWY0nxdo9veaNt3A29unmq3qVJCuOvoRjv0r2vR/jN8OtXs1tW1FLVGAQ2l3aOgA6AH5SmOPXFAHx7JM1wnn3LxyuCBuDH8xUdvDA9wN1vKwwRtJOG5r6F+L3g7wMTJqul3elLJOyn7NYzLu6feVFOCD34A5FeF3NvHazu0InC9AMFeM9aAMee7EcqLDbQwBWxgjk/jVi3kt5t2Y3E+cKFYgN35xVi8tklA2P54Yg4B5Hv71r+D9A/tTX7K0jsbi4aWRUJjjZigJ5PHQD19M0ARwQ289oZUmiW6j58oRsSw9u1Pm/wBMjgmurbZbhsebAgwBnqef8K+kJvgPpUEq3llrV3ZTKNzlkSSMYHUA4x+dcFrngaLyLiDQvF1vqbrmQxCycbhnpvGVJ/GgC9ouieILnToEXX7TRtKkAED310I2kz/d9T7V6F4UntPBGny6a1rd6qVlIe8jIkQyNj5MsQRk9hmvF31aGfRItF8QanKs0MuY4pbQShDjg7uo+leqeBU1ObQo7LWrjS4NMLL5M3nhZjtxztPGenHBoA9E0hrvWAkk1jeaNBCT+6EgVnfjqAOVx/KteGxkggkSO7mklZtwlnAcrzyBgDisOdHvL1tKe6ttRsUjSSWFpjHdo3DIdykArx7H3NLd+K5bO+giudGu1tZCVe6WSNkiYdjg0AdTTZEEkbIxIDDBwcGoLAIluoSEW6sxKpkHrk9uPfio31CNb2S2ENy5SIyM6QsU6/dDYwW9utAFmXzQv7gR8A4DZHPbpUdjbJbW0UaxxIyqFIjUAD2HtWNr2p32j3S38ux9GEeJIljJlDnoc5/D0/nW3Z3MV5axXEDbopVDKcY4oAjS0IvpLlp5W3YCx7sKoxjGO/PNWqKD09aACmxyJIgeN1dT0ZTkGmSyyJPEiwM6PndICMJxxkdfyqRFVFCooVR0AGBQAtZWu6LFrKJHcXd9DCud0dtOYg+ezY5I/GtWigDiYfh14V0ki8gsZImgy+RM7Z/Ak1n3Hwl8IarIbuTSo4kmG/bESp55JJz3r0aigCjY6ZbadpEWm6dElvawxCKNAu4KuMdD1/GrcEawwxxJ91FCj6AU+igAoopsib42Tcy7gRuU4I9x70AfN3xzFrfa3dCNbWWRHHml1bzCoGNpB4AFeC30sduZY40YAndw/wB0ewr2n4s6ZpOhazK1hqN5fXUvzNM9yJSrdwykAHj+deOa/cRy3AlRwzhtrOYwp/CgCjeWzyW8S4eRm4OF7etNl05I7cOqBWAwC/VasWEltGczNNIr/KMNjH+fSq2qmZVQQZkRTzk54oApXo+yRkRyxySf3VH3s+nNVdPika4Bl8mNj8x8z5v5VdsJI55QXBII5wvQ8VaW3kmkkjWJYzjhwoBx/k0AVLizS4JjhUtKD97bnH0qkbZoDuYNGQMgkc/iPpWjBCYpZFkZjCO3mZzjr05qSWB7iFmecLCegGARz0PPNAGKoa4fa79BkECllgSBQ7yYUeq5q88iopDFcbvvD16darQXDu4WNEDHqW5FAEeLbzEaNjgHIBBH/wCqirswgRNssqM3AKj/ABooA5YZbBVmDj3JJ+nFTwTSRzZYlWwDjHX/AOvVdAnd2U+uOlKWLSDl2x05yaANNrm5uJsSxxgNgA45/P8AxprLNFtwoQg46ZGfrUCAqu7kZ4bzDg9OxrZsri3TdFMrhWHBDcLmgCOwvHmAVpGif+LGBkn2NdNo2kXd7HGLOJrmI+ysTj0ya5sxWNu5ZSAx5DHvn0FOt3kt55GhuVC/eJV9tAHv0HwXuPEOh291a6fdafdiPBtr0LGZCO64OCOnJx1ryLxD4e1bw3eGDUbG9s2Q4/eRbVYD0PQ13Xw6+K/jjRrSK0tL+PVLWEFlt7xVchfQNkPj2zxXrWkfGrw94jjl0rx/o0Wm2sicy3B82F27jGMqeeDz9RQB846baajqkqnTtPVpUOd0bqp/Ek/Sp7y4ke9a2v5Z4p1G11JJVcds4xXqvijwf8J7i+FzovjJrBJ2X/RkMk8ZyR0PVR06k15jr2m6ppuovpt60V1ax8JJFLvQr2O4e3rQBRtg8m9WlIjByCqhRivW/g38TtB8IrcW+qWty6uQqXccYZ1GeQRwSOnTpivHNWtbWK1zFJNDNjIiV/lP0JOap6ZCTG5V2+1ryEk4JHsRQB9Y+PfiLp3inTL7w94YmkfzUX7RfsrRxRxcE7f4mPYjAHWvLLLw9rGkSxmOefUdJiws0Vu7KGBGc7Aew5zXAad4k1m1uHVJry2kddv7qQhXHpwa6qTxnqNxYCw8Q2LtpxOTLap5dwD7MOv40AfSXhjTPBfirw0iadp0LRbNrF4ilwp9S/DZz3zVDSfg9pGkanNd2d/eurkFYbnbKgOe+RyPavGvh1470vwrqxFtp2u3cbAsJLi+2qvA6p0r1Gz+KevXN7btb+Fmv9NmwN9s53rnrnORxQBd1jxL4ZFrdpLbWOqTwZXba2z2rEjjaCQc9OzYrt/CGq2mqaDZyWVncWsXlqvkSRkeXgcrk8HHqDWDaanPrAmt/Ct3Z24hbZJZ3drgxepUAjPfJORk1b0i0tltNmpa69zCF/e2s7xqqMO443DB56+lAHWrFGqqqxoAn3QF6fSiWWOGNnmdY0XqznAH4mo7AW4s4vsTI1sRlGRtwIPcHvUkqB0YbVY9g3TI5H60AZumQWdjcXaRWCWbDDySqmEkz3DYGfcVGW0sq8cdx5sjuT5VvcNkt1wAG4/QU/Spr69sp4dYtYLW5OVMcchkUqeAc4FUPCvg+w8LQ3UemzX0kE/JhllDAE9SvAwfxoA3NOna4tVdrW4tSDtEc+3dgd/lJH61NMrPE6xuY3ZSFcDO0+uDWPp3ifS72/l0+KWRNQh/1lrJGwkUZxnGOR71rRu7yHKhY8cA/ePv7D9aACIyR+VFJvlbZ802AASMdR6nrwMVLRWZoesR6xHNJDaXtvHG+0NcwmPzPdc9RQBpAHcTnI7D0paau7c2SpTtgcj1p1ABRQKKACiiigApDnBwMn0pabIGaNhGwVyOGIzg/SgD5p+LOtWeo3EtrqkttDeRuUkhtrZo3TBPBc53fhXg+pXFtbzvEpkSMnG6TjHpj3/xr6A/aH8NXCX0WpfY7OQXBOTBlHJ9XBJ5PqOK8K1iJp9puYwE6KvOB+lAGS95kKn2U3ER+63HX16VWeaaRgWYDnGxQTn2rdS1cSw29vtcOBhgnzHj1zWgbCOC1miaeRZTySlvu7dCaAOX8zJx5bROCR8pxxnj605zdsFWNdqYwxJ5NK9mUvnkjAYhs7pAQT+FTPHPdvuZg6Z6KScUAV3MEA/eecqnrkcHH0p813HJZFQGAXkZBGB/hUWpQFIiBHwB0wf1qnCuIiHk2MvOGYZx7UAZsm1i2396h5yAMGlEyRMpEih+QQe3FNuyZHKqUjOcLtPXrURtfLUyTMrsBnhs0AWFDO5OQV6Hn5s/SimxGIbjjHH3sdB7UUAZ0kaJx5gLdCMcD8altEnJKxJ97uajSbCgOMhegwMGprIQSOEkeSI44YHv/nFAFqFGgbbcL5vqpNaU0kcQ/wBEgwpH8K5H6VZS3vIbUqTDdR9ssCcVHYT5LG3l+zMeqgZB6fpQBUhmRgXnywz029Ppn/PFPxpwmWSFv3q9VbuKkvpLpmdZXh8tTy2N24+tOt4AuzzY45EZS25MEj60ASwYnKzWkIQ92DYNWk1NmUi9mWUJyFlAY/h+lQs8lvBlX3wA87AAQKzJVRpgLbLh/wCE4J/WgDaEsMrLK0LRLnPyggDntW3b61DDDNBb5DN8qt5Yb9TXNWkABKTh4YyODu60TGFFWC0jl5JKlzxQBob7mWUG4dJFLgknJ2it29XSGgtzbW0jXWMPIhwD+H41zEazSRqzrKHHGN+KksLK/mmaO2AMucKqnPPqaAOh0/w7eTxvdJe2KouWRJb1UZf+A/8A1q6bQtI1TWdIu1Bt7xo3yETOenUHkcVy7aBfWqB9Wtl88qNuJVz9etb3hTV77Son+zosU54BAIIHpwcGgCloK2lrqFzZ63CdxG1GlkKbDnr059K6/SbkwbrWxsBHaOu17m2u5ncg8fKM4/SsLUtA+2sdS1K8ieTdl1i5Y59eeK1rCLQ5PCN0NNuoYtX2gC1d5A7YI6Y46e/86APTfCMPh3QVttSk8LazJNGhC3F3KHd/VgkjAHj0z1rpofHfhnVYYzpVreTzuDizjto0ZCP72fX6muJ8MyT6xBY6PoEl/pt1tVZnMCvEgJ+Y/vMmuqufgZofmSXNjqusW1+3KzeYjBT67do/nQBv+BvFF7fW0y69bXNneJMyJaG3+6n8J3DIP6U3xjq+saduvLeDUfse3Lw20PnMfQgjG335NT23h7xBoPhNtO0bWH1C+5K3N6QGBP1DfrXGePtGnmsbfTtQ8R6u2tPAJGjtiFjLHrkLjIznHFAEXw313xPceIPOlvJpNGOfNtr+UBoh/f3Od3HHSvQ7Xx34fv8AVhp9vfbpA2BKn+qZh/CH714p4G8FeL4IrpI0tLmxmRvMivLkbpF9O5U+/HvV9PDjwa9BFeaPqumR8JE0MIuk3ngAyIw+X8KAPSNT+JOkaV4vj0m8eILMoH2iBWlwewcgcDnrz+Fdw/zPFNE0Oz+JiMkqR/Cc8c4rhbP4etFZzQy3aLM5yLiDejqPTOcn8/wrqtA0MaPGq/2jqN4Qu3N1cGQfUDtQBe/d3gkSSKTy0bGJFKhyOeh6j9KmLnzggjYgjJcEYH65/SmTwmQqySvG6g4weMkdx3rKUPpcst9rN5YiILtM2wxn6csR6UAal05it5WjeGNx/FJwoPvWeNUnt5LK3urSeea43EyWseYk54yxPHFcF4p+LVtp1w1pp1kZLkMPmnYbCPoDn/PSif4pxTwRRAR2EkmN06SCbYM9lxz+NAHqlICDnBBxxXB3fiux1PULDT5tKvJYpiGS6dNqAd2I9PY11Fra2ukRTXEcgELDOxFRVJ9sAZPagDVoqjHs1S2t5hLIqCQSgRtjODwG9R7VeoAYsYVgU+VcHKgDBPrT6Kw9X1aGyuYI5NI1K6lmBG63tfMCj/aYHA/OgDyH9pDWdt1Y6dZwCS8jQyu+/wC6p7EdPz9a+b73UL2WdorlgkbksFwME+or2/4571gWOGxvrZNxeWea3WNmzyAxXrivGvDL6bbaq0+ppLJbxk5/dbsntgUALaTSyW/kwSpEf74UAr1711GiWV9HIoS7tbmMj53lcoDweM9feqeqatpxn8zTLB1tZMMRLCq7f90gcdqjTVo9oe4sJrqFeohkIGPoKAMfVoRJdgzNHsQnakJyM57etM8+GOPCxyDAwxx1/Kus1DV9B1C0SCy0A6dG3DSu5Zsd8cVlWvhy+llMkMPn6XGcu8pCLgHuRzQBxOqWwnJkjnREOflVsn8axTbyrL5W9Xj6DPU9Otdzqk+ktdTpHbW8RRiAyIeQPTNaGnfDHXLuyh1NdLkitZiTHJNKI1cZ689qAPOY7OcgPBFuAI4GCD7VPFb75csFHT5FOea6zU7BNL329x+7ugdvlK4PP1Fc7deRaXIZ4JMsoPDYGf60AQzeUP3f3WOGBONo/Ciq975EuJGwHHyqNwIOe3WigDHWYBGWRd5J5Of61IrRFASiADkDdkn61XwFYE5KZ646irYjjkUeSyADgjbk/rQBZikaA7i6O56LjBArRC2t+owWgk6EqefxzWDcL8+VKF+53Yx+tTQywArmBw+dpYNwefWgDTureW18sFJJomzgL0/OrcUdu6CaAGNlyGXePm9ailkaZQsX2qNwvBD8DA9xWWEZC7TzAsD34oA6KMWsQfy5ZSXIJDpkf5/z6U230xZUaeKBW2c4MwFYTXhtAVB3Z6dcVWgd55T9njVc/eG44P8AnFAHTQ3VgHdL21x2ASQn9e1Na8s0Hl2+4w/3WfOD7Gs+OSa2gZwE+bqGHJ9uaRI2vA7GAnPDFMDH4UAXjK4aSG2aUhcD5eT/AJ4q9o5VISxLZzg7uG/Q1Dpd9bwsYGs+eAQSQxNPn1G0KrCLRll3cKeO/fn+VAF6/na5ZFxLLjAwx6D2NTz2/wDosc2n3ytghWhdvmU+hz1rAlnO4rb2bRleGdnyR+PSrUS2xQyMsqt0Lbi3PrjpQB0dul5a2Zl1CMrCw4IbAPTritDw14jjS7+xtcQ2azAqLhYt+zP4ZqhpfiO5ttNTTzdWtxA7EslxGG29uM/0rpvA2jLqN8qLp1q0MhDm78vAjI9O1AHq3hGXR9Fv2bT/ABhYJIYvmkuYS827GSApxkewrt7jxU+q6fJa+E9ciutaUHaslrsDkegfaAPxNeZazouiW+q21zq2n2dxGhGLuK4ZGkxyC4Py/lWL498Y2d7qdjZeH91raxhQzu6ghvQN2HvmgD2K01T4gPoJF/pem2t3GhEs89wFB/2htJANeeeGtT8XHU9Y1EapaQOoa3QXEJmdnzwUbGSvPeu21JPFWm6JYQ+H9Xt76aaAMtvPGhixjkeZnJHXnvWPonhbxTc3Ntql9Obe/MwMsdtIPITvnI5HXp0oAu+CvClzfSzTeJ7TUFvJ0OZYlWNBnq2T8wP0r0PQ/Cuk6HN5um28kb4xlp3f8cMTzWJY6jq1/ql1DB4g0lbePGxkRZi4P0YdK6mBv7Psg2pagJSWGZpQkYyTgAYAGPTqfegC1PNHbxmSZwiDua5nxH41tNCkjaex1Ca1KFmuIYSVB7AZxnPPtXH/ABV8ZwafLJCLI30cSZVgCyK2M7s9MivOfAviuTXri8stV1JU+0H9xai18zf+JPH1oA9Wn+J3260U6Fo2oiR2AWa+iWOHHfkMa8m+IWs6vqWrCHxLeXLwQHzEWyUCFTn26/Ukmu60fwl4o0t54obWwttJkBOySUAlj3I5ArzH7Teanrd/p8/iSLSmilMZRwDF1x8uKAOfku4dVmuA2l2bQhuJoIirnH94scFuntW/p0+hCCzi8P6nLpOpo4M1xeAFR6gYB9c1zfjfw01vriWltr8V+SquXiO1ckZxjpnrS6Dps3286fGtu95nhwCwz/tHp+NAH09Frep3+lWEGnaPLqk7RrG+olkjgzjDPyQSOPugd8VxHxp8ZRRxP4fTQANRfbi6Zl/de6Ec546nHWut8CR6lZ+DhY3Qv7S9ndoo5oI1kWHPRwDkD6V5V8SfA8Wj63Bfa74it5bmdtwF2r5m55+6Me9AGp8N4/GcN5bW0kK29vKcxzO64kOOeeucV7/YWn2SLa0808h+88rEk/QdAP8APNcRoGj3Fpp0E8V3BqGnqgLQWsYVlXH8DZB/DOTXY6HqVtq2mx3diJVhYlQJIyjAg4IwffvQBfooqnrFzPZ6Zcz2lrLdzohKQx43MfbJFAHNePInTT7yaS7gMAiaR4JUUYRRktnqSO1fJGt6xbNqG62gl8sHcu9VQH8u3Neh/E7x34y1OzuNI1S0TS7WUlWiVdruB2Yknj2FeCanKgjUqC6qcbx247Z60AdZa+IYppjHNb2cTvxvClh6c+lbmlX+gWAMWpJNM55H2UhFU/iM15fpt9DA5aZpWHXaehq1PqOX8y2hOGPAY8f/AFqAO0v7n7dqYlitQExlUWQFQMd/WrNhpE88gF3qkdvZysWCj2POVFcTZaqZMlZCsi9OcCtVGd7GQNKkYQjdnnI+tAHqmk6h8P8ARIkjt9Gur7Vo3wbqcqY8+oGenbGKxPiL44l1ZIVMskdnENsUMeEXB5OcfT0rg7nVooLd47TZtPQnBOTxx+dclqt3e3aC4d5CQc7SeMdsCgDU1LVo5JN0y7VPRlPIBPXNYF7dxuzM0rSnPy5HHr/hVMXMksm10VyeoP8A9elmUGNmMKoB0JP9BQBEbhtzFR17HnFFRBSTg4HfniigBVkZRjgr6EZFAchywAzzxjimUUAWDHDxiXGcEZGcfWrNtb4Tlm55JQ54rOq9p7sA4UkYx04oA1WWVLTMUrMvUKPlplnBHdPtlZgcg5/z71VSeVpJkZyV44PNbmlQRyWqu6AsCRnpQBXvtDk8nMGXHX5xj/P/ANeseSzu7UlprZjjoy8D9OtdMl5PbNIkMhCZI2kBh+Rqq3zE7uc9aAKVtduV+SLzI8D7oy2K29Gjso4VuNReVY2Y5wdrDmspXeC03QsyEgHg1Wiv7pol3TMcrg5waAOh1M6BL5n9nXN2zA8LPjOe2CK3PD3w+1vxPayXWnaXd3SQ8GSFep9OvJrz+SV5PvkH8AK7Lw3ruraOrPpWp31m5+UmCdk4x04NAGVq9tcWN09rd2Fzazr+7KupQg9OcjrTtO0iWW4ETSSRu3AEhznmrMPiLVv7ca4kvpZpkkUq0+Jef+BZz+Nek/E+ztRYaRqaW0Md9PCpkkjjC7jjrgcfpQBxV74fS0s1RrqHzWOTGH+Y9Me1WdM17xDo1m1taXUUMDNnymO7cfb9KwR+/nmMoDFApUnqOf8A69bHg2GO7ugbhFcqMgntzigDo9B8Rgzxf22VvYifnt8Flz2+UkdzXrPgjT9B8U6rLYWthLDPEu+aYRB4lGDjGc4J4rynXbK2g0xZ4YUSXzSu5Rjiux/ZnuriTxTdRvPL5bx4ZQ5AP5UAe2Dwr4X8KWMt9ewyyRBgXll3yiPPHCqMKM+gror3V9O0/SPtshP2AD70URYY+gFRWo+2zzW10Wkg2n5CTg8jr61g+NtNsoYtGsYbaKK0nvFWWONdocEjOcfWgDoPDh0S90mK40KKzNjKMjyI1Ue4IA6+ua85+Kyy67ZzmDVbDTrTTJSi7mIeRxj8hnjp/wDW6Lxro9j4e8H30uh24sJMAbrdihIPrg818x6yN2qwxOztGxywZycn3zQB1fijStZksIpj4ps9TiaPEthG+GT35645/E1h+DtPtrvVLZPtVnp9zE2Fmu5Cit3+8MgVja8gWXcuQyyFQcnIGAcUum6fa3GrWUc8QeN5QrKSeRzQB7T4vv0kjtbTUp7bU5lIMUml3m4qe2QeM+9cYdN07QdaS91uwmu3lff9limQyEk/xY+lcR4pt49Ju5v7ODQbHAXa5OPzNdbaRRjwImohF+2tIQ02PmI9/WgCfxfqnhC71uxmstHuIMqvn20r+UwIJztOcc13umy6De+GZbnRdJfTNJhH+lXLSqzsvcdSTz+FfO2vuWuYnOC23GcCu98Mny9CEahdkgJcEA5OD6/QUAe5+HPFVl4njnn07T7sLYqqPeqPLCgdMJnDYx+A9KX4kWVjqunxR6tqYneMNLFFbWXmkcdeCSPxIrwDTPEusrJY6NHqVzHpjlg9vG21WHHXHJr3291O60rwVZy6e6QSPF8zLGuT09qAPK/Dstwl2n2B/Ot87VS5mEBQ+hOeg44r3nw/cPpPh37Rq91EbdMENE/mhB06gc/rXynr8jreS3Kswmcl2YHq3XP512E/i/XbTwGqW+oOqu+GGxDnr6igD3mfx54fTR7jUYb5Z4ov4VG1mPoN2M14PrfxYur3VLmK21a7srebd5aiblPoRXmPiJ2ZS5ZgWGSAcAk4zwOKwtIjRJ3dVG75uSM98d6ALXiXVLoTtcm+lu5XbDNI5Ynt3rlr3U5FiYyRgxPg4GBxj0q1qEryXRRmO3BOBxzx6Vz+sKAxxnqOpJ7UAWkfgPbRKvGTv4wfrWlDcwC0RQm5gMHjOPyrn7AkREgnrjrWkihLMuuQx6nJ9aANi3ltlXzJR8w5Cqp/z2/Wq1zq/mpsWBliHJGc49KpW5JkZCSVKAkE+uP8arrK6JtVsD6UAJd3ULbcMVwOhHSmyzEI4lZXXGRkcj1qlfOfNTpgLxwKrOzOcsSTQBJJKjNuVWV/UNTN7YwGIA7A0yigBScnJ60UlFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound imaging demonstrating cholesterol polyps and thickening of the gallbladder wall. Note that the polyps appear much denser than the surrounding liver tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6819=[""].join("\n");
var outline_f6_42_6819=null;
var title_f6_42_6820="Achilles calcaneus enthesis";
var content_f6_42_6820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Illustration of a typical enthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 289px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEhAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKz7XW9Ju5ClpqdjO4uXs9sdwjHz1Uu0WAfvhQWK9QATjFWrS6t7y3S4tJ4p4H5WSJwyt24I4NAE1FAIPQ5qtqN/aabaPdajdQWlqhVWmnkEaAswVQWPHJIA9SQKALNFVbzULOykt47y7t7eS4cRwrLIqGRiQAqgnk5I4HrVqgAoqna6pp919rNrfWs32ORorny5lbyHAyVfB+UgckGltNSsb11Szvba4Z4UuVEUqsWifOyQYP3WwcN0ODigC3RVG11fTbtbNrTULOdbxGktjHMrCdRjLJg/MBkZI9ae2pWKC7L3tsos8/acyqPIwqud/Py/Kytz2YHoRQBborP/trS/ssdz/aVl9mkAZJfPTYwJwCDnBGeKktdTsLs/6LfWs+Tj93Krc/gaj2kU+W+pXJK17aFyioWurdZZomniEsMYlkQuMoh3AMw7A7GwT/AHT6Gizure+tYrmyuIri2lUPHLC4dHUjIII4IIIOaskmooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKoeILsWOhajdscCC2klyP9lCf6UAeN+FGGn2PhjVpAxM9xdaqwzy7PbpECf8Avo/lWvZa/ead4XtrK2cGW3URh5Oc/MTk/hiquowi10XwzagnEGnLGM9Twh/pVR1H2CP/AG3Ax+Br5rFYyr7WUU7I93D4an7NSa1NRtXmvdQ0I3Zylnftc5zg4ETjH/j1WPFeuJ4j0s6VIpEMt1avvHby7iOTP/jlY1lze247jzG6f9MzUMGGuYz283I/M1jDGVoQVpdTSWFpSk7o2Ne1e8vPEumyXUiGCx124hQAbSY1hjZR15+Y9a2NL8XXMt8kcqgIzKAR79a5S8T50ZiCV125bkc8pFUujDOpQdOHQ/rXXi8XUU4qLsc+Gw0OSTkhdH1OawsvGMUcjZ1LWrx1ZuTGrRRqOvpWpoOuxabqq3BhAjTT4LEKoydsbPjn/gVc7EpRLtTw322bOTnnalKPvHnoB/M1zVcdWjUdpG1PCUnTV0b/AIQnW1l8HR3D7zp+n3ULsEAGcptP5J+taWkanajXvFMM7FrfVrzzIyB/D9ktoSD+MT/pXO6ZkXWnEdCkyH/vkn+lR2JzrERHUzDt71u8yrKEfMyWBpOUvInlm8zwrpw352gpwMfdmkA/TFT6HqKaTa3uozJJJDZxPcOkeNzBVzgZ4yfeqSEt4bt9+QVklGfUCZ6I1DaBrCsOGtnUjPY4B61lzc2KUma8qjh2jt9euZLO+8W3mxDHHoMMiZ+UllN2SC2en3fpz61seB7drTwboUEhy8dhbqxxjJEag/yrlPiTIsdr4y2YWQeFpjv5yo/fY/r+Vd1owUaPYhMbRBHjHTG0V9OeAedfGXxzqHg/VPDtvZ3drZWt+l49xcT2b3JTyo0ZAERgeScE9s56A1z/AIh+JHi630rwe9raW0WoavptxezQw2jXZLIoZAiq4IVgQTydue+K9I8SQeGbzVLC91uOKa7sFnjty7thVlTZICoO1gV4+YH2rLt/h94K1Cw063t7OZrewSRLUR6hcKY0kPzqGEmcHHQnFU4SSu1oQqsG+VPU6LwRrJ8ReENI1d2t2ku7ZJZPs5PlhyPmC554bI59K26qaVp1ppGnW9hptvHbWdugSKKMYCirdSWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxfxevWsvA10U25uJoLP5v+msqxn8fmrtK4X4sAzWnh60CeYJ9Yt9ybAwITdJzn0KA/hSYGB4xUR6jDEPuxoyj8CBWXIP+JZbEAf6wZ/Jq1fGn/IY/GU/hvrKky2mWmM5MuB+TV8jW/jTPpaX8OIyyYJcGU9IoZX/8cIH6mq9mX8q1kc/OyrI3sWGf60pz5V2ctzBtBHqXUVb1RDHeFG5KYBOPasmv3SfmWn+8a8iSeNHsrmQE5TWHddvTkQg5/Ck0Rguq25P95f8A0IVIF8zSLt8YEep7l6c7mhHeq2mPs1K2JGQWGfzFb1necJeSMqStGS8yqvyzaqmcbNSnU857JTwpBZiDg4AP50joYrrWA+d7alO559QvT8jT8D5/UorfTkisayvUkaUvgRa0/wD4+NKYclZmXr2ZGz9abYnGrQ+0oPX3pNPYC6tCThVnUfmGFNhJj1NCeof+tEneERpe9InYBNBjUHdtllGTxz5jGmL/AMi7rWHKf6M/zAZIPGP1pW50UqMZFxNn/vs/40ttA93pV9bRRmV5Qi7AMlh5ibv0zXTF/wC0xMJfwGdB8RIvP1XWLTJU3fhS/UliQvysg7c8eYc49qmvPF8el6DpNvAjSzvZxOSDgDMYx/MVd8XRGXxZaIoT5/D+qKezk+ZZ4wfTk/pXmN1lrHR2zndp1t+flLmvuMBRjVn758ZmeInQp+51IrmeW5maSdy7sc8mtzwZrEmmatECWaF/kK56da56tOytpLL7Nf3NrcTLJKsNrbQAebdztnbGm7AHCsxYkBVVmPAr2q/JGm1PY+cwyqSqp09z3S0mFxbRSjo6hqjtNRsry5ure0vLae4tGCXEUUqs0LEZAcA5Ukc4NeePp81/bRN451Q21icE6BaMFgVf4EmlxvlP94AqhPG0gZbsvC66LZ6VFa+H4La1skztigQKuepPHUnqT1J5NfNypytzJaH2cXor7m3RWVea9p9nKEnuEVj6nFX7a5iuULQuGA44pOnKKu1oO6JqKKKgYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB498Vvi/eeENVjttE0SHVIICDezPc+WYyGIaMKRndjaQ3I56GtT4a/GTw542SG3aaPTdZkZh9gldmIwQOHKhSTngA5rmL6eK/wBT8TJjaYtTmhbBPONp/rXkXxL0fTvt1vELZBcSJ5nm5bIAJ461ySxXJK0lod2HwLxHuw0f9dP8j7RqO4nitoJJriRIoYwWd3OAoHUk+lfJ/wAPviR4l8Nz26XGoSarpUIK/YpQqkjGFxJtLDHHXjAxXnfxk8f6p458TLLe2CWsFvAkKwJJwSMtuPPJ+c/h+NawrwmtGTVwFejJRnHR9Vqv8/wPs6f4h+EoP9Zr9gPpJn+Vaeg+JNH18SHRdRgvPL+/5TZK/X0r831gkdsC2HPTDj/GtCxu76xnjuLRWhuF6SxyYYfrVOqu34mccHN7y/8AJX/m/wAmfoTr3i/QNAu1tdY1OG0uGQSBHByVJIB4HqD+VZyfEnwg/wB3XLY/8Bb/AAr4cuNb1a/uzeagjy3rAB7t5QzuoGApyenAH4U+a+1K8t9jKwVs4AdDisJYlp6JW9f+AzRYGb0Tu/KL/Vr8j9Bra+trmxS8t5lktnUusi9GX1FNtdRs7u4kgtbqGaaNVd1RgxUHIBOPXafyr88/7Lu5AkTsyAAhcngc9MA+9bXg5P8AhE/F2g6q8hlW3u45ZY1UfdV1JAz6iq+tQNv7KrWv+n/B/wAz79opkMsc8McsLrJFIoZXU5DA8gg0+uk81O+oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzHi6BbrWvC8Mm/YL2SUhSACVt5SM/jiunrnNdV28XeGOnlK1yT8ufm8rA57cFqAOO8crjVoj6iU/wDj4rHiG+0skJwPPYfkrVs+O8jV7cc42S8f8DWsa3yY9OUKxJuJDkYwoCnr+Yr5Ksv38kfR0v4MSsJXihkaPG/5AMjPV1q/4jjEeuSDuU3fqaoAD7jd3QdcfxrWr4khafxlJbQqXmOmrdBAf4PNCk/mainBzou3RlTmoVVfqQQMraPdE/Ltv4mHvueIVTgyl7bZJGJBnFX47aSLSdWWQEPb3NruXoRukiI/SqFwNl4gB6Ov8hRVTUYOQU2m5JFnV1K6vqQJU/vt4A7AmTr/AN8/pUEQzuGTkxLjPsx/xrS1+IrqbsAB51nHISO5V5c/+hrWbaAG5iBHVHU+vVT/AI0Vl+9fmFJ/u0RiTy4zLnHlusnXHQn/ABqec7L8kdnzVK6H+hXSdSUYfrVq4O65DDnJH8qxv7iXma295ssPkaZOnOEuXGcdN3zD+dOs4xNpt3E5ARmiznGOJUPf6UyQ4g1FMHd58b/XMYpYcnSLsLjd5kOOn/PaOuul/vETnqfwZHdeKCqeM9ALk7ZrS7tcdjvktjz/AN8V5JBcG70DRphjakH2bhcD91hMf+O17hq9to15qFhNqUMMt1ZvvtnbrExI5H5D8q8K0qBrbw2Ld0KNHql+dp/utOzLj2wRX3OWzXtrI+GzZxlR0eqLmlwPc6jBBFje7bQT06VnfDXxxP4j+KfiOaOzaex0aGaO2upmPl2UORGEiUDHmTskTEsePLk28EipNVuLjTfCev6nZyNFdW1pugkXqrlhgjg+h7Vy93oPjDwR8UL+28H2cNp4X1m7tbV2nMUcF2UhLthnzsBInPy9zgZJXPTmFSLqxg2YZPDljKb6mp4z1q61fXroNI2zzNoUE9ia9F+Ftv8AYtKtmu76GFrlyIYpZVVpCRgBQTk846V5Tq4EWrvKskUg3glopA67v4sEcEBsip/F3w2g+JPha21DRZmj8V2NuLeGBpAsV0iktsJP3X+Ztp4B6Hrkezmd4YNKktND1KestTX+JSXMGugTmRWWJDg5GOB2rv8A4P6608NxBPJuOQRk89QP615R4dtPEl38N0n8bW1/Bq9rPPFGdQR1nmhLRsGbd8xwzyAE8YAA6Vd8A3c1tq48tsBimRnr860KMcZgV5BrGZ9RUVDaOXhVj1IH8qmr5Bq2h1BRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD58ljNv4z8a25UozX4uAGxnDr14J/u5/HoK89+JAJ1OzkcDHklcnj+I17H8TLdNP8AiBbSARp/bFmIlAABaSAyMzH1O2RB+H0rx34kKFFvIAdytsIzyeWrzMSv3jse5k8nGqrvf/hv0OOtgs1xlm4/zzRFbxxvPCPmckSDPGRhRVTzvLu1beoDLgA96lt59+qO+04SPG38v8awaPpa9T3V6m9HOERBEu9sAjB6+o+v+Fc75ry3jhlBVVBAJ71rW7iVGQEJnkZPvWLDtGoSszAKyD86UUrM45t3Wp0nhK4+x69b3EkZAZXTZn1U85r07xNotrrb6P8AaV+WNrheCxycxhe49DXkccqC4jeM5kBGAD2r2rTWN5bWzHOVlVvzJz/KlHc5Mc+WHNHSx4fGpVvvnBAIBHtVLVTvePueTn16VozLi4fBBVcLkf7o/wAazNTIRoM/xFlH6VN2+p3wjGOqPtz4ZS+f8PfDsh72MX/oIrpq4r4LS+d8LPDbDtahfyJH9K7Wvdi7q58ROPJJx7BRRSOyopZ2CqBkknAFMkWikVg6hkIZSMgg5BFRJdW73Ulsk8TXMShpIg4LoD0JHUA4NAE1FUzqmniQxm+tQ/nC22mZc+aRkR4z97HO3rU1ndW97brPZzxXEDEhZInDqcHBwRxwQR+FAE1FFFABRRRQAUVDDdW8800UE8UksDBZURwTGSMgMB0OOeamoAKKKKACiiigAooooAK5rxA2PGHhVckEvc9+CPJPH16H8DXS1zviLK+JPC74BH2mdTn/AK95D/SgDkviAB/atp6+XN+W9KxdOyZdOTnDSyjjuducfpW58Q1K6rZ9MGOf653x1i6Xjz9MPBP2ph7j93J/hXy1Zf7U0fQUn/s6ZRkyr+mHXH13iuy0nRb+b4q22v8A2cNpP/COmxM/mD/X/aQ+3b977vO7pXIXo2Xky/3XBxj3Feq+EJvN0e2JPO3/AAroymVqkosxzGN4KRzviPRNVlufFf2W08y3vo7FoCHQEujkSkZPBVQhGeDjjvXJ6zEY9QkXbydrKMYz0rs/F/j6Tw1rtnpj+HNVvDeyCK1mgaHZM+3cVG5wRj3AqpbfEG11TxbJ4eOgXpuYJIop5JJIAIWkQN0L7jgE52g9K9HG4H6zZp2aOHC4v6vfS9yjrlndyJp1zDFvRY3gn5A2xt5bA++Njce9YVhHNJNGYULMjZYeg2kH9dtbtp8VfDtxPqFuLO7FxaajHpzW8oU7t8hiEqAn7m4EH0445rqPG+iLdeG76LTkMF3L5YR4WKMP3i9COnGa5q2WOTU1LY3pY5JcrW55o0e64ljPyhmKg00kmOIng7E/kKlnnSeVLuHAjuEWZMdMMqsP0NQHiPnouR+RNeC9LrzPYWtmWrliLh48nbJBHIR7gBa0NDsxqEFxal2jEw2+YoBZMEMCAeOqimaPapqniiy0+R41M+lSTD+9lZUGfpzW78Jo49X8GabrJVkkuVd2Rhggh2X8OAK9PD4SpOcaiWh5+IxMI05Q6mB4kuppNSDu7AhQaw7tdqXEbckSCUH13Jn+YNb3i6LytUTHKmMf0/8Ar1jTDfI24jLwBj6naWH8iK9HKqjp45I/KpN+2nFlO4l2+GtW3YKrGrEH2b/69T+IbMa3Z32n32Zo7xNjI/ILcFTg9wQOay9VcJ4Z1tmG4C23FfUBhXRamiQ6jLHHkNkNzk9gep+tdnEcJQrxqJhUco04zT2Z5fJP4atZ7fw7o0V/b6nyZIJl3Kkw3FlDcHBA3DAx71qeGtautC1eBgxCRy/Oh6HnBFa+q2uraX4m0HVNE03Qr2z1i/jtLt57QNeqZFkEwE33liEcbPn+HHORuBpeMdOhjv57uymglj3lJjbyiRYpxjzIiR3Vjj8q+syPMFi6CoVddD6mhLnpRqeRS+I/jXxFZePEstUv4r3w3qMEbWwMKqQAmyXawAIYSqWIOeNvQGp/CMUo1gLEC2Nhzt7b1rQ8LJpHiGOLRPEunw6hbTTYjWTKumcE7HUhlyVTOCM7Rmn/ABR+LvhbwO8en+CLfT9X1ggxu6tugtQFwmWH32DBeM9FIJBNVPEf2bGVCSunsdKj7TU+jNO3fZl3dcD+Qq1XnXwG1fxXrngGLUPHCqNQnkDwOIlj8y3McbI5C8ZJLHoPTAxXotfMt3dzoCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHAfFzQkvbPTddDlZtElMu0DO+NyiyDOePlGc+3414V8S7LzNK+1x9VMcg9NrZ/+KFfUuvaeNV0TUNPY7RdW7w7v7u5SM/hnNfPmqaebvTptPutpeCVrOQn7paJwCeR0+XiuPFx2kd+Aq+zqJ+Z4TOQZEYKcquN56D8KXSpxNd3TqCBwFz3+VP8A69VtWeRYzHArNMT5aIo5Zs4r0Txz4EPgePQ9NlEbam9lJNdzxuWjkYznaBkDkLwTisPZ3puR72IxKjiI0e+pzMBTaQpKk8hmPA9jWaCkeoOHG5dg4Hr61bYgAKeNwycVSkIiv23rnK9QM1gupvLp6l6MxAKYjJu3c5Fe5eE283TomPXCkY+rV4KlzGY1jiB3btxYjtXufgRg2lWJzkOAo/76NKK1Rx5i/wByzyDUVNteTQORlSCSP9wVSnt/tNkZgCRA3PHqDz/47Wj4j58QX3YBk/8ARa1c8P263Ok+IkIGY7Bp147rx+fzVCWp3c9oc3ofTP7P8nmfCTQgT8yCZD+Ez16HXk/7NGoC8+HAh27TbXUq9eCGbcPp1P5V6xXt0vgj6I+RxemIqJfzP82Fee/GeDVNV0TT/D+kadcXv9qXaLd7CURbeP8AeOGlwQhbaFGeuTj0q7c6le+LdVfTvD9zJa6LaS7b7VIjhpnU8wQH68O/b7o5yV7WrOc8D8PnxdpvhTRtC1Cy1+y0/SdRmtb+XTome4kttpaAxMq5ZNx2sUGcKPWodW0jxE934o1nQ5fFltcw6VZvZO8JWa7kVn+SQbDvIHVRg8/MK+gqKAPELqz8QX+q2sl3p98yQ+NLa4Q/ZWAW3Fud0nA+4GJG48Z4zWJa2njPTfA3haytIta06xH2/wC0/ZLaUzxTG5kMRdEUybdpyMDByM8Yr6KooA8KurvxwfE2gljr17EYbNJYoreWzUNgebIzBWjOerLIVI5AxxXUfEbS7uT4l+BdUiXWGsoDcwzvYRmQQswTZuAU7Vc5DMeMDqOtem0UAfP2kXPxDQaxJqE2uLqn9n34kthZyvCZgjmFoH2+WCGChQhJbPIzVnUF8faZbXiadd+Ir37XoNpdyvLFvkhuGmCzJD8oAcR7js69+uK94ooA+f8AT7XX7N9duNNg8UR6Vda3atczvbyC/ltBBhmQMu8/OFB2jcB+NbOnW/jPVW8I2Go3viCws7htSFzcxKEnWFdptvPbaQjkZ64J+ua9nooA5T4V3GsXPw+0WXxKtyurmIi4FzGY5chmA3AgHOAOvXrXV0UUAFFFFABRRRQAVyvjdhFfeG7jC749QIUkgEb4ZEOM+zGuqrm/HMkcFnps8zuiR38K/LGHJLtsA56csOaAOc+JAH9oadjBys/1zmPj8sn8K469eWLw/qE9sFM9uoljy23ndt69uHNdn8SQRcacf+mkg6/7J/wNc9oViurS3mmSEbbiMKQeeN6n/wBlr5mur4yx7tLTCkevqF1u8HY8gfXkV1/gbVILWy0m0uGcTXbNDDhSVLBGfBPb5YnP4VxNxcG8h068YYNzYwSMPQmPkfnmtHTrz7HaaNP1NnqJfAHrDLF/7UqcNUVHEtvYrEQdWgktzqfHFjYah4x8FR3WotaXsF5LcWsH2ZpBclYiWXePlTCgnJ/Kuc8N+E7TWPiBqvi7RtXsZ43vYvPgutFzNAyxIdkcrsGQlXU5C9x1xRc67Nqfi3whdSRoFtLucOT1xJCUGPxbFT3upSaLr2ufY+YNRmhvhg42uIEgZeO2Ioz+Jr2v7Ro8ntL6HlrBVefksZFp8N9H8QsZrHV5ft+h+Ip5p5/sTJuzIsz25BYbgCUw4JHXA5r1Ww1yw1EWAtpJCb22N5AHiZd0alAScjgguvB55rzzS9bfRtR1KW1T91qEi3rp6TEuHP0KiMf8Bpnhi7Eet+EpAyRQ2rX2mOueCJUFwn0x9nI//XTpY6lVlyReoqmEqU480loZMsSW0K2q43Wc81sRnkKsrqgP/AFWoH+7IPXn9K0vEdu9t4l1yPYVWSZJ4ztwGGxQ31+Z+fes1hlsjGCu2vmsVHkqyR7uHlzU4s3PCvHjzw3JgYOm3ERO05z5hbGf+A11Pws0y80bw1LpV9DNGbScxxtL/wAtFKI24HHIyzD6qa5Tww7r4u8MFSRGyzxMexOyVtv1+XP4Gu28eeMrPwfa2L3cTzT31wLa3jDpGpYjOWkchVGO5P4V9Ll7vQR4WMVqrOU8d2U8F7DOykxsojyATzjPQZ9D+VYeqWFzYw2Ms0ZyzyQttXO1W2HJ/I811WsfE2PSE0Rb3QL8X2qtOsMCT25GIgpLeZvCFSGBBz2I61L4uuGvdAsr4xNALmPzBC20tGChOCVJB+oOK6MHgoxxKqXPlsVlkKfNXT+R5feWkt/oWr2lum+ae0KIvqdy8V1UMena9NpU+neI7SeTUIUZbITLLIjeUp2oq8r0YsW6YFZnhmYQ6tE5O0hTg5x2rsvib4kn8IeHdAutGews/wC0dUt7Oe4lt/MSOORXZn2qVyQRnr6+tepnNCNZpSM8uw1PE0nCZmaxp+maYZtL8UarANMksZbuOyiDJepNGhZpYHT5vuJMcDk5YdMiuK+Evw/kup/GV1CL8eF9SufO0xr5gXnzvBcqSWyG4y+GPGRnIGrqXxI8UtpHhaYWVsLu+v7uFJ00yWdpo4lwk8UO4ONwZhjPTPbis34wadpk2m+EtV8W65faRp1nHJqN1YWOjzxfa5WlVzwDsikZ2x+8Odzk55JrhoN4e3s3ax71OjGlBQjsjC8T+HpdEmeGYyYki6p1GRj+teezfD3QNRtyiXl1ZXmfklKK0J4IAZRyOSDuBPGeDxX0LrnxJ+HGv+Dx4gvNS8q1mke1VJIj5+9WjDYTqcCSNjjPysPpXA+N9AfQr2NFAaKRAyOpyrA8gg/TmvrcLiaGZR9lWXvGcounqj0f9myz8VaX4Pu9O8XTxTJbzhLArdLOywCNQFypICDA2g4PJyBxXrteD/CXxIbSee3uJAFYLt3HvwK92Rg6hlIIIyK+ex2EeFquHQ2hLmQ6iiiuIsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxDxZGE1rVVCbQt3kg9yUUk/iea9vrx/wCIcJTXdRYcGWSNx/3wF/8AZa58V/DNaH8RHh3gHSLfUPjloenTRb7Vb2ecoen7oSOufbKj+Ve2/tKWFonh7TtWkizdR3S2u8f882RyR6feVa8q+FQI/aN00Hji9P4bZK9s/aItDc/DiWUAkW11DKQPc7P/AGes4r/Z2erXmnmEL/3V/X3nyxMI3UGNNgB2njAB/wDr1WkCmXY20MB1PcVM7FcseV6H6djSSRqXBdQNo6juPSuFHsN6X7Efl20AzI6bvQEV7B8PZM6LpbIc4PUegevJlsrSSLehjOOmGFeqfDLLaJYAgKoYrx/v0RVpI5se+ahI888WxbfFGoJkgBkbH/bNK0PBPz3WpQ8fv7GSMD1yy1R8YM7eMNTZs9Y+Mf8ATNK0PAGH8SWiHo/y4HuwqOp0P/d/kex/sqSZ8I38XGUlRvzDf4V22oXtz40vp9J0SeS30GBzFqGpRNhpmH3reBv0eQdOg5yV8f8AgNYajq669odhdfZNGV4hf3MTETMP3n7qM/w7udz9QBgcnI+kdPsrbTbGCzsII7e1gQRxRRrhUUdABXsUf4aufL4y31ibXVt/fqGn2VtptjBZ2EEdvawII4oo1wqKOgAqxRRWpzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcP8ZR/xQ7yFlQQ3tpMWK7sBLiNjx+FdxWR4vsV1Pwtq9m8Zk860lRQOuShAx7+nvQBy3xNANlbSgZXzA2QOxz/AI1geEpfs/iOKT+8j5/D/wDXWv4ieO88HaJLBN58cttCyy5++NoOc+9czpdwlrfWl1M4SKNm8xm4AVo36/iBXzWL0xit5Hu4bXC2Ytzb/Z7G3j4xbXNzY+uBHNNsB99mw/iKgMn/ABL7heu2RJfw3Jn+tbOvIsd34ksiCJYtRXUI1I/5ZvDAC3/fZkHrxWNAqtcbWOUljaI/iCR/IVhjIcldruaYWXNRXkI7iCGSU8+QyT4x/wA83Dn9FrV8UADUc5yAOorLtkEjLFcnKvmOQ+zAg/oad5k8thbC7bddR74pT/tZ3D/x11rBP9y15m7X7xMSbhISB6qfxx/gaq6nBdXPhrXYrAlb2JYbq2YDOG3GI8f7rvVwjzLMMpHHB9uK2fA8yR+Jrcy42TW0kZB6EqVcfzP5Vtg3bERuZYlXoyLvjyaG5bS762IaC6jfa4H3gypIpz+FcoO3T8K10Kn4f2NgMfbNAnawkjHDBYXeGM+vzJGGHqCD3rIGD0xjrVZnG1dsnASvRRejmEGhx3TMUGmahb37MP4UWVEkH/fuST+Vdr8Qbe21ifTNBfVdNtby7Mksdnf2C3kd0qAbvkYrgruByGB571xemWCaza6lokzmOLU7ae0ZwMlRLHtz+BIP4VetfENzr/w80bxReW0Vvqem6lHLfW7jLW6GXa6k9VxFIsn0AzXsZVK9Gx5uYRtVuO0/4P6VYP4ZF9dw31lpM17PNaXVorQ3DXCqMKpJEaoVBAw3Pp1rr9cOkx2kWmrsto4bZniRISIkiRduAQNo25Hy9h2xWZ8RLuaIwRwyzRA5yYmxnjv7flWF4LuF+1XVjK+9bhR5iSSFt6nCnIPbnFdH172ddQsfMV8xj7b6s4nISoIZ8xvuQ/MjKeqkZB/EEGvQLFNL1XRLB9Yh+1Np08OowIZ2BimjBVGCqRwB2OVOc4Oa85hVxpGliYkzpbJBNkYIkjURuCO3zI1b2koi6jp8yjP220uLSUcffASSPPr8tu4/GvpcyvLC863PLwlSVGrJQ7M6+bV9H1rxBpdxfWJe906VzaTeay+WzDax2ggHI45zUfxFsrKS50fX4tQ0201iAG2hh1FsQ30EuBJbsACfm4wwVtpHQjIPHSbLe7fzSFiRjv3dAvfPtitY6DE+hzeIdG1JtO1TR2kv7K8vo82UcTwxmaH3gbyyWK4ZGZiD2PyeCxM6snGZ6OVY6riJyhV6HhXxN+MOn/E7wzb+HtO8DTJrszeXbPHN5rW5MsbkRKqAuXCYPC496w9U+IninWbTRdE8TaeIZ9McLEwt2imlB2qqMp64wQCBz/P3DxN438cT+KvsJ8BvBps0CI2qWMU87IWUkuJmijwoyAVKjGGwSCCPNdfhn1UxC/lea4gz5UjHJX0wT7819bleBlVXtoSs0etUnbRoubZbG5CuNsoA3KexzyPzBFfTPgS+a80W2LnJ8lT+pr5ov5pLi6WWUATOoaQDpuJy36k19E/DL/kC2/8A1xH/AKE1elnkU6EZPczo7nZ0UUV8kdIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmvxJhxqYfb9+JMe5BbP8AMV6VXCfE5c/YyDg7WAP4isMQr02aUnaaPC/hzGI/2lrBF6LFeZ/KQV9N+J7K11DQL62v4klt2jLFGGQSvzL+oBr538ARg/tMQsFwPsF1L+cjD+tfTUi742XsQRRhlamrm2Nnz1W15fkj8/reciEAkjjripYJtyGMnsSprOicmPb12nH5VKJiGJPPY15yR9NOS5pDtr/ZsHaDn7xNexfCpdvhiwKkEGQ+38deOTW8MPViwP1r2z4XwL/wjemrnCkbgT/vU09UceNt7Fnn3jRCnjDU1/i3R5/79pWRpkskurW8VsXWNpkiZ4yQxywGFIBI+oq/44mjvPF+p/ZJg9qHVGmQ/eIRQQPxGCaseBIEXxNpAIO1bhCoBx/EKUbQkm9Te7qUNNrfoe2fs96fHo/jDxzp8RykT26ocAfKpkA4AHY+le5V4p8H/l+LPjpB93bGf1Ne116dGTnBSlvr+Z87jIqNWy7R/wDSUFFFFanMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeOaZiPw5qOmxN+40nV5LCFNuBHGiREKB6DcayLmxfVNKv7CEMZLiEIoU853qf5Zrp7zThpWt+JbJXDLeSw6vgno0jyRuBz2EUX51laDObfVIpByUBOPXg183mGmKT9D3MHrh2i5qoN3qtjrxbMGtaHDEvJw0ih5+PfGPwrFWN2VkjO2UZKezD5h+orpmsk/4QPyIiXm0DUpQgZuVVZHwM+8Mi/nXPwsovEZD+7J3Kx7g9P0pZmrVYyHgHem0RLMk8izwgrHIRIoxgjnpj8Kt6kv+kyMAAsoE2R3YfIR+QSq13F5F1LGMbd25R6KRwPzqzeq01lbXAP8Aqnbf/un/AOviuFL4onW/syIbMZiuYz0GHH4gj+lMi1A6RjU8bhZkyMMdVZWQ/qyUQOI51BHyuDESO2SMfyNT6YImvFjugWgdSHX1A5/mBSpytKMhzV4yRu6zpKaV4r1q4jZHi8QRpeY9JIFijwPqhZq5cDaw9srzXTX06/8ACC6LeXAY3GhzfZ7on72E328h+jbdw9iK5yVC00iKRuJJU+/au/NFepF+Rx5fpBotaFMbbW7WVc4DY/Hr/SuksLGxWf4iaFKFttJuIo7lmGW2xzWvkuQPQeQTj13VxvmeWRKB9wh/++ev8jXSX0cieMfD2qv/AMgu8t59GuWBO5ZXcmHjuDmQZ7Z963yepZygZZnC6UyDVZtVm8L6Vc63DDbX4EqzJGwmXYGYIQwOOUCn2JxWbohdNYt/JSPzSQpd1JCx713AY7njGeOKteHkvbnwDb2+pALqljPcwXMeMbSWMsf5xSRn8azbO4FrdRXGZMRkMVjON+CDtP8As8c/WjFrkxF2fnGYr2eM5nsVNZVodd1q1dWQQXrMgIxlZMyHH4vVmGZYNDN6dxOmTQXuFGTtWQhwPqjuKk1yC2/szw/e2CTi3vLNYs3B/fMVRNm/1bauM9+vel8MiO5mnsJziG6haBz6Bs5/nX3Mn7bAu3Yp+5ifUS9O67eRRw5WQceoB/rW/oMNjf6p/Zt/qVxBLrGkvbjThGWWSKPKtMrcop/egbSM9OtcyUdYxFL/AKyEtA591Yj+WK6nwbLIupaL5X9mNBGZ4JpbsAXKs43KkLeh2nK9wB6V8Pgny13FhlUuTFuL8zyXS/Bfjbx/4e0DUtN8Usmh2E0yrcvNKj3SCUOziABjuWQSJ88mCI0ICjlk1jT7uTWSEtpBuIP3fU1seGdI1fxP4RsL/wCFv2vS7Se7LLLc+IJ3GntHMm8fZVAhcPtdiDv3b88ZxT/2ldV8U+BPFXh7xPpM6f8ACOER2s9kjbUkmWQysHXph0UKG5ICsOO/2GX5j9T5ly3ufUzhzDNZ8O2umvarf31vBfTqXitXkCySKMZYL6Z4+vTNX/Bvja7s7zyJAqwBCqjPTBrybxz8QdM8efF3TNc8PWl2lpb2MFu8d55cb5WYs2MMRjDDHOSc10qfu9Wl5wFZhx9a93BVPr9GXtVcxkuR6H1lZXC3NrFKvR1BqesTwjIZNDtCTn90P61t18lVjyzcTpTugoooqBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVznjz/kAt/10X+tdHXP+Ns/2N1OPMXP61lW/hy9Cou0keIfDGMyftG30h6R6TKB9DOa+j68L+GtpHH8ctTnjD5fRssSQQSZz0r3SnS/hxIcrzl6/oj4D8Q2TadrmqWuMC3upYuPQOQP5Vlyx7j5yMASNp4r1v9qSwGnfEe2vLWNV+2WKPJgAbnDspPHU4C8mvIDIpLTKCYmBBUdq4ZQak4o+kpVeelGb6ouyAHDRsATjgCvVPDry6pZ2GjWTvHYomy5uozgvk4MaH8cM3bkDnp5JAstyIyQ3lqwDsOAeegNe6aKPs8WnJGiRxptjAA4ABApKPI9dznxlTngktjy/XrSHTvEV/aWaqlsrbkUDAUN82B7Ddj8KTQpni8VaJ5Z4S9iB+mR/hVW8na41e9uDyrAY9eEWqekzmPxboIP3pL2NsewYf41hFXmejVly4bXsfTXwkTb8W/HhHTbD+pNez1478GpFf4j/ABBycvutMfTEv/1q9ir1KH8Nf11PnMW71b+Uf/SUFFFFbHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcP46t0i8QaNeuVVLiKfTnJ9SFuEJ+n2eQf8DrhoD5V0NwwQWU5Hsa9N+IGjSa54ce1glMFwsscsUoXcUIYZ491LL+NeWTSfbk87Hlm5US467CwyR+ByK+ezeNqkZHtZa7wcTqLdriPxfqti2RpuqaQl4C2cNcgeU4H/bOBD+dcy8IsZWt1+7btsXP90dD+WK7C9uFk8NaBrQYqbC6jkkUjho5MwyKfoJCfqtY/i6yFrrEx7Ehee45/wAKeYx5qUKiFgZctSUChqn+stpOokUpn3BJ/rU1j++sZouxzjP0qOLM2ksDzJFnqe+Qado0iidlPAbBGa81fGn3O9/C/Izx88LYOGC7l5/iFSPIEl85eV5I+hH/AOqn3CfZ7p1wcFiw/OocFS0Lr8kZwhx95eo/w/CsrWXoXv8AM6iztAmp6lb3TrLZ69AtykeOI2hCLIvvuyz/AJ1zEYMLorn54m8tjn04rXguJZdES6tYftGo6HItxHEPvSgho2T/AIEjCs27aK5unkjYPbT4kB9QwB/lXfjJqpThNHHhYuE5xGTgRTMGGV4fb6gjn+tbkBeT4da3brJ519o7/brfPLs0W2dP++mV1yO2axGB2EOQZbciNv8AaUjKn8iPyqx4e1E6N4ksbtmBtxi3mTHzbHbasmeuEZuf+untSwE/Z10n1HjIc9HTodXpvlTeNvEtrFOr2+pWdrq0QBBzLtktpdp7gLDb59C3vXH6jam0uihGM/N+tXrLwrdaJqb6J4auntr3QgdQ0xXwUvLO4Iaa0dj93dcwbiwBKq0YGckVb1Se08RaTBq+lLKFDPDNBJGVkglTO+Nh/eBGPQ9QSCCfXzChzx510Pg86wrqU/ax3Rm3TnU/Dr20LtNqNqRcBTksSXPT1Hz4+mKwbG6NvPHcQnsGB9QRxW7oWpf2ZeieWWNLfHzGVtqrjkHngc1mXti1te3dikKraxq15psytlbm2ZlZwP8Arl50KdeRk17GQY6M6fsJnkQUq9L2kd47mpoqwazr95p5kMdxexjUYzjgbRGkn47ixxTtJ+32vja30TUvCmpGyt9SSaDV4X/ck+U+x3yMEH5lIU/KcA4JGcHT7xtM1Sy1GNd0tnLux/fjOVdPydiPcCurstTvbrxrpsN/qWutbarLBfafDB5SwJHFFI0kTkANgOy7s5Lfu8HAYB43LadGr7WK3PUy2NGrL2jXvo5vVZLrxboOueKfAOgSWV15f2ZJbDWZLO+aWJcoZbVF8qTaXOFkbcYyCPvKteSeKdB8S+KtPsrPxb4xe8vbfdJHbTJmJGYAD94uMt0GSMLzz1z7F4y8XjTvEEniDwXpmva9omoIn9rtp1p51nOEAQSxS9pFRiGK5BMKKxXY1eQaL4k/4SzULl7W0aDYu9Ywd21AQMkgdeRXo5TQoV5ONb5HtVG1seYaDaT+HfFdq19bMGt543kilT+7KM8f8BOK9ruf+QtcY6b257nmltY7LUL2ObVtPt7y4gUCKWUEsgByB7jIyM02E7tSdjySWNfQ4HB/VeaPQxnPmPpjwMCNDtM9fJH8zXR1h+DxjQ7QekQ/rW5XxmId6svU6o7BRRRWIwooooAKKKKACiiigAooooAKKKKACiiigAooooAK5/xucaMBzzKoH5GugrC8Zxh9GJLhdkisM9+ox+ufwrOqrwa8hrdGH8PLaIanqtyqjzWigjLewMh/qa7muU8Ax4hvZOxdUz9Af8a6ulQ/hoJKzZ8x/tbXKjxD4fgVU8z7LJLnjP3wAPpya+f5JejKCiY2uAeGr1n9pDWdP174nxJYXBmitbJbZ5F5UuJHLBD0PoSO6kdq8thsLpNP+0zJmzMvlK+DjfgHGcY7+tZ4jljJNPoj0sDJyp8j2uzb8M2TXzQQwKzfOW454HNe0XC+SsBGAEZ2/LBrgfhRboNJunP+tW4dckDIG2P+prt/FMn2Xw+9wDgpDOeD/sZH8q5E7tl4mV5RijwdblmjcgsN2CTn2FWLCM/2r4duRz5d+m4+g3f/AFqi06FJntokUl5WC7cdBnGa1rGERahd2Q+aS3uWRAOTuEhAwPWs4y5ZHq10pwdNdvyPffgo0j/GXxwxJCeRECO2cjH8jXvdeUfBvTRa6pqV5LGVvbyPzJiy4I+bhTxnj0Ner16dBNQSZ81iJKVRtdl+SCiiitTEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZKu5Me4NeKajB9j1XULHbta2mYgA/wDLNyWU/mW/Kvbq89+JGm2lnPDrjKIy7C3vHGfmi2koT7qwAH++a83MsP7Wldbo7cDW9nUs9mZfh6Zb7S77Q59uy5SZU3dFLgEfk5JqiiXA8J2lveyJLqGmY0y6kXo0kJK78dtyhHx6OKrafJ9i1a3kfjZKEYntzj+ddB4lsGjuI9Uinf7JqLJa3duMbBMVKxz567spBF1xgnjPNebRm6+GlTe6O+rFUa8ZrqYGnSKszwuwHnD5B6sAcj8hVUsbedZeT5RDn3GOf8aUFkO5VJljxIgxnJHJH4gY/GpbpozMk0DCSFxlWHQgEg/qK837KfY7l8TXcs6yn71HXkNkgjvzVWfmKCXoFzG38x/WngOYGt5SGECB4GA6xcgK3qwKgk/7QpLfEqSwuM9CB6jNVNe8/MUfhXkaPhO4+ya/bbQALkGFmJ6OBuQ+/wB0is3UbYWOo3VooOyNy8Qx/wAs2O4D8N23/gNFlALmYW7Tvbs5+WdcbomHRxkYyBnrnrVy+eTUNMtdQlUfaQohucLjbMhZJFx2+ZTxWy9/D27My+GvfuiC4h32dvfDJKgW0g7YYnDH6NsH0NULiGKe1kil3Km07mUZYIQd+PfHzD3UVraLPFIz6ZdKfIuQwDDpyORn14JH0pv9j6jE+pIiG5vNMVZnjiTLTKV3goO5O11A9Ux3pRpznyzpK7QOpGF4zdrgdV1q50+18Rs8J1/w3JKmrR24V/tOmyATnyh1LERxKDx86TAd66f4h6zNpVlp97omgRatbalIBdXsblUhj2fLK5RGZlCkndggBfcA8on2LSbvTLnw5rKW1nqyNaaXdhDNbzXQlbNncAqSY2cs64IdG+0gOocKeh0+e78B2MM76PqEfhyYHzrGAC6k0qXOXdWViXtiN7f312gKuGCJ9XFOUFzHzdaEZXj0ONjljuLeC8tvMWC4XzYt42uo9D7g/nVyK3urqwSO0e0i/svyf7HtpWCLLIw8uSBn5IWQF05zyyt/CK7DxfpEeo2cV/pE8MplIlRw25JUYDBDDsRgg88VxGJLeVRIpDRuj4z0ZWDKQfYgHNeLGU8FXv0PjWpZfiHzL3X+Rk6vc2Nn9qOo3SadeLE7tp14GiuHcA/JECMS7m4QoTuzx0OOn8P67eaPpuk35upfsVppnny6NHETPcy3U+yzBOMKW+6FJBBPIGDjt/C3iMX8cMFwoMi8Zx6Y/WsHV1mvTrKCSwkvJ9Vgmt5kQIEW1kieOKVgAzEOjk5zjeQOK9rFZ3CVJOo9D6HLcNRl+9oa3PJbi51DQte8TR6bq2haZDKYJW0DRpTIlvIIBl0JRApb5ZDsBzjDcjnl9O1iLwnbajqdtpkV1dXIEDh3KqVIdznHuP1PpVPSPD9p4c8SalFrxuG1V0RrN4+IVLRMGDgeoKAds596nS3gu43tbnd5UgxlTgjgjP5Ma+yyb2eJwF4Lfqb1bxnZnQ+BtY0TWfAkmuX95pelX0d21pNFLcCMEiNWDKpOfmJb16e1W/Deh3l/qO4QsY2TeJByrA9CD6EV59b+E/DUTlL3Tric5wZftLI457AfKB17Gvr3wCNMbw/p8Wm2qQQW9rHDEgJYqijaoySSeFHJ5qK1fFYCm/bLmv1uNKM3obujW32TTreI4BVAKvUUV8rKTk22dIUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigArC8ZoW0UkEfLIpOe/Uf1rdrF8XY/skZ6eYv9aip8LGtyDwTCYdLm3DG+dm/Rf8ACsfUL258aX0+k6JPJb6DA5i1DUomw0zD71vA36PIOnQc5K0re4uvF6HR9Fnkt9CiYrqOpRMQ07Z5t4G9ezuPu8qOckd9p9lbabYwWdhBHb2sCCOKKNcKijoAKIR5YpCu3qz4w/aajg0T4uWdtYQpb2dvpMKRQxqAqqDIAAKvNpEY8Hf2eYlKxBpgxHJcMxJ+uAK579pzW7TXvjBeNYZkj062WzlYdC6F935Ftv1Br0BFM9psiPB3YHqMnNeRm83Bwt/Vj08saal5fqc78KQfsWoR8khi2T3/ANUK6H4pzfZ/CakNtV98fXGcxtWX8JYCYdTDjaVZhgj3hP8AWm/HCRrfS9Pjk/493m4XPXCc/wA60i9TWpHmxKSOI8B24uNdMsiloYYiRkcbsivUfDPhrS7fU7rVZIkubm7lE22UHELbicjnB69x2rmvBumfY9AgkkjCzyM7Oe/3sAfpXZWF3DbW2+WRVAHOTiufDVFUxEl5fk0a42TUeaL6nrnw3O/UdQY84jTn6k/4V31eUfBXW4dW1HWVtyTHGkWGII3csM4IFer17VJ3gv66njVYuM2n5fkgooorQzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs/XdNt9W0yWyvE328pUOvqAwP9K0KOtKUVJWY07O6PCSk6x7bjPnxs0Mv/XVGKt+ZXd9CK6rS8614Ru9NlOZPKdASeVkXDK357TVbxzpzWWvzXUeFtL3aCoHHnhTlvqVRRVDw9dmz1S3cyf6PK4hkU9t2AH/PYPpmvl4r6viHDoz35P29BS6ozY7t7lIr2RGglfEkkZGCj55BHtxVmS0CPPDCNqIguIx6J91gPoyqf+B1a8UW6W+sSFQuyddwOOrAYb+Qptjbvf6ZP5JZtR04/abQqeZAR80bY+8GwePXb6VjClerKk+ppKpamqi6GfubYrBiGjyQAfvKcZX8dq/lQriKQSZ+QAgn1B6f0qxeRxoYri2ObW4QTQuOhQ8qfyqqPlPB+lc0rxdn0N1aSuupK37m43e55x1rVZ7qPUxE0UbaPrCBxLxkagI8bfo0cGfdpPesmRSA0bKNgG6E/wB5O4P+7kD6Cp47sHTJLC4VpISdyjOCpBBV1bqrqQCGHIIzXVh6saMpRns0c9am6qTjuiCZZoLl/IXdPHJujQnG5geF/Hp+NdVeTW13Z6V420iRmfT2aKcltoezaTEu8eqDLjPQZ9a5JnZvvMd443k88dD9enNammajcadM2ptIH0beIdYsiimNlfCi5JP3QikBh0ZRk/drpyusoVnHuY5hSc6al2NXUNJ0bRr+88NavHFB4X8QAf2btXYtteMPLkhRv4GcFZUxyW+0EnpnOvPFPjfSrpNKlTT7/UtOhaS8igtZJJbyAn9zcxhXUqCFkjk2q7JIAVjcOorc+z2HhO+OhawiT+E9VYLYC633AguG4kt3L7jsfJdCScfvQSAEBqeNtX06+vlghYTXunkxma2naOe1ZsZXepB5KqSpypKLuU4FfQVqsaUeaR8zisRChDmmc5DcSadIy2Ky2ts58xbRjtWHd8xUL0TljkDjNaUcljq7pFPILa5Y8FztDN6Ang9M8VW+2S3seNQtvtpGMz2UeJ/954uhz32HjrjB4oeTDcySwWM0V4V/1luV/eqP+mkLDcOfUf0rwHzL3viifISU17/xwZ6F4d8LjTt139oeRmBZQW+UcDGPy/WsmWKZpJf3KwyyTz4CHI/1rKrZBPUBSfcngHiqnh4ala6NqixWhTy4JhaKZWVHkKDCmLJQDcTztHTpXG3Hh3xixhhg8SvJGIJZktxptokEVy5Z2E2cKyBjuL7Cc7iq5IFLF0qGIpxpqSi/M+xynlhRUqcbJlb4gTeBojAmt3droniExt5aXEcwfG4bWbapG0joTx1HY48p1TWLe11Wx07Qr211fUbqRY4xZ5kTezBUTJAyScdPUVBf6r4R8QWVhrnjPxdqt9rVu3lCxGn72WMS8Y3fuyuG34PX5hjPX2DRPAfwv0Y6f4osfHC2bXzYtLhnsokcoysdkbxYVlYLkgAg4Bxmvscrx1bL8OsPB3RrVgqkuZnIeLbOOx1aSGFgyqWGRyOGI/pXtfwXunl01UPRYFx/301eK6t4K8SrfyR3FxcNJlgHYJj7x4PyV7j4L8JJaWEEemeMNZjn8lfNSNLNgD1IG63JxknvX0GbYmMsKoWbb66fozCnH3rnpVFc1/wjmqf9Dn4g/wC/Nj/8jUf8I5qn/Q6eIP8AvzYf/I1fJnSdLUc08MGPOljjz03sBn86yNM0a/s7xZrjxLq9/GAQYLmO1VG46kxwq3HXg1znxu8PQ698PdW26WNQ1KCBmswsPmSo5IzsABOcDtQB3cMscy7oZEkXOMqcin1heCNGs9D8MWFrYWMViDEkksUcez94UG4kevHNbtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+OYxcaX9mkJ8iYMsigkEjGOo5HU8g10lc74zbbaw+5b+lRU+FjjujX0qxttM021sbGFIba3jWOONBgKAO1WmIAJPQc0kY2xqD1AApJlDxOrAEEYIPerJ6H5n63qs0/iLWdScbje3MzPnHJaQse3r7V7zod4JLWGROc7iD06Ma8D8UThLmTT4cm3gnlKsRywLsQT+BFeqeE7O+0nwrp8t4R5e51K4GUy5xzXkZrBThFt6no4BuEpKx6f4ZsoLK3uL2L7tw5Doc8H5Rn/wAcFYXxO0VfEFtavJN5aQzKFTaTvyvI6jH3R+ddB4dYyaAOes7VU8RqWudOjwCglL/iCuP5mudVHCkpeRsk3Vb63I5oVW2CBcBScD0ySa86+KSvbxaLcox8sXLQyr2O4Aj9ENekXLfujj1rn/EVmmoaBqcDqSxgdk5xhtpwf1ry8LU9nUUn/Vz0KquvdOo/Zm1KO21W/hkZVRoFTJ4AO8/5/GvpQHPSvi79nrUXbU5DK+BPb7cgY58wDt9a9NbRLUT3uoWKPFdyTu0kiyt+8IcgHk+1fTYepyXpvoeTj481T2keqX5H0JRXi0fxf0jwtbW2k6naarPqCIT5iLG4boerOp6OOtZt18cJ5px9kgtLW36D7SS7n3+XAHbjn6mt6mIp092ccKU57I97oryjw38U4705vDHKpAwIBjnPvXa6J4y0HWZ0t7HUYJLpiR5OSGyBkjB9ADRSxFOr8DCpRnT+JHRUUZorYzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwfGemDUdBu1Ti4RRNEw6h0+Yfn0/GvJgzXEavLEbeRx+8iHWJ+jL+BBr3SZd8Tr6jFeU+M7E22szTgEB9ob0Jx9768AV4mb0dFUR6uW1NXBkSibVNIkM+Hv7MlZsdOcFXH+yfX2NZdlezWFxHewkhoWDuh/iUEEj696nt2lH2e8tRJJeaeWYWqn/j8iYHfCfVtpkKA8byvSpdWW3cW2o6VP9p0+4HyTBSAdpKk4PuCK86cW4KvDpud0ZWk6M/kSvpw0+8uNNMwazvS19pTswCqDhGtFA6FR5DKP4vMfGdhrJ7Yyc+taOmJDfwPpN9IyRuQ1rMpw9rLjYrxnsyhsj6moZpBeW7XDFBfwSG31GFVx5Nx1Ix2DfeHswp4lLEQ9vBepFBujL2Un6FZg7oVjG6ReUBPU+n400FWAI6HkZ6j/AANL7/yoYkuW7Nywx1OMZ/QVwX0O22pZitZZdMub21tZLyWyPmvawqWlniXBkjRRyXKEsnqyqO9dFfaRZT6HF4m8H3K6nFDDKHtYh50GqW+SJIig+8+A6oezHBBBIrGsBPFHHqmkwGXWtO3PHGp5u4RzJbY9WBJU9nWPPGQd4XvnMnjjwJdnU9GuF/4mOmwIT9rCEL50QxkTIoI2gDzAqjqFNfSZZRp+yU7anh4+rPncL6FjwJbW/wDZ11okFxJr/hW5idra8mmWfYCdk1rKc5Y7iWBPZmQgeWC3O6t4XTwzqO6VL3U7B4tsd4GD3VsBgbJVGPNjCgbZMNIoUqd2RXWyQm9Q+Jvh/eafO9wm2eH70GoCIkBd6n91KMNH5mGwDhlbYmzh9P8ADd8thNdpea9c2ssruLfXI2F3by5JYbs7WToAU+XjIJ6124vSm9Lnz+Ytqg7R5iuQ8Dh7aZXU/dkjO4EevFaD6pbahbx22u2cV5Cn3XOQ8Z/vI4wynHdSDWUcZKzRhuec8HP1HNWYIo7h1SO78lz0+1Recn0yCrfrXg05uL9x2PkKFSUJfu5W8mdDZXMF9pNyNM1C7vLaLEbadcYMsRDL0lbDlQDu+bdkEjOMYiuGMFu7q0kTRx5BXkp8vp0OKkWO4stKEF7o8ctrM8Ua3lldDad0iBWZHAdOcEgF+AOTk4JRIFcW8ZaVVIjTg5IGAPmIB6CuPNb+2g5b6H6Hlzm6CdTc+ftV0vSPsF3pgsLSWK5TP2p4gZ43wNpV+qgEDgcHnOc1wdr8L7zU/Dt3qGn3kX9pW85X+znXaZYRGWMiPnlt2FCYycg5r1PX7fXnkmuPEumJpdwoQRQiNY2kXAywUE8ZwM+x9KwiucZ5I71+yYfL8PjsJTlazt0OCU5QkzodK+KfiLxNoDRa7aW9vdWgSNLuENGZxtwd6H+LvlcDnGK1vhrf6h/bjCOaV1MRyCa5JXFw4F1Kwx0cnP4Vs/FLVr/4aeB9Fu/Ctx5N9rDvHJfDBeFIznauehYtycdFI71piVSy7COna9xRvUlc+r4N3kpv+9jmpK+Vf2Z/AnjO78Z2/jrxZPqEdi1s8tu91clpLxpAUBZCS2wLlstjPyEZHI+qq+KZ1hRRRQAUUUUAFFFFABRRRQAUUUUAFZGv+JdE8O+R/buq2en+fu8r7RKE37cZxnrjcPzrXryv4yeGNY13xF4TvNKsL+7tLFL5Ls2F1DBMoliRFCmUgc4IPXjPtQB6dZ3UF7axXNnNHPbyqHjliYMrqehBHBFTV4XYeF/HWi6XpMcemx3sh8OXGkTRWt4kCW0zSFo5CCQGO3aCV75OcddXw14L1z7VJca3HqAkt9BsobXytTMf+mJCyyfdcgsGI+ZgRnkZoA9for570rwR4ys/DerWg0WOZJ5LVcXM6C6lRXJkbCzGJmHBBYru5yDwK9E+EWnaj4a8Mz2PiPfau+pzCyiubiN28psGNQVJGeGO0e/FAHoFcj4/dvLtY16Hcf5V11YHiC2F1qmmRt90s2foMGpkuZWE5cupv1neIdSXR9Gur913CFc46ZJIA/nWjXkH7TXiA6L4AaOKVFmmnjG09duSf5gU27DtfQ+RPDFg/jHxxcS3AxC5lkbbleOcdM/3hXu1zMkMbKAPK5GD3z1/nXCfCfQpdO037QRtedSxLDkAhcAZFdzcWkL/AOtZ2PoGxXy2Y11UrWvoj3sJTcKd+rNLwPHF/wAI7sgLGMXL4yc9hUXiiNo9atf7pV8fX5K1/CEMMWlbYhgec3BOecCs/wAdp5WtWDYILpKAexx5f+NbSd6PyMo6Vde5QlfdjHSqlxghwe6kH8qkeQAZBBrNvbtU3EkZAPHHpXmQi2zuk0cX8Gba5bxXrlnp8iC9sLdru2ikGRKUYEx4AySxKDt35FfQvhuJ/wCxIJLqMxXE++SeIgjY5dtwweQMk8Z6V86aJ4Vv0+JekJZ3E0F7MIb28VSQ0URkjJyNvA5/i44619R6Lahzb25YyCMKpbux7nj15NfVOKXvHg87lo9kYus6bJ9n+0WsKyyjJVDuJPHQAd+BXH2+oalb3hgvLu30sM/S7jVVHOOeCcdK9n8TWVraeHJVkjuJBMpj2Q8ynKk/IOOaw7PTLV9Pjg028EkpTEcN6kRlU46MApP9awqrqaU6lvd6GJoej6lfBnh1Dw/qUeAzLA0pPPf5cVmeO30fwhZibVdGupomUs5sZX3LggH78gHf+dY/ifTrBZ7qDxhp+taYqyMI9S0aWWOP3LGRgg4wOBjJNdp4Q0LS9O0Wa4t/EMmv2XDNOXgukQbRwzBcDgg0nDyXzEpa6szPAPxD/tTSli8K6gs8duADZX7CSSIHkDKZOAARyT09q6u2+I95ZzNBruiXKsP47Qbu/wDdbH868i8ca18N01ATSykyqWDvpd6kb5z3VJFUnnuOma7vwZq2haxaQ/8ACO+I7a4kxgWd5LbvcfdH8K7iRj37Gr5qsHo9PvB+za1R61pesW+pQiSBLlB6Swsp6Zpb7VobOMvJFcuB/wA84WNeVeKdOvpLiBbi7t7ZgpASKZkkYZ6hcYNVhpOvQRItlqt55Y6w6lZQZJ9QPLOe361tLFqKvKLMlh23o0eo2/irS7iVkjlPy/eZsKF+uTW1FMkqhozuUjII6GvB/Hcuuab4LnvbJI5r+DMjrJb7VZFRiQAij09qn8IeKjceFrG/0rUmt47hn/dp5bYZXZec5P8ADnknrXI84oxgpyTte23U1WX1pTcU0e5lgOvFKpDDIORXkt09zrOPteqXrMGDK0MoiwRkcbMevI796sPrGq6Df2W2/aa1uZBCYpwH2MSMENgNg555PTgVlHiDDOXLZ/d/wTWWWVorVq56nRXnmk/EGWGWa38R2RjnRlAazjZkwRnJ3HI6j8jXZ6Zq1pqTOLaVWZecb1JI9eCa9WjiqVZJwknc4p0p03aUWjQooorczCiiigAooooAKKKKACsLxPpA1CzmKLmXAx+Gf8a3aKzq041YuMi6c3TlzRPEbqCfSr1I5A0UikNETxnHPH0qayvLeFriGWLZZ3R3FFHyQS7QpYDsjKFyB/Eue5Nen+ItCg1e1kjb93IUIWQDJQ8EMPoQOO9eVXNjd2d1Na3kaJdwossiR/MjI3R1J5K5BU9wR6EZ+cxGFqYRtx1iz26OIhiVaWkkQSRFJNjnaVbMbjqpHQ/UVuX041OGPVLO2MupQxrbajaRDDzKTlHUnqVcHB/uu3cVhAkgKxyAOPp6GpbS6ltLpbiDmVFKbWOFdT/CfocMPofWuWhWVNuL2Z0VqTnaS3REGQMHU+ZEecqD8w7H/wCtU81rJHCs6jzLdgCJE560t8kLZvLUMIpm3svQoT7djnOfemQXMkUDwjBhclgPRjyfwOCfqaycUm1I0u2k0XPD+oxaZqUdxeSLDZLlpLhjhYhxyx/hXjljwM84GSO+1jTtRsLm61nwzFby3k217uxkJVb0oAo2vnCS7BtDEYOEDEBQV82sbsWN4t3IpaGLLTBV3EJ/EwX+IAZJXkkZ611WmW8vhazTUPBKWup+EHJebTbN/MMGDtaS0IOCvDM0XdgxX5mIb3cnleDieRmcffTNfU/H2nabpE19Pp+stLAw8+yisXkuYVKuVkeMdIz5bASfdyCM5BAg8WeItO1f4V+INW0HUop7c6bdm3uYHxl1if7p65BHbnitXxFo2l+IrS2ubhriGe33Na3trI0M8BPUgjqMqpKMChKLuU4FZev6zbR6VEs09zdMg2yzwW5kI+U5dkToOp4GP0r1alRQXmeLWrxpLz7Hz4bizl+EV/cRavaSa2fsBPk6pPLMu5gH3iQDYeTkJkfkK9V8IfDjVdJsYI9QuoHneVpH8i4knXbhQCryANk88YxxVWXS5RbC5tzDdWr8iaEh1YZ7kf1pbDUrvT5V8pyir8u3oAP6fhXkVcVCXu1adj53EZhSqPkr0bfP/gK51ul2ElhoF6NO1i11GK51VBzKoitI2kRJYlOTlvv4GfvvgAdK5L4k+JU8GaLrN/btdG7sQipcRwCSCKaTBRHJPXBB6YGVyeQDuj7NqllDqNzpNol8XV/NeBPN3I3yuHxnsCD7Cuf8Y6G3ibR9S0OTVFsdPvo/NuldEdpJFAKMikbiR5aA/N0HAzXFUqYbE4qFNxfQ+tw2mHUqe1jwPw9Z30sH9s6iXZrsnZNLKJJJgmYjk5JwCu3n09K2JdZ0TQ4RJ4gjvZFlz5YtUUkY65JIFR2umro1kunRXP2oKzS7wpRQWxwoOT2Gfep45PKKiSCCZVbeEuIVkUH1AYHHpX7Th8POnhI0qbs7HnSknK7LHh5vDfim7itNC8S2yXUxVUtb9DbyszEAKpPyM2SBgNknoK9w1z4SWnivwDD4d1q5lhaF45op4uWikUsDgHggq7DB9Qewry7XLbw54jSz1zVtDjbVLRwVltm8gS4G8eYqjDfNk54PJ56Y7rwJ8SdQ1DU3i1HByhbjpnJrxcXSx+IpNVLWiaxcIvQ9e8OaWuiaBpulJcTXK2VtHbiaY5eQIoXcx9Tiua0vx42sa1Nb6PoGpXmkwXZsZdURoxGsgOGIUtvZATywHrXaROHjVh0IzXBaR4F1fQdQux4f8UG00W4u3vPsElgkpR2OWUSFgdhPbGcd+9fMHQXvD/xB0rXPG2q+GbWO4S6sQ376QARzFGCyBDnkqxwfoa0/Avia28Y+FbLXbGGaC3u9+2ObG8bXZDnBI6qa4vw/8I00LUvD2p2ev3r6jpssj3DzKXjuhID5oCbv3e4nOctz2NbHwv8ABereCNMg0qfxBDqWkW8brDANP8l1dpN5Yv5jZHLDGO/tQB3VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ+vaPZa9pcthqUXmQSYPBKsjA5V1YcqwPII5BrQooA47QdYvdH1SLw74pl8y4kyNP1Ijat8o/gbsswHUdGHzDuBqazeQweIdFgkYCSYy7B64Cj+tXde0ey17S5bDUovMgkweCVZGByrqw5VgeQRyDXmonvLP4k+GNI8UTedcWwmaw1EEILxGRhtkA6SDHIHDYBHoKja/vETTasj1qvlP9rq9m1DWrfRrdgPLiilYE/8AXQ/1FfVUjiONnYgKoJJNfEXxO1uTxP4+vb4gbBHGi7SSBhRxz9TWcmaI19J8QWFppsUTMYsKAS4CgHA4Bz7VYl1yFmIEqBh1BYAj681nfD68OmeL7W5m0uPULGKJ98UrBUZipA3AgggZzjHUA9q1vEGkWWp397qFwHjubuZppDDtUbmOTjIJx9Sa+cxVDD0ZWUrtns0Ktaor20Ot8D3qz6cWBBxOw4+i/wCNbmtaMviHVYoZmeC1sUknedRgljs2oCeDkK3HsK4r4cW7WkdxZQzyzr5jShpTnHCAjPT/APXXqUk6/ZEijVAu7Lv0L9ev5mumhRU4r+U56tRxb7nil1d+Wm5ztbGSO2ayra4FzqHmS8wQnzpR22jFZ3i7WEh1++soFZ0iKYIB6eWpPTjvWWyeIAmkiO1ij0vxBMbWG5SUNIyq4STgNlcE/wAQxxU4bBS5veWiKrYpcuj1Z6R8OVn1TWdT8aXaJHNq6CO3hReIYQcAAHkZ2jpxXvHg62DJHM/GArHP41wvhDQIbaGG2gVltoV2RjA4Ab2GK7tpWsY7OwtAfOvD5O4cbBjluPQZ/GvSk7s4orQ2nMepX7iVD9mtWxGwHDt0J9Dggjj1qa60qxkjBVFgkHzCWEBWz65FVZh/Z+nx20Ll5Igf3jHlz1Jb1yTmsy01vz0BDhgDtdcn5D6Vk5WdnsylC6uZviO8sLS4hsvE8EDWE7FIrtkVkOBnMu75V4A5zya4+28M6L4Q1dzZ+Ib3S5J2Mwsr+6VrKccjhWKjbzjgEAba7zxBp1h4h0uSx1JFeCXvtVivIyRuBxwMV4rrenf2hqUPg7x7dXEbNuTStfjJM6IDgCQnfkExoThk++1Uo29BMv3fhvwP4v1G5spbjSLLVXkJ2W0tuUl53Eq3UfdbgA1gyfAlNJu5F8LeNvsuopn9w98kMinkHOw5HGe3avHPFHh/XPA/i+WG7k1HdGzm0vbeYhpI/mUOGXOMjqAe9exaaknj/VbaW+h8TeH9WW32i+0uGaNJwoBLSjZkuSxyxfq3TnmVTVLWF7PtqV7Tn+Jq67mrNF8UtFs/s2saNYeIbbHyT2skzTqBx/rFBPOAfz9ai0HWbywn26NreqWN6wJ+y+LrdhB2zieVwe3Ax2PvVTUIvHng6++zyax4kvYzzHJLdTTqwBKj7rYB4zjNSXfjmW9YWviPw94fvrlRuK6lprRygdsNKx45Pbuazc+Rc1ml6O3+RcUpvkUk2ul1c6q/8ceMbAFPEPgnTtQsmGGm0tZrpGH0ClcEZ79xU1j4q8DanZJayaZqej7GLKsVmLeNee3Qc5rB03xi9swEqarb24GPKTUzNCB6CJYhxjtnpxXV2l94U1yLEMdjJNnmOXSfJHHu/wBRWE6iqL3Upfgawg4P3rrzNCzstFkmxpviFZDxiMXEbyf98hs9ak1vRI45rOa71aQ+VOkgXCkfKc85PHSsu08HafHr9tqXk/2cbchv9Au4tso3IcOqpkgbfXufWtzWIILwMbC7S5ckfu5YMr0/vbsVwVsLa0oUfXVHTCu5S5XU9NDmPESXTas19pd9o0kEpH7u6u0Q8Ko6Z9Qa3vCt3aW15bXeo3+kWpjyxNrexHLZA2nJHBBauX1PS9ZtmiDeGtCuUkban7yMHpzxzWLqE1usE9rqPhqKxuo2KsIIslSQcEME/Hiop0/YuNVUXp1uOc1Vi6PtFtt5H0dYazY3xIgnTcG2hWIBJ9h3rRr5/tdI8S20D6tfpq1nYx7JYpIrgyPtbHJjX5h1GRwQM56Gun0j4mm1t9NhuoxeCd2hD/OkihHK7mB3FiRzjivejmEYtQrRcW/J2PLWGk1zQkpLyZ6zRTY3DorrnawBGRjinV6BzhRRRQAUUUUAFFFFABWF4n8OWuuxxSMTBqFtuNrdJ96Jj6j+JTgZU8H64I3aKmUVJWY4ycXdHid5aTxXz2lxbG1v0QzPbsQQyg7TJCf4493HOGGV3KN67qq/OQAQG9+leueJ/Dlj4htokvI8XFuxktrhDiS3kwQHQ+o4ODxkDI4FeV31jeWF4LXUYQty24pJH9y5A6sg/hPIJTtn0r5rH4L2D5oLQ93B4v2q5Z7kMMjRvIB6gSKex7fT+tMIH8A+Unp3FWYXMoTyngju4/8AVPMCY3HdJMclTweOQQKlnhguLWS6t1NvcRHZcWUrgvEw64I+8pBUq44IZehOBxeycoc0XsdXtFGfLLQgsbgWt3FcMzBIm3syKWKgc5wOTjrxk+1dvp+jBYv7b8A39lElwwaSyjZW0+92ZTOUBMT4G3zE4+UbkfaBXF6dHcPeRNZIr3CNuSN5Ngdh/Du/hJ6Buxxmu28Grpl3qt1d6PLfaVcxlRqGizIkeGK/u5HiwdpKAYZCAwXByVwPYyZO0mebmjV4oyvHNzb6sNNh1y51Twtcwz74POlAtrtiuBG8iMUYH+4zK+FYgbcmsG90zUNLlXzg4fqHQnt/+qum8e+LoLDVpNEm8y3kaFWDXCr5NyJNy7E5y5BU7htwMj1GeQsZ2swY4JZ7WMHmOJtyD1+R8gfQY9KvHypudndM+CzedGVXlldNdSSKa0815mgktbxx813p8n2eZj3LFeGz/tA/nWraXEk08X2e+sb1s8w6rbiB5CegE8IABz6xtnjock0Gilul+RtNuZOowWtXP1+8ufpUU+j280MsOuWWrwWToQ00FsLtB9DFvPfqUA61nSda6irSRjhpYnmUVacTtL22vmsrUXOnJDLI4ULZTm4jXhiCWZEIXjBJHUgc5rgPH2pWGkX9laaho99qGrSJ51rHbZZlUNtLhVBztJyc4HvXd6bLpP2XQIdE8SgafZgxSWazBpJ1EMqlGz86sCyuQQCPLxgdvEdb+HOuXnxi+2+BtFtJfD8Vx5d02sJBNbszsZJSIyA7IAwA6sMcMBjF/UqCxcarlaW9j7KE5Kly2MO/imj1Fo0AE527Awz8xAx+tY9p480JYbm28a298mpW7kwtp9uiiZcfccFhsYEY3AEEHpxz9O3Xwk8IXFwJF0KzhwcbUiTaRx2x9fyriPix+z9beJ7/AE++8I3Vloc0KeVcWwt9kEqgkq+1MYfkg5zuGOmOfusVncpxj7H3Wv67HHGilueTeG/El/qfh2V9RsoIYGmH2WSJCgb5eV5+9gFea6n4d2Fxda0WijJQRH5u1e3at8KvCOoMrJoWmW4/6Y2saA/kKn0z4YeD7JAG8O6TOcYzLZxv+PIq1najQ5OW8n5/8APZe9c7C1UpbRq3UKKlrmv+EB8Hf9Cn4f8A/BbD/wDE0f8ACA+Dv+hT8P8A/gth/wDia+dbvqbnS1j+KfEmm+F9OS81eZkSSRYIo442kkmkb7qIiglmPoKgs/Bfhayuormz8NaJb3MTB45YrCJHRh0IIXIPvWb8RvDF/r66Ne6JcW0OraReC8t1uwxhl4IKPt5GQeozj+SAjuviXoFpaWc12mqwS3c0lvHbSadMJ96KrMDHt3dGB/Gur0q+i1PT4L23WZIpl3Ks0TRuB7qwBB+tedeIvBGu+MNQ8M3Hik6UItPup5LmGxuJ48xPGqoEcAMW3AknK8V6NptlBpthb2VorLbwII4w7s5CjplmJJ+pJNAFmiiigAooooAKKKKACiiigAooooAKKKKACuD8W6LY+IPGtpp+pxGWE6e8i7WKsjh/lZWHIYdQexrvK4XxNqtpofj/AE+91Fmjtm0+SPeqlsN5g6gc9x+dTLYa3PDPHvxk8T2ct/4U0KfT9UNq7Wh1TJElxg+zKoYAFWIyCc4xXO+G/Al5aWAudYkkkmldmK5QqM8DoT6evesn4AaFPqGsw380G60hkZmk3D7xTI4znvX0tJGGtyDyPrXgZ9mfsKsaFDsr+uuh6eV4VSg6lXq9DyS3t4rNCsRBGck7cVH5E+p3i2Vn97G5myPlXueSM1rJoVzfiaSKWKKNZChyxznn2NbccVtpNiba03OSSzyEYL59unYVz4TByqtTnsdOIxKprljuQ2Fra6LaG2tD5h3ZeZlwzZx6DpwB+FV7/WFeF7QTvCp/dyTpnKbgQMDHXqe/SuW1/wAU29jdLaKWN0wUldpwqnPJP+etP1MSXvhW407T/nu7bfdIDx5jBW4545JFe1JKCSWh5avN3Z5x8SLy98PAWH2K1+1yqF/tFMrJKhB4IDHHcc/3RXTfsveBZda1fVtVuRk20MXlAhWyzyE7s5yCPK/Wp/D3irQvFGjLpPiJGa2LlxGVY7JM/Kw2kc8+uK+iPg94R07wp4Yjk0ySRlv0E4Lrg7Czug4J6CTFXGo2uVqxMoJLmRsW2lDS7ckjACnPTgde1Z+nzqs91qMzli7GOBSD8iqSCR9Svt1q98Qry4i8I6p9ji824eCWOJQcZcxPjr05xXyTqfxN8Twa0nh24gggnMi22RKGK7sAdsdCKlWbtcettj6Y1zxRa2wzIw6n+96fSvNNU8cad4e1yCXf/oOoSYucB/3fzYDABTkgsD0PSqej/Dy31q3juvEV3JcTOA5QopAJ68jHYCud8WfDrTVvIn8OWcf2myk3shOwSfMOpJ9A1ef/AGphZSdNXfn0+87FgqyXMdT4x+JuoaNdwWum6ULtJo1mgmNyY/MjZVYHGOOG6HB9q8m+IHxP1jxL5WmavpcNrhTsdZzI6DcDkHOOq+le9eDLiLXNCs9EWXytTskESQ84Dc7lz0xwTmvI9P1vw+fiR4gs/Fkbttla3XALFGjefcOGHcrV08dOzkqd0lfTciphY6Lns2ex/BfWlvfCsSzavbazc28KAwsj/abRNp/drkMJM+WOFAx78V6bpPiVrp0WSBSjgOkqHaCjfdOD07dT+FfKmqahpWiXazeDtTXUXkyxsJ1aIDsBnHYFj1/hr0Hw/wDEDTJ9PbTJoAttIP3umyo3llgASdy5PBHr2q4ZhaSlKDUX/Wz1X5GMsC1F8kk5ef8AmtH91/I99e1juGSe2uZITgnZGfkYnuy9T+lY3iPwnoOqy/bdf8O6Xqssce1p5rYSSBQCQFBBY8k8A9+9eNJo3hESv/ZOuz6VI5z9nmtSBntghW4HTn0rsrW18Y6bEJLW5a9iIwJFZNuP+BKD+laPMYJ3UXbutf8ANCjgJyjq0n53X5pGpeab4Q1FpLKDTYtOlUYM1rD9nlTsOqde+D6VzOp+C77TtYW3j06HWdNMQkF9NJHG6uSQYypbJxjOQAPmA7HM83i/XmV7a7NiVI2NHMQcjpzhTmq+i27h5Hh+yW6uWYmEnk/QivOxOKwVeNqkrP0af3r/ACOqhQxlBrkjdddVb7nqvvJzp0tjb3Eg02G3ARuY2XPAJ7GuY8Ma2NH+HFpJLJNJcPO4DOTkDHTIFdxrPiHV9F8P3F8l89xNDG7+WQMEKpPp7D86l07xFfapoVnqFysUkE+WTc7A8EjoB7V5ypYZU7xq6X/Lodjq1pTXNT1PLH8fwSyqs0su4HhhvyvuPlrVsdXTU7kPH4i1NZIwJDDJuZCOMfwj+fevSdO120tLl5ItOtYJ3AG8b3J/PpWR4nvZvEGU1bQYp7WB2eBo3JdvqpYDOPeu3lw0YXp1rS9Vb8TndSu6jVSl7vo7/eilB4zaYyvBO9vLO33pHklRGzk/KMZG3cMZ6kc8YOno/j2y06S8/tMwXqxBHkmt7UxsOAOjZz2754+mMTwne+GvDN1JMdIu7iV0EcatAhMS5OcZfHOefpXrekaxpGuW6PbGNmkG0xSIAwxyVI9vxHFehh/a1JKSxCv2sn+VjknGjTTSoWXe7WvzTt+ppadfW+pWUN3ZSrNbyruR16EVZpqIqIqIoVVGAAMACnV7C8ziCiiimAUUUUAFFFFABRRRQAVl69otprdkba8jLJvDgqxVlI7hhyDjIyOxI71qUVMoqatIcZOLujxzxHol1oISS9lEtoWKm8C7Qp7GUdEz6jK59MgVnSksE8xV8yNdqS4G8LzwG7qcnjpzXuMsSSoUlVWU9QwyDXnniHwTPaNJc6BGLm13bzpm5UYZJLGCRjhT3EbYTlhlcgr4eKyuUXzUPuPWoZgmrVfvOY0y4+y6jbTCeOA+Yq75z+5YngK5HK56buxxweh7S6m0nVtVt7HxBbHRfEsJP2C5Vx5mDg7refbhhnhoyMEqQyMpG7m9KgiUy3kEK6paQKYtT0mSE/brfI+YeUeJFAIOzHzq25Gb5FfQ0izhudJe88C3cWseGw377Qb2M5DrgkQvIQ0L9HCyAqx2kGMMXrry3DzoQamtzmx9aFWS5DRuNQ1HS7VLfXjZa/NvLLNaxraSqpzx5bsykjHVXBOQNowScyHStG1uVk0u+MFwoy1vcRmKQZ6Ha2CRk4yM1W1YQ+IZ5J9Kkmklt1AuLa4t3gnhyDtLxOAwBwcNjBwcE1z86rIixXsEdwincqTqG2n1HofpWGJre/y1oaHxGOxX71wxNPT8TY1HwzqFgCzhZFzjKgj8TUGn6zqGjv5sVte3YT5TBAheRs+gqSz1i4tiot9fuLQkhUh1OMX1uSewDFJc+mJevUEYFbml6n4ljnLnT/C2oIOkltfTWsrDPJEbxOoP+z5nb71FPD05SUqU7BQwdCpNVMPUt5dS/roNytney2YEphXM0nEkW5W+TH44P19q4Dx3He3elXWnadq82myXUWWZC6j5ec7lGR07de9dlqskt7qKXt3ot5YXCWvleZJcxyRkFgSqqjEHPOGIBwDwKydWtvN0u9aNMymIgHvjHQV5UkpZnBN9V+Z9pBWonlWp/E3xrptjosGma09z9gZpLxp4EaTUd0u9UJIJQBCE+XB6nngD134bfEXX/E2r3kfibwqmgackSyW8z3glZnJA2bcAnIJOQBjGD1FeATK0Uw3qRIuCPUcVLaXdxbXAlhlcSZByCeeQa/Ya+Q0KiTpe6eUqzW59mKVYZUg575pa5L4daq+p6SzynLKVH/jq11tfJVqTpTcH0OlO6uFFFFZDCiiigAooooAKKKKACiiigAoPHWiuP+LM2qr4Hv7Tw/aT3OqahtsYREhby/NO1nYgfKqqWO48DigDropElQPE6uh6MpyDTq+etAsfF/hjRNR8MWGnavpyJrFrPaT2qm4CWsrgSoJNhU7MZOR/Ec8VqeOIvHGneJWtbDUdfewgt4TYXcNs9z5sgJMnnrEm0sTgfMFXb0xQB7jRXimm3/i9/izbMYNfg0ptRuYbiCeOWS38kI2yQPtEYUkDAXkdCTnnW+LEviePWyNKOurY/wBlyGxOkxF92o7/AJRNgHEe3b975fvd6APTHv7NL+Oxe7t1vZF3pbmQCRl55C5yRwfyqzXlvgHw/qUfxR8Taxrkd2Lg2diqSOg8l5GibzRG23kKwx8p43c5yK9C1jW9K0SKOTWdTsdPjkO1Gu7hIgx9AWIzQBoVxnxTsGu/DfmxgF7eVX9yOQf55/Cr3/CfeDv+hs8P/wDgyh/+Kqlq/jLwbf6dNbt4r0D51IGNRh4JBH973pNXVhPyPKvhnFDpnhq1tY/l2Im4cn5vLUH19K65rtAmdw+tcNoFwiWI8twynGCOQRgcitNrsEYzX53XpOVRtn19KUeREF4xtNQlHZ/nFYesamZryLTrNg1/OQfLHVU/ibkY4HNa2qD7Qd0eCwAAGevNcpoV7aaTr8t9rdzDau8OzfM4C7jwAD06CvpctxUXRjTfxLT/AIJ4+NoP2kprbc5C9tI7XxC6Sp5UIQBck8nHXr65rVuLyXRL2GeQ7bcsPKl4IYgg46Gum8Tr4TvmDDxDp6XGF2osm5iBnnhq87v2aaS5szeINOBUNdzKI1jBByRuIycFjgHPy16s2mvM4IxdzsPCvw+sdU+JcPitSn/CKRbZRIWI2XUZXbFjdvP3VOenzYxXvV/4jheRnEoXeeBjoO3avmpvHOnaXY22l6TcL/ZVnloslsuzEsWO5d3fGDnpVWH4g/bb0QrdRw7zs8xmGIweMnKgH86pwbWok1c9K+J/xQsNDvrGxS+AuYpfMlCx7inCkZ+U+taPh/4h+EPGNpaWmuXUN5OgXaGeSJlJ9kC56Cvnzxno2rSLJdvp895bu2Fvbf8Aeo/y+qZA6evasLXPA/irw1YWOqano97aWN2izQXAGVKkBhkqTtOD0bB9qz9hGsr7Mp1PZu259j3/AIcW5sfN8H3oRyvFuycEY4G6QnuP1rmdD07VvD+qyT+Krb7GkkmVmLqyNjIPK+5H515B8FfH+u6ZNJanN1Yoi7Izt3khzwPlLEnJ6Z6fSvqfwz4l0Txno0tq7fvjEI7m1lV45EJXkDcqk9DyvpXk4rLVGL0sn1X6nXSzC0lG92ujv+D6/j5nmw8MweKPilpd5pt79mt7OOW7vJowCSu1VUDdkZO706Zr0q7tvD2ohdSvk26vHEIt26TOepAUEA8s3OO9YWkaLFoWoa3p9hcRta3MqyMVyZFTqIid5IGWz0GfpWhdSqgH0rzq+NjhYRw0Yqdlq356pfJf8A6adB4ip7a7j2Xp19X/AMOcxqHhfSrq4aU2uJmYnf5j+vpuxXFwfCa0m8Vw32vSS6hpYbMlog8osCT/ABq+7v8A/qr0s3cKElpFXHqaY+tWcXHnx59Ov9K8/D43EUJc1PX11O/EYaFWPLLT0dmNTwN8MoF/d+HZyccK8twQfzc10Gl6X4I0pN9ppi2p56B2P6E+lc6fEFr2dD+P/wBamnxBb/34lHuR/hXqRz7FpW5F9z/zPOlk2HlK7/T/ACO2m8SaDJlTeXip02i1kx+qZrkvE2s2kFzax6DoM+uRShvNZpZIPKIxjqvOeagXxJZIMyXNsv1I/wAKfB4v0cEia+tUA7kgc/lWVTN69RWdGL+TNfqEabvGb/8AAv8AgFHXdS0ax0tzrfhia3t5Q0beVPNKfunIwvPTNc9ba94DutM07QtN1u9sJA4jgtX02V5CzHAXDEnJJ9e9ct8U/iBBeNY22lSpKxu0UBTnJK47r616Rr954d0eaKfWrmytbgdTIQpGCSOn0q/bckYOvRTcui028vmHs3Jv2dR3XfUzrn4WSWM1vd694xisNP3gBZLWNXfgEjJPynAb1+lVdf8AD0OnSR3PhfxVBe2VzItulvKse9WI6h8YbkNxgdR1rT0fWtB8Q3L/ANifadWliILm3gnlVMnjcwUgZIPX0PoauajeeIr22+w6D4NvJWAJElwfsqrxjdmWMDOT0zmumVapViqdHCv1a/WyOZRVOpz1K/yTt+F3f7jP8IeGbu/a8hPidLbW4OIbZII5CvGQW7c5xjt1rpLX4Y61PHb3F/4rmhvi6zzC3tY8CTBGFYYOMMRnAz1wOlYtz4Z8dzvd36aXbQ3N0oUxC7i3xlTuDbgMdgOO5H1HrHg2TV5PDln/AMJHbC31RVKTIJFfOCQGyvHIAP416WDwkWl7egoytvo/6dzkrV5Xfs6ra7ar80tPTTvqa1tG0VvFHJIZXVQGcjG445P41JRRXrnIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYfiHwrpWuzR3V3b+VqcK7bfUbY+VdQdfuSDnGSflOVOeQQSK5/U/Ceo2ep2+taV9k1TU7fO5rt2tZ7heytLDhWxzgPGwGccZJrvKKAPPNW1Dwz4iurW18U2t74d1kP5dk19ILSdmbGBBPG5SQ5Kny1dsMF3LkCq/j7Sp9H0kagb6xuIImCyLqEbLLJngLG0IBaRjwBtOSRxxg9r4qv8AStO0G7m18RPpzIYpIZI/ME275fLCc7y2cbcHOcV574c+Hl6ZYtbiuJdFmiZpNN0aUm7tbIEcFkduJD38tkCgsq8/NUTpxmrSVzKpRp1VaaucVFoWqNfx6t4l0nUNPiRn8lHT7TFacLjJh3MXYMcuUVVwV4Oc9R4esJNV8u60fUba6gXBMlpOsoAORyAcjoRyAcg+hrtE1vxTpEMZ1/w9HqEaxgPc6HP5rF+MkwSBGUEngK0mO/rWXql94H1u5eW5SysPEBUmKa9R9PuVcADb53ySZ4UEK3QDtXJUwFOWq0PPnlFCclJXViCVXjnnWUSby43FnyDhQoKj+EcdPWsnx1d6honwt8T63pLGLUraLMDYEoUblDOF5GQpPUcYzVie+sRo1m2jXN3rF9qIcafbGQtPOSXw5dukK7SfMY/dA+8zAG74J8P60PBniS18TaZDa3WoXk7iDzxcLLAyKAGxx0ypHfGe9ePgMsqvGc9ZWSe57spxhSUInzpY+Ptc1rRIRP4U0291ONmWbUZXaJXUsCoEa7VBCgrnv8p9c7mqacJWjl0qJpEZRuRDu2NjkZ7807VfCl/pd19mh09lj2gqI1OASB/WquueMNT+EfiSyW60ZL/Tb20Evkynyw7+YNzLIATuAUrt5A3AkdM/rftKeXUFUU3LyueZZ1Hax7v8Gra+t7CcXiMgJXAPX7q16bXi/wADNW+J+sa9ql3440tdO8PyxlrSCSFIHikLBlVVA3kBGwS/90d91e0V8liq/wBYqupa1zpiuVWCiiiucoKKKKACiiigAooooAKKKKACuZvfGdhb+IpNFhtdRvbuDyvtTWlsZEtfM+55h7ZHPGcDmumrl7zwZazeJJ9atNS1XT7i6MJu47SZVjuvK4TeCpI4G07SuRxQBzXh/wCK1pN4Q0bUtYtZ31G9tJb6a306BpBDBG5VpWyeFGB3Jz0FbUfxH0K48RW+jWH2u+uJVgcyW8OURZlDRsckHBUhiQCADzjmqCfCjRYdI0+wtb/V7X7JZy6ebiGZBLPbyPvaKQ7MEZPYAj1qe7+F2hXWt6bqEkt6I9OMBtbQNH5cXkqFQK2zzAPlBKh8E8kcmgB2j/FPwvqmptaRXbwR+XLLFd3KiOCVIz85VieAOvzAccitaPxpoM+oWdpZahDetdwzTRS2jrLGVixvG5SRkbhxWb4a+HGkeHNRW4024vRaoZDHYyGNoU35yAdm8jk4BYgVb8T+B9O1++0+8N1f6bc2KyxxyafKIiySAB0b5TkHA6YPvQBkyfFnw6totzHHqc8P2NL+RorUsIoGYrvb0AKnI6+xrvYJY54Y5oWDxyKHRh0IIyDXlEPwfiXVHtv7VvY/Dn9lw6cYop1We4CSOzLKfLxsIYfdIPWvV4Io4IY4YVCRxqERR0AAwBQA+mTqWhdRySCBT6KAPlDStRjMLeW48rzDtJPO3jFaYvMgEEVxWrw3PhrxLfaRfxTQeVPIIfMBTzIgzKsi5xlTtOCK17G682MDdzk9DXx+Iw7jJtn0VKqnFJGzLesGyGFczqnkTzEzqsi8HDLkfyrcaBmjJAJ+lYmoROAfkPT0qKKSehdRtrUwr/Ura1O6G0glYYGTEpOPqRXnvizUdR1G5ZRGY7UN8iRgLnj+LHXvXbSWN1fXQtdNtpru7bBEMCF3I9cDnFep/Dj4C3WoNHfeMxJaQA5FkpxI3+8eQB7dfpXv4KDWsUeRipp6Nnzh4b8J+IPElwYtJsLy9kVSxSFGbABAz9OR+dfQ/wAHf2eEdLi98f2sgWRENvbJOyOrZO7ftIxwF49/avpPRtD0vRbdIdKsLW0jRdo8mJVOPcgc9O9aNepY4dWjx+L4BeG4ZHEOqa8tsxOLdrvfGnPQAg/411Uvwy8OXVhHZajHfX9pGAqQ3V9LIiADHyqWwv4V21FHmS4Jqz1Rzfh/wN4Z8P2xg0nRbOGMvv5j3nPrlsntS+N0e18M3E2m2bS3MBj8pIIS7hfMUNtCgn7ueldHRU1I+0i4t7lU0qbTS2PCLLxn4bt0kll1aCG6uCGmW5kKsrAYxhgD+FZN54quNanaDw1bz6mwBObSJ5APm6khcAdOte7ah4Z0LUZjNf6LplzNknzJrSN2yevJFXNP02x02Mx6fZW1qhOSsESoCfwArxI5BRU3Ocm/U9FZlUUbRikz53Twl8RNSOY9M+yIed1xOg9/u7s/pVqH4T+ObjJuNU0+D2O5j+hr6Jor0YYDDw2ic08XXn9qx4JF8HPFB/1uv2X4I9aK/BW9OBL4nYj2tm/+OV7VRWv1Wj/IiPb1esmeF3vwN1CVcQeKgh/2rRj/AO1K8v8AEPwn+JVnefY7OwGpRZBW6t7lETkdwzAjHI6dvpX2JRR9Wpfyh7ep/MeQeCPghpOieG9RttWkj1PVr+HabueBW+zPhgrRA52Ebgcg5yo56V03hr4b6TprtdauBrWpSACSa7TegI6FI2LBOvbmu5orT2ULqVtUZ80rNXepBa2dtaAi1t4YQeojQL/Kp6KKsVrBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMMsauymRAyruIJGQPX6U+vHfiBa6hp/jzX9RXSdTvbTVPDT6dbvY2zT/v9xwjBQducjk4HvQB31xpNjP4ni1nVNQS48hB9gtpGVY7ckYaQDPzOeRuPQcDuT0g56V86w/DfWNU8U+GbG9tYLWOy8JQQyz3um/bbdZ1mOYhllUSYbPBJwDxg5r6JRVRFRAFVRgAdhQAtQ3lrb3sDQXkEVxC3WOVA6n6g8VNRQBzkfgnw7BqIv7LS4bG9EfkiayLW7eWW3FMxkfKW5I6E1Pd6Fcuu2w1/V7Beu1DFOCfczRu34ZH4VuUUAcmNM8SW7AvPoerLkcT2r2rgdxvUuD7fIMYxznI1NX8OaPr1vapr+j6dfeQ3mRpcQrMsb9yu4f05rYoptt7gFFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q+O3w4Hi/SH1bSkb/hIrGDZbKCAsy7gxRsKWPG/aMgZbngmvmrT9Qv9FujYa7ZXVhdLk+VdxmJ8djhiOPSvuquQ+Ifw90Dx5YLBrdsROmPKu4cLNFjP3SQRjk8EEfkK5q+GjWWu5tSrypbanz/pmr288Jy6hgegI/xqKaCbUbuOzsIzc3MzBVjjG89OpA5wOpqxcfs7eMbW/wAaZrelSWRc4aaRxIFzxkCPBOPpXu3w08A2XgvT85Fxqsq7Z7s9WGfujgYHANebTym07yeh2zzC8bJalb4X/Diz8H2oubpYrrXH3CS5+8FXoFQkAgYAz7k9sV39FFe1GKirI81tt3YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel is a an artist's rendering of a sagital section through the area where the achilles tendon attaches to the calcaneus. The transition from tendon to enthesial fibrocartilage to calcified fibrocartilage and finally bone is indicated. Right panel: right ankle and foot.",
"    <div class=\"footnotes\">",
"     TEN: Achilles tendon; CAL: calcaneus; EF: enthesial fibrocartilage; SF: sesamoid fibrocartilage; PF: periosteal fibrocartilage; RB: retrocalcaneal bursa; UF: uncalcified fibrocartilage; CF: calcified fibrocartilage; T: Tidemark.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wagget, AD, Ralphs, JR, Kwan, AP, et al. Characterization of collagens and proteoglycans at the intersection of the human achilles tendon. Matrix Biol 1998; 16:457. Copyright &copy; 1998 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6820=[""].join("\n");
var outline_f6_42_6820=null;
var title_f6_42_6821="Bilateral pneumothoraces PA";
var content_f6_42_6821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of bilateral pneumothoraces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with ARDS, increased permeability pulmonary edema, and barotrauma. Supine chest radiograph shows right subpulmonic and left apicolateral pneumothorax. Streaky lucencies are permeating the otherwise consolidated lungs as a reflection of interstitial pulmonary emphysema. The patient has a tracheostomy tube in place with a markedly hyperexpanded cuff, due to tracheomalacia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6821=[""].join("\n");
var outline_f6_42_6821=null;
var title_f6_42_6822="Doripenem: Drug information";
var content_f6_42_6822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doripenem: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/43/37555?source=see_link\">",
"    see \"Doripenem: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10805264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doribax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9537604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doribax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5432406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Carbapenem",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5432441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A switch to appropriate oral antimicrobial therapy may be considered after 3 days of parenteral therapy and demonstrated clinical improvement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal infection, complicated, severe:",
"     </b>",
"     I.V.: 500 mg every 8 hours for 5-14 days.",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA guidelines recommend treatment duration of 4-7 days (provided source controlled). Not recommended for mild-to-moderate, community-acquired intra-abdominal infections due to risk of toxicity and the development of resistant organisms (Solomkin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia (healthcare-associated [HAP], including ventilator-associated [VAP]):",
"     </b>",
"     Canadian labeling (U.S. unlabeled use [Chastre, 2008; Rea-Neto, 2008]): I.V.: 500 mg every 8 hours for 7-14 days.",
"     <b>",
"      Note:",
"     </b>",
"     A VAP trial showed numerically lower cure rate (versus a comparator antibiotic) and increased mortality; doses were twofold higher than the Canadian approved dose (FDA communication, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infection (complicated) or pyelonephritis:",
"     </b>",
"     I.V.: 500 mg every 8 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intravenous catheter-related bloodstream infection (unlabeled use):",
"     </b>",
"     I.V.: 500 mg every 8 hours for 7-14 days (IDSA, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5432442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5432443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 250 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-29 mL/minute: 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Hemodialysis: Dialyzable (~52% of dose removed during 4-hour session in ESRD patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Intermittent HD: 250 mg every 24 hours; if treating infections caused by",
"     <b>",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"     </b>",
"     , administer 500 mg every 12 hours on day 1, followed by 500 mg every 24 hours  (Tanoue, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     CVVHDF: 250 mg every 12 hours (Hidaka, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, doripenem undergoes minimal hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5432449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doribax&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5432404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5432444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse intravenously over 1 hour. Use of 4-hour infusion has been shown to increase %T&gt;MIC.",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling recommends a 4-hour infusion in late-onset ventilator-associated pneumonia (&gt;5 days ventilation [not an approved indication in the U.S. labeling])",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13487446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration:",
"     </b>",
"     <b>",
"      Compatible:",
"     </b>",
"     acyclovir sodium, amikacin sulfate, aminophylline, amiodarone HCL, anidulafungin, atropine sulfate, azithromycin, bumetanide, calcium gluconate, carboplatin, caspofungin acetate, cimetidine HCl, ciprofloxacin, cisplatin, cyclophosphamide, cyclosporine, daptomycin, dexamethasone sodium phosphate, digoxin, diltiazem Hcl, diphenhydramine HCl, dobutamine HCl, docetaxel, dopamine HCl, doxorubicin HCl, enalaprilat, esmolol HCl, esomeprazole sodium, etoposide phosphate, famotidine, fentanyl citrate, fluconazole, fluorouracil, foscarnet sodium, furosemide, gemcitabine HCl, gentamicin sulfate, granisetron HCl, heparin sodium, hydrocortisone sodium succinate, hydromorphone HCl, ifosfamide, insulin regular, labetalol HCl, levofloxacin, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine HCl, methotrexate sodium, methylprednisolone sodium succinate, metoclopramide HCl, metronidazole, micafungin sodium, midazolam HCl, milrinone lactate, morphine sulfate, moxifloxacin HCl, norepinephrine HCl, ondansetron HCl, paclitaxel, pantoprazole sodium, phenobarbital sodium, phenylephrine HCl, potassium  chloride, ranitidine HCl, sodium bicarbonate, sodium phosphates, tacrolimus, tigecycline, tobramycin sulfate, vancomycin HCl, voriconazole, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, potassium phosphates, propofol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, amphotericin B cholesteryl sulfate, amphotericin B lipid complex, amphotericin B liposomal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5432408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated intra-abdominal infections and complicated urinary tract infections (including pyelonephritis) due to susceptible aerobic gram-positive, aerobic gram-negative (including",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ), and anaerobic bacteria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Treatment of healthcare-associated pneumonia (including ventilator-associated pneumonia)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13487443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Treatment of intravascular catheter-related bloodstream infection due to extended-spectrum &beta;-lactamase (ESBL)-producing",
"     <i>",
"      Escherichia coli",
"     </i>",
"     and",
"     <i>",
"      Klebsiella",
"     </i>",
"     spp",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10907726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doripenem may be confused with ertapenem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Doribax&reg; may be confused with Zovirax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5432419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (4% to 12%), diarrhea (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (1% to 5%; includes allergic/bullous dermatitis, erythema, macular/papular eruptions, urticaria, and erythema multiforme), pruritus (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Oral candidiasis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (2% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Phlebitis (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal impairment/failure (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Vulvomycotic infection (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Anaphylaxis, interstitial pneumonia, leukopenia,  neutropenia, Stevens-Johnson syndrome, seizure, thrombocytopenia, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5432414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known serious hypersensitivity to doripenem or other carbapenems (eg, ertapenem, imipenem, meropenem); anaphylactic reactions to beta-lactam antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5432415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, and skin reactions have been reported in patients receiving beta-lactams.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Superinfection: Use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ventilator-associated pneumonia: Not approved for the treatment of pneumonia including healthcare-associated pneumonia (HAP) and ventilator-associated pneumonia (VAP). Demonstrated numerically lower cure rate (versus a comparator antibiotic) and increased mortality rate in patients with VAP in a Phase 3 study. In Canada, doripenem is currently approved for the treatment of HAP (including VAP) at doses less than those used in this clinical trial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Valproic acid and derivatives: Carbapenems, including doripenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Administer via intravenous infusion only. Per manufacturer&rsquo;s labeling, investigational experience of doripenem via inhalation resulted in pneumonitis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5432425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5432410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5432411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Information related to use during pregnancy has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5432413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6189124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if doripenem is excreted into breast milk. The manufacturer recommends that caution be exercised when administering doripenem to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Doribax Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $25.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $46.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5432447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs of anaphylaxis during first dose; periodic renal assessment; consider hematologic monitoring during prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Doribax (AR, AT, AU, BE, CO, CZ, DE, DK, EE, FR, GB, GR, HK, HN, ID, IE, IL, MY, NO, NZ, PH, PT, SE, SG, TH, TR);",
"     </li>",
"     <li>",
"      Finibax (KP, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5432431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to several of the penicillin-binding proteins (PBP-2, PBP-3, PBP-4), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis; bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5432433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     As with other time-dependent antibiotics, doripenem shows bacteriostatic effects at T&gt;MIC &lt;40% and bactericidal effects at T&gt;MIC&gt;40%. Of note, prolonged infusion time (over 4 hours) was more effective in increasing T&gt;MIC over 40% to up to 81%. Pharmacokinetics are linear (AUC directly proportional to dose) at doses administered over 1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Penetrates well into body fluids and tissues, including peritoneal and retroperitoneal fluids, gallbladder, bile, and urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 16.8 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 8% to 9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Non-CYP-mediated metabolism via hydrolysis by dehydropeptidase-I to doripenem-M1 (inactive metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (70% as unchanged drug; 15% as doripenem-M1 metabolite); feces (&lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialyzable with reduction in systemic levels by 48% to 62%.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chastre J, Wunderink R, Prokocimer P, et al, &ldquo;Efficacy and Safety of Intravenous Infusion of Doripenem Versus Imipenem in Ventilator-associated Pneumonia: A Multicenter, Randomized Study,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1089-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/18379232/pubmed\" id=\"18379232\" target=\"_blank\">",
"        18379232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Food and Drug Administration (FDA) Drug Safety Communication, \"FDA Statement on Recently Terminated Clinical Trial with Doribax (Doripenem)&rdquo;. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety.ucm285883.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety.ucm285883.htm",
"      </a>",
"      . Accessed on January 10, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hidaka S, Goto K, Hagiwara S, et al, &ldquo;Doripenem Pharmacokinetics in Critically Ill Patients Receiving Continuous Hemodiafiltration (CHDF,&rdquo;",
"      <i>",
"       Yakugaku Zasshi",
"      </i>",
"      [in English], 2010, 130(1):87-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/20046071/pubmed\" id=\"20046071\" target=\"_blank\">",
"        20046071",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenkins SG, Fisher AC, Peterson JA, et al, &ldquo;Meta-analysis of Doripenem vs Comparators in Patients with Pseudomonas Infections Enrolled in Four Phase III Efficacy and Safety Trials,&rdquo;",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2009, 25(12):3029-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/19849650/pubmed\" id=\"19849650\" target=\"_blank\">",
"        19849650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keam SJ, &ldquo;Doripenem: A Review of Its Use in the Treatment of Bacterial Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2008, 68(14):2021-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/18778123/pubmed\" id=\"18778123\" target=\"_blank\">",
"        18778123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kollef MH, Nathwani D, Merchant S, et al, &ldquo;Medical Resource Utilization Among Patients With Ventilator-Associated Pneumonia: Pooled Analysis of Randomized Studies of Doripenem versus Comparators,&rdquo;",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2010, 14(3):R84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/20459721/pubmed\" id=\"20459721\" target=\"_blank\">",
"        20459721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo TS, Borchardt SM, Welch JM, et al, &ldquo;Doripenem in Hospital Infections: A Focus on Nosocomial Pneumonia, Complicated Intra-Abdominal Infections, and Complicated Urinary Tract Infections,&rdquo;",
"      <i>",
"       Infect Drug Resist",
"      </i>",
"      , 2009, 2:41-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/21694886/pubmed\" id=\"21694886\" target=\"_blank\">",
"        21694886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(1):1-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/19489710/pubmed\" id=\"19489710\" target=\"_blank\">",
"        19489710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkins MD and Elborn JS, &ldquo;Newer Antimicrobial Agents and Their Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2010, 65(9):1853-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/20605846/pubmed\" id=\"20605846\" target=\"_blank\">",
"        20605846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      R&eacute;a-Neto A, Niederman M, Lobo SM, et al, &ldquo;Efficacy and Safety of Doripenem versus Piperacillin/Tazobactam in Nosocomial Pneumonia: A Randomized, Open-label, Multicenter Study,&rdquo;",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2008, 24(7):2113-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/18549664/pubmed\" id=\"18549664\" target=\"_blank\">",
"        18549664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanoue K, Nishi K, Kadowaki D, et al, &ldquo;Removal of Doripenem During Hemodialysis and the Optimum Dosing Regimen for Patients Undergoing Hemodialysis,&rdquo;",
"      <i>",
"       Ther Apher Dial",
"      </i>",
"      , 2011, 15(3):327-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/21624085/pubmed\" id=\"21624085\" target=\"_blank\">",
"        21624085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA,",
"      <i>",
"       Handbook on Injectable Drugs",
"      </i>",
"      , 16th ed, American Society of Health-System Pharmacists&reg;, Bethesda, MD: 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhanel GG, Wiebe R, Dilay L, et al, &ldquo;Comparative Review of the Carbapenems,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2007, 67(7):1027-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/42/6822/abstract-text/17488146/pubmed\" id=\"17488146\" target=\"_blank\">",
"        17488146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9358 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6822=[""].join("\n");
var outline_f6_42_6822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10805264\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9537604\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432406\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432441\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432442\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432443\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804872\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432449\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432404\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432444\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13487446\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432408\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13487443\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10907726\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432419\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432414\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432415\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299228\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432425\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432410\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432411\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432413\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6189124\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321785\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432447\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961932\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432431\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432433\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/43/37555?source=related_link\">",
"      Doripenem: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_42_6823="General principles of fracture management: Early and late complications";
var content_f6_42_6823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of fracture management: Early and late complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6823/contributors\">",
"     Allyson S Howe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6823/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6823/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/42/6823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H66786295\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures are associated with a range of potential complications. Acute complications occur as a direct result of the trauma sustained and can include damage to vascular structures, nerves, or soft tissue. Delayed complications may occur after initial treatment or in response to treatment. Therefore, reevaluation at regular intervals during healing is prudent in most cases.",
"   </p>",
"   <p>",
"    Major acute and long-term complications of fractures are reviewed here. The management of specific fractures and some specific complications are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786302\">",
"    <span class=\"h1\">",
"     LIFE-THREATENING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain fractures can cause severe hemorrhage or predispose to other life-threatening complications. Femur fractures that disrupt the femoral artery or its branches are potentially fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/1\">",
"     1",
"    </a>",
"    ]. Pelvic fractures can damage pelvic arteries or veins causing life-threatening hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/2\">",
"     2",
"    </a>",
"    ]. Hip fractures, particularly in the elderly, may prevent ambulation, resulting in potentially life-threatening complications, such as pneumonia, thromboembolic disease, and possibly rhabdomyolysis, if there is a prolonged period of immobility. Patients with multiple rib fractures are at substantial risk for pulmonary contusion and related complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41960?source=see_link\">",
"     \"Midshaft femur fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link\">",
"     \"Pelvic trauma: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18937?source=see_link\">",
"     \"Hip fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"     \"Initial evaluation and management of rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786309\">",
"    <span class=\"h1\">",
"     ARTERIAL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper fracture healing requires adequate blood supply to the injured site. However, fractures can involve sharp bone fragments that injure adjacent arteries, causing hemorrhage and potentially impairing bone healing. Certain fractures are associated with particular arterial injuries (",
"    <a class=\"graphic graphic_table graphicRef61068 \" href=\"UTD.htm?7/13/7388\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases, the distal and proximal pulses of any fractured extremity should be examined to determine the adequacy of arterial flow. Immediate reduction and immobilization is required for any fracture associated with neurovascular compromise.",
"   </p>",
"   <p>",
"    In cases of high-velocity trauma, angiography may be needed to define vascular injury, as the presence of distal pulses does not always indicate intact proximal arteries. Signs of disrupted arterial flow may include a cool extremity, mottled skin color, and loss of sensation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786316\">",
"    <span class=\"h1\">",
"     NERVE INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerves are susceptible to damage from fracture fragments acutely, but can also be injured during treatment from complications of casting or by excessive callus formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Compression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Transection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Compression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Transection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain nerves are particularly susceptible to injury because of their proximity to common fracture sites. These injuries are described in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef51146 \" href=\"UTD.htm?19/12/19659\">",
"     table 2",
"    </a>",
"    ). As an example, the median nerve is often injured in association with distal radius fractures, with a reported incidence of 0 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/4\">",
"     4",
"    </a>",
"    ]. The mechanism for median nerve injury can involve swelling around the distal radius or excessive wrist flexion of the cast, both of which increase pressure within the carpal tunnel [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With any extremity fracture, sensory and motor function should be examined at the time of presentation. Pain often limits the initial evaluation and adequate analgesia must be provided. Immediate reduction and immobilization is required for any fracture associated with neurovascular compromise.",
"   </p>",
"   <p>",
"    Complete or partial nerve transection, or excessive nerve stretch or compression, from fracture fragments or the force of the initial trauma can lead to chronic nerve injury. Nerve injury that is not present initially, but presents after immobilization can be caused by excessive pressure from the cast or splint, or from stretching of the nerve from abnormal positioning during immobilization. Generally, such delayed injuries result in neurapraxia, in that the nerve fibers are not permanently damaged, but physiologically the nerve signal is interrupted. Transient neurapraxia generally resolves by two to three months with proper treatment, which includes ensuring that the nerve is allowed to heal without stretching or prolonged compression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/6\">",
"     6",
"    </a>",
"    ]. Reexamination following immobilization to characterize any residual deficits is prudent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786323\">",
"    <span class=\"h1\">",
"     COMPARTMENT SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups of human limbs are divided into sections, or compartments, formed by strong, potentially unyielding, fascial membranes. Acute compartment syndrome (ACS) occurs when increased pressure within a compartment compromises the circulation and function of tissues within that space. With fractures, bleeding or swelling within a fascial compartment creates the increased pressure. ACS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long bone fractures are the injuries most commonly associated with ACS, particularly fractures of the tibia, distal radius, supracondylar area of the humerus, and femur. In addition to excessive intracompartmental fluid, ACS can also be caused by casts or bandaging that limits the space available for soft tissue swelling.",
"   </p>",
"   <p>",
"    Early recognition of ACS and immediate fasciotomy may be limb sparing. Early symptoms and signs can include pain out of proportion to the apparent injury, persistent deep ache or burning pain, paresthesias, and pain with passive stretching of muscles in the affected compartment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786330\">",
"    <span class=\"h1\">",
"     THROMBOEMBOLIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major orthopedic trauma substantially increases the risk for venous thrombosis. Therefore, patients hospitalized with major fractures receive prophylactic treatment to prevent the development of deep vein thrombosis (DVT). Of note, even minor fractures are associated with an increased risk for DVT. Given the increased risk for DVT associated with trauma, imaging studies are needed to assess fracture patients with suggestive clinical findings. The diagnosis and management of DVT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786337\">",
"    <span class=\"h1\">",
"     OPEN FRACTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures are those with direct communication between the fracture and the environment due to traumatic disruption of the intervening soft tissue and skin. Open fractures have a higher incidence of infection than closed fractures.",
"   </p>",
"   <p>",
"    Management of open fractures depends to some degree upon the extent of soft tissue damage, the degree of wound contamination, and the underlying health of the patient. All open fractures receive the following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immobilization",
"     </li>",
"     <li>",
"      Antibiotics",
"     </li>",
"     <li>",
"      Tetanus prophylaxis as indicated (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Analgesia as needed",
"     </li>",
"     <li>",
"      Prompt surgical irrigation and debridement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, early wound closure reduces infection risk and is performed whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/7\">",
"     7",
"    </a>",
"    ]. The pathogens and antibiotics used for prophylaxis against open fracture infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classification systems have been developed to determine the risk of infection in open fractures. Risk increases in correlation with the size of the wound, severity of soft tissue and bone damage, degree of contamination, and whether wound coverage is adequate. The most commonly used classification system is described in the attached table (",
"    <a class=\"graphic graphic_table graphicRef72480 \" href=\"UTD.htm?17/32/17931\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    In addition to fracture characteristics, the number and severity of patient comorbidities also increases the risk of infection. Host factors associated with infection and compromised wound healing include age &ge;80 years, nicotine use, diabetes, active malignancy, pulmonary insufficiency, and immunocompromised states. The following infection rates have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class A (no comorbid factors): 4 percent",
"     </li>",
"     <li>",
"      Class B (1 to 2 comorbid factors): 15 percent",
"     </li>",
"     <li>",
"      Class C (3 or more comorbid factors): 31 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66786344\">",
"    <span class=\"h1\">",
"     OSTEOMYELITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis is infection localized to bone. Trauma, including fractures, is one of several possible causes. Osteomyelitis is discussed in detail separately; aspects of particular relevance to fractures are described here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Posttraumatic osteomyelitis accounts for up to 47 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/10\">",
"     10",
"    </a>",
"    ]. Open fractures are at greater risk, with infection rates reported to range from 2 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/7,8,11\">",
"     7,8,11",
"    </a>",
"    ]. The extent of soft tissue injury at presentation appears to be the most significant risk factor. With open fractures, copious irrigation and fracture stabilization are important for reducing the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute osteomyelitis usually presents with gradual progression of dull localized pain over several days. Local findings (tenderness, warmth, erythema, swelling) and systemic symptoms (fever, rigors) may be present. Decreased range of motion, point tenderness, and joint effusions may be seen, but are also present with uninfected fractures, making clinical diagnosis potentially difficult.",
"   </p>",
"   <p>",
"    In some cases, osteomyelitis presents with few symptoms or signs. This is more common in subacute or chronic infections, infections of the hip, pelvis, or vertebrae, and in young patients. Chronic osteomyelitis may present with pain, erythema, or swelling, sometimes in association with a draining sinus tract. Fractures that are healing slower than expected or that remain extremely painful despite adequate immobilization may be complicated by osteomyelitis. Intravenous antibiotics and surgical debridement are the mainstays of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21949930\">",
"    <span class=\"h1\">",
"     NONUNION AND MALUNION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete healing of a fracture where the cortices of the bone fragments do not reconnect is called a nonunion. When a fracture heals with a deformity (eg, angulation, rotation, incongruent joint surface), this is called a malunion.",
"   </p>",
"   <p>",
"    Nonunions commonly present with persistent pain, swelling, or instability beyond the time when healing should normally have occurred. In most cases, symptomatic nonunions are treated with open reduction and fixation. Some nonunions are asymptomatic and treatment is unnecessary. An example of such a nonunion is spondylolysis of the lumbar pars interarticularis, where a fibrous union can provide sufficient stability and often forms without causing persistent symptoms.",
"   </p>",
"   <p>",
"    Common reasons for nonunion and malunion include a tenuous blood supply to the fractured bone (eg, scaphoid, proximal fifth metatarsal), behaviors that interfere with bone healing (eg, smoking, alcohol abuse), poor bone fixation (ie, excessive movement at the fracture site), poor apposition of bone fragments (ie, fragment ends too far from one another), and infection. Patients at high risk for nonunion, such as those with diabetes, osteoporosis, or neuropathy, must be reevaluated frequently (usually weekly or every other week) during the course of fracture healing.",
"   </p>",
"   <p>",
"    Some medications may inhibit bone healing and should be used cautiously after a fracture occurs. However, many studies of medications that affect bone healing use animal models and therefore, should be interpreted conservatively when considering the effect on humans. The following table lists some of the agents known to adversely affect bone healing after a fracture (",
"    <a class=\"graphic graphic_table graphicRef53621 \" href=\"UTD.htm?23/59/24507\">",
"     table 4",
"    </a>",
"    ). Drugs that affect bone metabolism generally are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs that",
"    <strong>",
"     may",
"    </strong>",
"    impair fracture healing include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal anti-inflammatory drugs (NSAIDs): The effect of these drugs on bone healing is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H22#H22\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Healing of musculoskeletal injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids: Glucocorticoids are known to impair bone metabolism and reduce bone density, but animal studies of their effect on fracture healing have shown inconsistent results. Effects may be dose dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some antibiotics: Multiple fluoroquinolones have been implicated in impaired fracture healing [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/13\">",
"       13",
"      </a>",
"      ]. The mechanism is thought to involve effects on cartilage growth and production. Studies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      report mixed results in effects on bone healing [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bisphosphonates: In animal studies, bisphosphonates are found to aid in the formation of dense, strong callus. However, some authors suggest that these drugs may arrest bone remodeling and weaken bone [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Controlled studies of fracture healing in patients who take bisphosphonates are lacking.",
"     </li>",
"     <li>",
"      Chemotherapy agents: Some chemotherapeutic medications inhibit rapidly reproducing cells, and these may impair normal bone healing following a fracture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of environmental factors increase the risk of nonunion, including cigarette smoking and excessive alcohol use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6823/abstract/18-23\">",
"     18-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain fractures are more often associated with nonunion because of their tenuous blood supply. These include fractures of the following bones:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Scaphoid",
"      </strong>",
"      &ndash; Scaphoid fractures have a high propensity for nonunion despite optimal care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"       \"Scaphoid fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fifth metatarsal",
"      </strong>",
"      &ndash; Fractures of the proximal diaphysis of the fifth metatarsal (Jones fracture) are at high risk for nonunion despite optimal care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=see_link\">",
"       \"Proximal fifth metatarsal fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hamate",
"      </strong>",
"      &ndash; Hook of the hamate fractures are commonly misdiagnosed as wrist sprains and frequently result in nonunion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=see_link\">",
"       \"Hamate fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tibia",
"      </strong>",
"      &ndash; Open tibia fractures with significant displacement are at high risk for nonunion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=see_link\">",
"       \"Overview of tibial fractures in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21949937\">",
"    <span class=\"h1\">",
"     COMPLEX REGIONAL PAIN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex Regional Pain Syndrome (CRPS), also known as Reflex Sympathetic Dystrophy (RSD), is a complex disorder of the extremities characterized by localized pain, swelling, limited range of motion, vasomotor instability, skin changes, and bone demineralization. Fractures, with or without a nerve injury, are a common inciting event. Early recognition and initiation of therapy is important for successful treatment. CRPS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=see_link\">",
"     \"Prevention and management of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21949944\">",
"    <span class=\"h1\">",
"     FAT EMBOLISM SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat embolism syndrome (FES) is a difficult diagnosis associated with closed long bone fractures of the lower extremity and pelvis. FES typically manifests 24 to 72 hours after injury with dyspnea, tachypnea, and hypoxemia. Neurologic abnormalities and a petechial rash may be present. Severe respiratory distress and death can occur. FES is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=see_link\">",
"     \"Fat embolism syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21949951\">",
"    <span class=\"h1\">",
"     POST-TRAUMATIC ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures with joint involvement can cause damage to articular cartilage, ultimately resulting in premature osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21949958\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures are associated with a range of potential complications. Pelvis and femur fractures can cause severe hemorrhage; hip and multiple rib fractures predispose to other life-threatening complications, primarily deep vein thrombosis and pulmonary contusion respectively. (See",
"      <a class=\"local\" href=\"#H66786302\">",
"       'Life-threatening conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute complications occur as a direct result of the trauma sustained and can include damage to vascular structures, nerves, or soft tissue. Long bone fractures (eg, tibia) are most often associated with acute compartment syndrome, a limb-threatening condition. (See",
"      <a class=\"local\" href=\"#H66786309\">",
"       'Arterial injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H66786316\">",
"       'Nerve injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H66786323\">",
"       'Compartment syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major orthopedic trauma substantially increases the risk for venous thrombosis, and prophylactic treatment is indicated in most cases. (See",
"      <a class=\"local\" href=\"#H66786330\">",
"       'Thromboembolic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed complications may occur after initial treatment or in response to treatment. Examples include osteomyelitis, nonunion, and post-traumatic osteoarthritis. Open fractures are at greater risk for osteomyelitis. The particular fracture types and medications associated with fracture nonunion are described in the text. Frequent reevaluation of high risk fractures is imperative to help prevent nonunion or malunion. (See",
"      <a class=\"local\" href=\"#H66786344\">",
"       'Osteomyelitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21949930\">",
"       'Nonunion and malunion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21949937\">",
"       'Complex regional pain syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21949951\">",
"       'Post-traumatic arthritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/1\">",
"      Cary DV. Management of traumatic femoral shaft fractures. JAAPA 2005; 18:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/2\">",
"      Grainger MF, Porter KM. Life threatening haemorrhage from obturator vessel tear as a result of pubic ramus fracture. Injury 2003; 34:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/3\">",
"      Schlickewei W, Kuner EH, Mullaji AB, G&ouml;tze B. Upper and lower limb fractures with concomitant arterial injury. J Bone Joint Surg Br 1992; 74:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/4\">",
"      McKay SD, MacDermid JC, Roth JH, Richards RS. Assessment of complications of distal radius fractures and development of a complication checklist. J Hand Surg Am 2001; 26:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/5\">",
"      Turner RG, Faber KJ, Athwal GS. Complications of distal radius fractures. Orthop Clin North Am 2007; 38:217.",
"     </a>",
"    </li>",
"    <li>",
"     Townsend, CM, Beauchamp, RD, Evers, BM, Mattox, KL. Hand surgery: trauma. In: Sabiston Textbook of Surgery, 18th, Saunders, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/7\">",
"      Okike K, Bhattacharyya T. Trends in the management of open fractures. A critical analysis. J Bone Joint Surg Am 2006; 88:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/8\">",
"      Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma 1984; 24:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/9\">",
"      Bowen TR, Widmaier JC. Host classification predicts infection after open fracture. Clin Orthop Relat Res 2005; :205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/10\">",
"      Gross T, Kaim AH, Regazzoni P, Widmer AF. Current concepts in posttraumatic osteomyelitis: a diagnostic challenge with new imaging options. J Trauma 2002; 52:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/11\">",
"      Paluska, SA. Osteomyelitis. Clinics in Family Practice 2004; 6:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/12\">",
"      Pountos I, Georgouli T, Blokhuis TJ, et al. Pharmacological agents and impairment of fracture healing: what is the evidence? Injury 2008; 39:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/13\">",
"      Jee WS, Park HZ, Roberts WE, Kenner GH. Corticosteroid and bone. Am J Anat 1970; 129:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/14\">",
"      Kim SG, Chung TY, Kim MS, Lim SC. The effect of high local concentrations of antibiotics on demineralized bone induction in rats. J Oral Maxillofac Surg 2004; 62:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/15\">",
"      Haleem AA, Rouse MS, Lewallen DG, et al. Gentamicin and vancomycin do not impair experimental fracture healing. Clin Orthop Relat Res 2004; :22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/16\">",
"      Li J, Mori S, Kaji Y, et al. Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 1999; 14:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/17\">",
"      Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/18\">",
"      Kwiatkowski TC, Hanley EN Jr, Ramp WK. Cigarette smoking and its orthopedic consequences. Am J Orthop (Belle Mead NJ) 1996; 25:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/19\">",
"      Brown CW, Orme TJ, Richardson HD. The rate of pseudarthrosis (surgical nonunion) in patients who are smokers and patients who are nonsmokers: a comparison study. Spine (Phila Pa 1976) 1986; 11:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/20\">",
"      Chen F, Osterman AL, Mahony K. Smoking and bony union after ulna-shortening osteotomy. Am J Orthop (Belle Mead NJ) 2001; 30:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/21\">",
"      McKee MD, DiPasquale DJ, Wild LM, et al. The effect of smoking on clinical outcome and complication rates following Ilizarov reconstruction. J Orthop Trauma 2003; 17:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/22\">",
"      Furr AM, Schweinfurth JM, May WL. Factors associated with long-term complications after repair of mandibular fractures. Laryngoscope 2006; 116:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6823/abstract/23\">",
"      King AR, Moran SL, Steinmann SP. Humeral nonunion. Hand Clin 2007; 23:449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13798 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6823=[""].join("\n");
var outline_f6_42_6823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21949958\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786295\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786302\">",
"      LIFE-THREATENING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786309\">",
"      ARTERIAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786316\">",
"      NERVE INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786323\">",
"      COMPARTMENT SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786330\">",
"      THROMBOEMBOLIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786337\">",
"      OPEN FRACTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66786344\">",
"      OSTEOMYELITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21949930\">",
"      NONUNION AND MALUNION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21949937\">",
"      COMPLEX REGIONAL PAIN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21949944\">",
"      FAT EMBOLISM SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21949951\">",
"      POST-TRAUMATIC ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21949958\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/13/7388\" title=\"table 1\">",
"      Artery and nerve injuries associated with specific fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/12/19659\" title=\"table 2\">",
"      Fractures and associated nerve injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/32/17931\" title=\"table 3\">",
"      Infection rates of open fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/59/24507\" title=\"table 4\">",
"      Medication effects on fracture healing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=related_link\">",
"      Hamate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18937?source=related_link\">",
"      Hip fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=related_link\">",
"      Initial evaluation and management of rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41960?source=related_link\">",
"      Midshaft femur fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=related_link\">",
"      Overview of tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=related_link\">",
"      Prevention and management of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=related_link\">",
"      Proximal fifth metatarsal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=related_link\">",
"      Treatment and prevention of osteomyelitis following trauma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_42_6824="Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis";
var content_f6_42_6824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6824/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6824/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6824/contributors\">",
"     Karl F Hilgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6824/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6824/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6824/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6824/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/42/6824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive nephrosclerosis is a disorder that is usually associated with chronic hypertension. In addition to the level of blood pressure, it is clear that individual factors are involved. As an example, black patients have an approximate eight-fold elevation in the risk of hypertension-induced end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/1\">",
"     1",
"    </a>",
"    ]; this increase in risk may persist even with \"adequate\" blood pressure control. Although low birth weight and bias in diagnosis based upon the patient's race may be involved, the recent recognition of an association between two independent sequence variants in the APOL1 gene on chromosome 22 and renal disease in African-Americans, including focal segmental glomerular sclerosis and hypertension-related end-stage renal disease, provides a much more likely pathophysiologic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/2\">",
"     2",
"    </a>",
"    ], and suggests that hypertensive nephrosclerosis in blacks and whites may be distinct diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive nephrosclerosis is characterized histologically by vascular, glomerular, and tubulointerstitial involvement (",
"    <a class=\"graphic graphic_picture graphicRef53909 \" href=\"UTD.htm?8/3/8245\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/3\">",
"     3",
"    </a>",
"    ]. The histologic pattern of renal injury in patients with malignant hypertension (ie, malignant nephrosclerosis) is different, and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H3#H3\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular disease consists of intimal thickening and luminal narrowing of the large and small renal arteries and the glomerular arterioles. Two different processes appear to contribute to the development of the vascular lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hypertrophic response to chronic hypertension that is manifested by medial hypertrophy and fibroblastic intimal thickening, leading to narrowing of the vascular lumen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. This response is initially adaptive by minimizing the degree to which the rise in systemic pressure is transmitted to the arterioles and capillaries [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The deposition of hyaline-like material (plasma protein constituents, such as inactive C3b, part of the third component of complement) into the damaged, more permeable arteriolar wall [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glomerulosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomeruli may show both focal global (involving the entire glomerulus) and focal segmental sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Global sclerosis is thought to reflect ischemic injury, leading to nephron loss. This can be further categorized histologically as either solidified (in which the entire tuft is involved) or obsolescent (in which the tuft is retracted and Bowman's space is filled with collagenous-type material). The solidified form is more commonly associated with African-Americans than with Caucasians, and might contribute to the increased prevalence of nephrosclerosis in African-Americans [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Focal segmental sclerosis is typically associated with glomerular enlargement, which is probably a compensatory response to nephron loss. However, the combination of hypertrophy and a rise in intracapillary pressure in these glomeruli may gradually lead to hemodynamically-mediated segmental sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The altered hemodynamics may be due in part to abnormal metabolism of nitric oxide. In the spontaneously hypertensive rat which exhibits severe glomerulosclerosis with age, the chronic administration of intravenous arginine (the precursor of nitric oxide) significantly reduced severe glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/7\">",
"     7",
"    </a>",
"    ]. Renovascular disease may accelerate the development of the secondary sclerotic lesion by enhancing ischemic nephron loss [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two observations in humans in addition to the glomerular hypertrophy are compatible with the importance of glomerular hemodynamics in progressive renal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among initially untreated patients with mild hypertension, an elevated creatinine clearance (suggestive of glomerular hyperfiltration) at baseline has been related to a subsequent significant rise in the plasma creatinine concentration and higher blood pressure levels [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/9\">",
"       9",
"      </a>",
"      ], and to the development of microalbuminuria [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"       \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Part of the enhanced risk in black patients may be related to maternal malnutrition, leading to low birth weight, impaired renal development, and a reduction in nephron number. The decrease in the number of nephrons results in compensatory hypertrophy in the nephrons that are present and subsequent glomerulosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/11\">",
"       11",
"      </a>",
"      ]. The way by which the variants on the ApoL1 gene are translated into renal physiology has not been elucidated [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"       \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20724834\">",
"    <span class=\"h2\">",
"     Interstitial nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular and glomerular diseases are associated with an often severe interstitial nephritis. The etiology of the interstitial nephritis is incompletely understood. Studies in experimental animals have shown that severe stenosis of the main renal artery (as opposed to the intrarenal arteries in benign nephrosclerosis) can induce tubular atrophy and an intense chronic interstitial nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/12\">",
"     12",
"    </a>",
"    ]. The interstitial disease in the ischemic kidney is at least in part an active immunologic process that may be initiated by ischemia-induced alterations in antigen expression on the surface of the tubular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/12\">",
"     12",
"    </a>",
"    ]. In this model, the contralateral kidney, which is exposed to high blood pressure, develops similar tubulointerstitial inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrosclerosis is seen with normal aging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/14\">",
"     14",
"    </a>",
"    ], but is clearly exacerbated by chronic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/15\">",
"     15",
"    </a>",
"    ]. The overall incidence of progressive renal disease in hypertensives is relatively low and most affected patients have mild hypertension (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Incidence of renal failure'",
"    </a>",
"    below). There are, however, three major groups at increased risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blacks",
"     </li>",
"     <li>",
"      Patients with more marked elevations in blood pressure",
"     </li>",
"     <li>",
"      Patients with underlying chronic renal disease, particularly those with diabetic nephropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with nephrosclerosis typically present with a long history of hypertension, slowly progressive elevations in the blood urea nitrogen (BUN) and plasma creatinine concentration, and mild proteinuria. Blacks with these clinical features are particularly likely to have underlying nephrosclerosis. As an example, a renal biopsy was performed in 39 nondiabetic hypertensive black patients with chronic kidney disease who did not have marked proteinuria (total protein to creatinine ratio &le;2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/16\">",
"     16",
"    </a>",
"    ]. Histologic changes compatible with nephrosclerosis as the sole disease were seen in 38 of the patients; the remaining patient may have had primary focal segmental glomerulosclerosis. Similar data are not available in whites.",
"   </p>",
"   <p>",
"    Hyperuricemia (independent of diuretic therapy) is a relatively early finding in benign nephrosclerosis, and appears to reflect the reduction in renal blood flow induced by the vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/17\">",
"     17",
"    </a>",
"    ]. The urinalysis is typically benign with the sediment revealing few cells or casts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein excretion is usually mildly elevated (less than 1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    in nephrosclerosis; this reflects the generally focal nature of the glomerular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/4\">",
"     4",
"    </a>",
"    ]. However, more prominent proteinuria can occur, occasionally reaching as high 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/18\">",
"     18",
"    </a>",
"    ], with such affected patients being more likely to have superimposed renovascular disease or malignant hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/8\">",
"     8",
"    </a>",
"    ]. The proteinuria may be due to the less affected glomeruli having undergone compensatory hypertrophy with a higher intraglomerular pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence of renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interesting clinical paradox is that benign hypertensive nephrosclerosis is one of the most common diagnoses in new patients starting maintenance dialysis. However, in the absence of one of the risk factors noted above, the rate of progression is generally slow and only a",
"    <strong>",
"     few patients",
"    </strong>",
"    with apparent essential hypertension develop progressive renal disease. This can be appreciated from the findings in three large trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Multiple Risk Factor Intervention Trial (MRFIT) in which the seven-year incidence of a doubling of the plasma creatinine concentration to more than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      was less than 0.2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/3\">",
"       3",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_figure graphicRef62524 \" href=\"UTD.htm?31/16/32013\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Hypertension Detection and Follow-up Program in which the five-year incidence of more than a 25 percent rise in the plasma creatinine concentration to above 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      was 1.3 to 1.4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective report of 2125 patients in which the likelihood of attaining or maintaining a plasma creatinine concentration above 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      was less than 2 percent at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/19\">",
"       19",
"      </a>",
"      ]. Furthermore, 31 percent of these patients had proteinuria at entry (suggesting that they may have had coexisting renal disease) and there was no relation between changes in the plasma creatinine concentration and the degree of diastolic blood pressure control (&lt;95 mmHg versus &ge;95 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these observations suggest four, not mutually exclusive, possibilities to explain the apparently high incidence of hypertensive nephrosclerosis as a cause of end-stage renal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of hypertensive patients is so large that even the small percentage at risk constitutes a large number.",
"     </li>",
"     <li>",
"      The rate of progression is generally so slow that many patients at risk cannot be detected by five to seven year studies.",
"     </li>",
"     <li>",
"      In the absence of a kidney biopsy, many patients (particularly nonblack patients) diagnosed as having hypertensive nephrosclerosis may actually have a different cause of kidney disease.",
"     </li>",
"     <li>",
"      African-American patients have a unique genetic variant that likely interacts with hypertension, which is responsible for their propensity to focal and segmental glomerulosclerosis (FSGS) and end stage renal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term follow-up from the MRFIT trial, in which over 322,000 men were screened for possible entry, are compatible with the first hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/20\">",
"     20",
"    </a>",
"    ]. A direct correlation was found between the initial blood pressure (measured on only one occasion) and, at 16-year follow-up, the development of end-stage renal disease of any cause [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/19\">",
"     19",
"    </a>",
"    ]. The adjusted relative risk increased from 1.0 in those with optimal blood pressure",
"    <span class=\"nowrap\">",
"     (&lt;120/&lt;80)",
"    </span>",
"    to 1.9 with high normal blood pressure, 3.1 with mild hypertension, 6.0 with moderate hypertension, and 11.2 with severe hypertension (",
"    <a class=\"graphic graphic_figure graphicRef69454 \" href=\"UTD.htm?38/4/38990\">",
"     figure 2",
"    </a>",
"    ). There were also data compatible with a very low percentage of patients with mild hypertension",
"    <span class=\"nowrap\">",
"     (140-159/90-99)",
"    </span>",
"    being at risk. The age-adjusted rate of end-stage renal disease in this group was only 0.34 percent at 16 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of benign hypertensive nephrosclerosis is generally",
"    <strong>",
"     inferred",
"    </strong>",
"    from the characteristic clinical features, since confirmation by renal biopsy is rarely indicated. Affected patients usually have a long history of hypertension that is typically accompanied by left ventricular hypertrophy, a relatively normal urine sediment, small kidneys, and, if previous information is available, slowly progressive renal insufficiency with gradually increasing proteinuria that is usually nonnephrotic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/1,16,21\">",
"     1,16,21",
"    </a>",
"    ]. In the future, recognition of the variants on the ApoL1 gene on chromosome 22 will likely provide a sensitive and specific diagnostic tool.",
"   </p>",
"   <p>",
"    Most important from a clinical viewpoint, the hypertension",
"    <strong>",
"     precedes",
"    </strong>",
"    the development of either proteinuria or renal insufficiency, and there is no other obvious cause of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/22\">",
"     22",
"    </a>",
"    ]. In comparison, patients with one of other more common causes of the nephrotic syndrome, such as membranous nephropathy or minimal change disease, typically present with moderate to heavy proteinuria and edema. Other glomerular diseases may be heralded by signs and symptoms other than hypertension and mild to moderate proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the historical data are incomplete, a clinical diagnosis of benign nephrosclerosis may be incorrect unless confirmed by renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/21\">",
"     21",
"    </a>",
"    ]. This is particularly true in nonblack patients in whom hypertensive end-stage renal disease is much less common in the absence of malignant hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. On the other hand, nephrologists are more likely to ascribe otherwise unexplained renal failure to hypertension in black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is one disorder that commonly presents with similar findings to hypertensive nephrosclerosis but is potentially",
"    <strong>",
"     reversible",
"    </strong>",
"    : ischemic renal disease due to bilateral renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/5\">",
"     5",
"    </a>",
"    ]. These patients are more likely to have a history of severe or refractory hypertension, an acute elevation in blood pressure over a previously stable baseline, or relatively rapid deterioration of renal function due to more complete occlusion of one or both renal arteries, or to removal of angiotensin driven renal perfusion by ACE inhibitor or ARB therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of progressing to renal failure is directly related to the degree of blood pressure control (",
"    <a class=\"graphic graphic_figure graphicRef62524 \" href=\"UTD.htm?31/16/32013\">",
"     figure 1",
"    </a>",
"    ). Episodes of accelerated hypertension (which may be unrecognized) can enhance the rate of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/3\">",
"     3",
"    </a>",
"    ]. On the other hand, effective treatment of the hypertension to a diastolic pressure below 90 mmHg usually prevents continued renal injury although, as noted above, there is little evidence that diastolic pressures of 95 to 100 mmHg are harmful to the kidney over a five-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, two issues that are important to consider:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the type of antihypertensive therapy matter (ie, are ACE inhibitors more protective in nephrosclerosis as they appear to be in many other forms of renal disease?).",
"     </li>",
"     <li>",
"      What level of blood pressure control provides the maximum degree of renal protection?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are as yet no definitive answers to these questions but some data are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of antihypertensive agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors and angiotensin II receptor blockers are the drugs of choice for renal protection in patients with proteinuric chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .) Whether they are also protective in patients with benign nephrosclerosis was best addressed in African American Study of Kidney Disease and Hypertension (AASK).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     AASK trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of renal protection in black patients with presumed nephrosclerosis was also addressed in part in the African American Study of Kidney Disease and Hypertension (AASK) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This trial included 1094 African-Americans with long-standing hypertension, otherwise unexplained slowly progressive chronic kidney disease, and proteinuria (mean about 500 to 600",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    as mentioned above, this pattern in blacks was shown to be almost always associated with histologic changes compatible with nephrosclerosis as the sole disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients were allocated to one of three drugs:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (436 patients),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (441 patients), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (217 patients), and to one of two blood pressure goals,",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. The primary end point was the rate of change in glomerular filtration rate (GFR); the secondary clinical composite outcome was the time to first event including a 50 percent reduction in GFR, an actual decrease in GFR of 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, the onset of renal failure, or death. The main conclusions of the trial were similar using the serum creatinine concentration or iothalamate clearance to estimate GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At interim analysis, all patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    were compared to all those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/26\">",
"     26",
"    </a>",
"    ]. Among patients with proteinuria, the rate of loss of GFR after the first three months and incidence of the secondary composite end point were significantly",
"    <strong>",
"     lower",
"    </strong>",
"    in the ramipril arm. This suggested that there would be no additional information gained from continuing those with less proteinuria, and the amlodipine arm was terminated.",
"   </p>",
"   <p>",
"    At study end after approximately four years, the average blood pressure was",
"    <span class=\"nowrap\">",
"     128/78",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     141/85",
"    </span>",
"    mmHg in the lower and usual blood pressure group, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. The mean rate of change in GFR and the rate of the secondary composite end point were",
"    <strong>",
"     similar",
"    </strong>",
"    with both blood pressure goals, suggesting that the lower blood pressure goal may not provide further benefit in slowing progression of the renal disease. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Goal blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With respect to the different antihypertensive agents, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      had a significantly",
"      <strong>",
"       decreased",
"      </strong>",
"      risk of the secondary clinical composite outcome when compared with those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (6.9 versus 8.7 percent per year, risk reduction 22 percent, 95% CI 1-38 percent) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      (risk reduction 38 percent, 95% CI 14-56 percent). There was no significant difference between the amlodipine and metoprolol groups.",
"     </li>",
"     <li>",
"      Significant differences in the slope of the GFR were not consistently observed with any of the drug group comparisons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a ten-year follow-up study suggested that neither ACE inhibition nor aggressive blood pressure lowering affected the long-term rate of CKD progression among these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/30\">",
"     30",
"    </a>",
"    ]. Subjects who did not progress to ESRD during the AASK trial continued to be followed for a total of ten years. Although greater than 80 percent of participants were continued on an ACE inhibitor after the AASK trial ended, and despite an achieved mean blood pressure of",
"    <span class=\"nowrap\">",
"     133/78",
"    </span>",
"    mmHg, the majority of patients (67 percent) had a yearly decline in GFR of greater than 1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    On the other hand, the effects of ACE inhibition and a more aggressive blood pressure goal in the AASK trial differed according to whether or not patients had proteinuria, with benefits observed in proteinuric but not nonproteinuric patients. These issues, and our recommendations for therapy in patients with hypertensive nephrosclerosis and other nondiabetic renal disease, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H16#H16\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'AASK trial of antihypertensive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H371310#H371310\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'AASK trial of goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H12989828#H12989828\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for treatment of hypertension in black patients with relatively normal renal function are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations regarding goal blood pressure for patients with presumed hypertensive nephrosclerosis are discussed elsewhere (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Progression despite blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, the plasma creatinine concentration and degree of proteinuria continue to rise despite seemingly good control of the systemic BP. Why such patients are susceptible to progressive renal injury is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/5\">",
"     5",
"    </a>",
"    ]. It is possible, for example, that the variants on gene ApoL1 may play an important role in this setting or that some of these patients have a different renal disease that is exacerbated by hypertension. A discussion that also reviews the mechanisms by which the institution of antihypertensive therapy can lead to an acute, reversible decline in glomerular filtration rate can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20261?source=see_link\">",
"     \"Effect of antihypertensive treatment on renal function in essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not surprisingly, patient survival in those who progress to dialysis is generally less than that in patients with primary glomerular diseases. This increase in risk, which is also seen in diabetics, largely reflects the associated extrarenal vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3780969\">",
"    <span class=\"h2\">",
"     Improvement of renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypertensive nephrosclerosis is usually progressive, long-term improvement in renal function is observed in a minority of patients. This was shown in a post-hoc analysis of the AASK trial mentioned above, in which glomerular filtration rate was estimated a median of 16 times during 12 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6824/abstract/31\">",
"     31",
"    </a>",
"    ]. A positive slope (indicating an improvement of glomerular filtration rate) was present in three percent of patients; the glomerular filtration rate in these individuals improved at a rate of 1.1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 per year. Compared with patients whose renal function did not improve, those whose renal function improved were younger (51 versus 55 years), had lower median baseline urine protein-to-creatinine ratios (0.04 versus 0.07",
"    <span class=\"nowrap\">",
"     g/g),",
"    </span>",
"    and were more likely to have been randomly assigned to the lower target blood pressure (77 versus 49 percent). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'AASK trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11268824\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertensive nephrosclerosis is a renal disorder associated with chronic hypertension. Risk factors include black race associated with genetic variants, severe hypertension, and underlying chronic kidney disease, especially diabetic kidney disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristic histologic findings include vascular, glomerular, and tubulointerstitial lesions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients present with a long history of hypertension that is typically accompanied by retinopathy and left ventricular hypertrophy, and which precedes the development of either proteinuria or renal insufficiency. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients present with elevations in blood urea nitrogen and serum creatinine concentrations. Protein excretion is usually less than 1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      although greater amounts can occur. Hyperuricemia may be observed. The urinalysis is typically benign with the sediment revealing few cells or casts. The rate of progression of renal disease is generally slow.",
"     </li>",
"     <li>",
"      The diagnosis of hypertensive nephrosclerosis is generally inferred from the characteristic clinical features; confirmation by renal biopsy is rarely indicated. Other obvious causes of renal disease should be excluded, especially bilateral renal artery stenosis. Patients with renal artery stenosis are more likely to have severe or refractory hypertension, an acute elevation in blood pressure over a previously stable baseline, or relatively rapid deterioration of renal function due to more complete occlusion of one or both renal arteries, or to removal of angiotensin driven renal perfusion by ACE inhibitor or ARB therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective treatment of the hypertension usually slows progression of renal injury. It is not clear whether ACE inhibitors and angiotensin II receptor blockers, which are the drugs of choice for renal protection in patients with proteinuric chronic renal failure, are also protective in patients with benign nephrosclerosis without proteinuria. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of antihypertensive agent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/1\">",
"      Toto RB. Hypertensive nephrosclerosis in African Americans. Kidney Int 2003; 64:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/2\">",
"      Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/3\">",
"      Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/4\">",
"      Harvey JM, Howie AJ, Lee SJ, et al. Renal biopsy findings in hypertensive patients with proteinuria. Lancet 1992; 340:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/5\">",
"      Zucchelli P, Zuccal&agrave; A. Primary hypertension--how does it cause renal failure? Nephrol Dial Transplant 1994; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/6\">",
"      Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002; 62:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/7\">",
"      Ono H, Ono Y, Frohlich ED. L-arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats. J Hypertens 1999; 17:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/8\">",
"      Thadhani R, Pascual M, Nickeleit V, et al. Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet 1996; 347:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/9\">",
"      Schmieder RE, Veelken R, Gatzka CD, et al. Predictors for hypertensive nephropathy: results of a 6-year follow-up study in essential hypertension. J Hypertens 1995; 13:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/10\">",
"      Palatini P, Mormino P, Dorigatti F, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006; 70:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/11\">",
"      Regina S, Lucas R, Miraglia SM, et al. Intrauterine food restriction as a determinant of nephrosclerosis. Am J Kidney Dis 2001; 37:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/12\">",
"      Truong LD, Farhood A, Tasby J, Gillum D. Experimental chronic renal ischemia: morphologic and immunologic studies. Kidney Int 1992; 41:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/13\">",
"      Mai M, Geiger H, Hilgers KF, et al. Early interstitial changes in hypertension-induced renal injury. Hypertension 1993; 22:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/14\">",
"      Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med 2010; 152:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/15\">",
"      Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/16\">",
"      Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/17\">",
"      Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/18\">",
"      Mujais SK, Emmanouel DS, Kasinath BS, Spargo BH. Marked proteinuria in hypertensive nephrosclerosis. Am J Nephrol 1985; 5:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/19\">",
"      Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995; 345:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/20\">",
"      Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/21\">",
"      Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994; 23:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/22\">",
"      Beevers DG, Lip GY. Does non-malignant essential hypertension cause renal damage? A clinician's view. J Hum Hypertens 1996; 10:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/23\">",
"      Zarif L, Covic A, Iyengar S, et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000; 15:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/24\">",
"      Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol 1995; 141:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/25\">",
"      Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/26\">",
"      Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/27\">",
"      Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/28\">",
"      Lewis J, Greene T, Appel L, et al. A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 2004; 15:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/29\">",
"      Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/30\">",
"      Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6824/abstract/31\">",
"      Hu B, Gadegbeku C, Lipkowitz MS, et al. Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol 2012; 23:706.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3824 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6824=[""].join("\n");
var outline_f6_42_6824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11268824\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20724834\">",
"      Interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence of renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of antihypertensive agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - AASK trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Progression despite blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3780969\">",
"      Improvement of renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11268824\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3824|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/16/32013\" title=\"figure 1\">",
"      Blood pressure and kidney related mortality in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/4/38990\" title=\"figure 2\">",
"      Hypertension and ESRD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3824|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/3/8245\" title=\"picture 1\">",
"      Benign nephrosclerosis Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20261?source=related_link\">",
"      Effect of antihypertensive treatment on renal function in essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_42_6825="CSF secretion reabsorption";
var content_f6_42_6825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Cerebrospinal fluid formation and reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 709px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6825=[""].join("\n");
var outline_f6_42_6825=null;
var title_f6_42_6826="Cervical cancer in pregnancy";
var content_f6_42_6826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cancer in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Amer Karam, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/42/6826/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/42/6826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One to three percent of women diagnosed with cervical cancer are pregnant or postpartum at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. About one-half of these cases are diagnosed prenatally and the other half are diagnosed within 12 months of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/3\">",
"     3",
"    </a>",
"    ]. Cervical cancer is one of the most common malignancies in pregnancy, with an estimated incidence of 0.8 to 1.5 cases per 10,000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients are diagnosed at an early stage of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This is probably a result of routine prenatal screening, but it is also possible that advanced stage disease interferes with conception. Stage for stage, the course of disease, and prognosis of cervical cancer in pregnant patients are similar to those of nonpregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data from large randomized trials upon which to base recommendations for the care of pregnant patients with cervical cancer. Therefore, management is based upon evidence from randomized trials in nonpregnant women, findings from observational studies of pregnant women, and the unique medical and ethical considerations underlying each individual case. Treatment should be individualized and based on the stage of cancer, the woman's desire to continue pregnancy, and the risks of modifying or delaying therapy during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms and signs of cervical carcinoma in pregnancy are dependent upon the clinical stage and lesion size. In two series, all pregnant patients with stage IA and 50 percent of those with stage IB carcinoma were asymptomatic at the time of diagnosis (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Patients with symptomatic stage IB disease presented with abnormal vaginal bleeding or discharge; clinical manifestations in patients with more advanced disease also included pelvic pain, sciatica-type leg pain, flank pain, chronic anemia, and shortness of breath.",
"   </p>",
"   <p>",
"    The diagnosis of cervical cancer is often delayed in pregnant women since many of these symptoms are similar to those associated with a normal pregnancy. In one study, the average duration of symptoms before diagnosis of cervical cancer in pregnancy was 4.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability to detect early neoplasia by physical examination is limited by pregnancy-associated cervical changes, such as cervical decidualization, ectropion, and stromal edema; in late pregnancy, detection is further impeded by cervical ripening. Nevertheless, a gross cervical lesion may be observed or palpated at any gestational age. A gross lesion suspicious for malignancy should be biopsied. Women with pathological confirmation of cervical cancer or preinvasive disease should be referred to a gynecologic oncologist. Referral is also indicated if the suspicious cervical mass is biopsy negative for invasive carcinoma but the biopsy results are nondiagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abnormal cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer is often first suspected when a screening test for the disease is abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/6\">",
"     6",
"    </a>",
"    ]. While this has not been studied directly, the performance characteristics of the Papanicolaou test do not appear to differ significantly between pregnant and nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/12\">",
"     12",
"    </a>",
"    ]. Overall, the rate of significant cytological abnormalities among obstetrical patients has been reported to be 5 to 8 percent and is similar to that of the non-pregnant population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of an abnormal screening cervical cytology in pregnancy should follow the 2006 Bethesda consensus guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women younger than age 20 have a high prevalence of HPV infection and minimally abnormal cytology tests (ASC-US, LSIL). The spontaneous resolution rate of these abnormalities is 90 percent and the risk of invasive cancer is very low [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/14\">",
"       14",
"      </a>",
"      ]. Therefore, colposcopy during pregnancy can be omitted, but cytology should be repeated postpartum.",
"     </li>",
"     <li>",
"      ASC-US and LSIL in pregnant women over the age of 20 years may be managed as in the non-pregnant patient, with the exception that it is acceptable to defer colposcopy to at least six weeks postpartum.",
"     </li>",
"     <li>",
"      Colposcopy is recommended for all adolescent and non-adolescent women with ASC-H, HSIL, and AGC.",
"     </li>",
"     <li>",
"      Lesions suspicious for CIN 2,3 or cancer should be biopsied.",
"     </li>",
"     <li>",
"      It is recommended that endocervical curettage not be performed in pregnancy.",
"     </li>",
"     <li>",
"      If colposcopy reveals no CIN 2,3 or suspicion for cancer, additional cytologic and colposcopic evaluation should be performed postpartum, but no sooner than six weeks after delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat evaluation postpartum is essential, as persistent high grade disease is common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. As an example, one study reported persistent HSIL postpartum in all 28 patients with antepartum HSIL, three of whom were diagnosed with microinvasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/15\">",
"     15",
"    </a>",
"    ]. Another study observed that HSIL regressed to normal in 53 percent, 31 percent had persistent high grade disease, and 16 percent regressed to a lower grade lesion within six months postpartum, but about half the patients in this series were lost to follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Colposcopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal cytology warrants further evaluation with colposcopy and, if indicated, directed biopsies. Cervical biopsies can be performed during pregnancy without a significantly increased risk of excessive bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/18\">",
"     18",
"    </a>",
"    ]. Bleeding, if encountered after biopsy, can be controlled with use of monsel's solution or suturing. However, endocervical curettage is not performed in pregnant women because of concern that it may disrupt the pregnancy, although there is no evidence proving an increased risk of pregnancy disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colposcopic evaluation of the cervix in pregnancy can be challenging; it should be done by colposcopists experienced in recognizing both pregnancy-related and cancer-related cervical changes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As an example, the increased vascularity of the gestational cervix exaggerates the way immature metaplastic epithelium reacts to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , which may mimic a dysplastic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/20\">",
"     20",
"    </a>",
"    ]. Conversely, neoplastic cervical lesions early in pregnancy may be mistaken for the normal eversion of the squamocolumnar junction or benign cervical decidualization.",
"   </p>",
"   <p>",
"    If colposcopy in early pregnancy is unsatisfactory, repeating the procedure in 6 to 12 weeks may result in a satisfactory examination because the transformation zone may have \"migrated\" to the ectocervix, thus allowing a satisfactory examination by 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/18\">",
"     18",
"    </a>",
"    ]. The reliability of colposcopy with directed biopsy is not related to the stage of pregnancy when performed by an experienced colposcopist familiar with the changes of the cervix that occur in pregnant women. The reliability of colposcopy and biopsy in pregnancy is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 612 gravid patients with abnormal cytology, no invasive carcinoma was missed and complications of biopsies were minimal, with only two patients experiencing preterm labor and delivery (both had undergone cone biopsies) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, another study found colposcopy to have concordance, overestimation and underestimation of the final diagnosis in 72.6, 17.6 and 9.8 percent of cases, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/19\">",
"       19",
"      </a>",
"      ]. The authors also noted that the reliability of colposcopy and directed biopsy was not related to the pregnant state.",
"     </li>",
"     <li>",
"      A study of 89 pregnant women who underwent both colposcopy and biopsy for abnormal Pap smears reported 27 had a colposcopic impression that was",
"      <span class=\"nowrap\">",
"       normal/CIN",
"      </span>",
"      l and biopsy confirmed this impression in 22 cases and showed CIN",
"      <span class=\"nowrap\">",
"       ll/lll",
"      </span>",
"      in 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/17\">",
"       17",
"      </a>",
"      ]. Of the 62 women with colposcopic impression of CIN",
"      <span class=\"nowrap\">",
"       ll/lll,",
"      </span>",
"      biopsy confirmed the impression in 34 and was",
"      <span class=\"nowrap\">",
"       normal/CIN",
"      </span>",
"      l in 28. Of note, this study included a total of 1079 pregnant women with abnormal Pap smears (325 ASC, 589 LSIL, 164 HSIL), all underwent colposcopy but only 7 percent had a biopsy. No cancers were missed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Conization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic conization in non-pregnant patients is performed to exclude invasive cancer when a punch biopsy shows only microinvasive disease or adenocarcinoma in situ (stage IA or microscopic IB, no clinically visible lesion) because the maximum depth of invasion can only be determined by examination of the entire lesion. However, traditional indications for cervical conization in the nongravid population are not applicable during pregnancy. Diagnostic conization is only indicated during pregnancy if confirmation of invasive disease will alter the timing or mode of delivery; otherwise, conization is postponed until the postpartum period to avoid potentially disrupting the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H10#H10\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"     \"Cervical adenocarcinoma in situ\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If prepartum conization is performed, the optimal time appears to be the second trimester, preferably between 14 and 20 weeks of gestation. Cervical conization should not be performed within four weeks of the estimated date of delivery because labor may cause the fresh conization wound to hemorrhage or extend [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential complications of conization during pregnancy include hemorrhage (5 to 15 percent), miscarriage, preterm",
"    <span class=\"nowrap\">",
"     labor/delivery,",
"    </span>",
"    and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Fetal death is uncommon, but has been reported weeks after the conization procedure. Some of these deaths appeared to be due to chorioamnionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/11\">",
"     11",
"    </a>",
"    ]. The frequency of operative hemorrhage greater than 500 mL correlates with the trimester in which the procedure is performed: the risk is minimal in the first trimester, about 5 percent in the second, and about 10 percent in the third [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. In the largest consecutive series of cone biopsies during pregnancy (n = 180), fetal loss possibly or probably related to the procedure occurred in eight (4.5 percent) pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/25\">",
"     25",
"    </a>",
"    ]. Three of the eight fetal losses occurred prior to 14 weeks of gestation and one to four weeks after conization. Thirteen women (7.2 percent) lost greater than 500 mL of blood, 11 of whom were in the third trimester.",
"   </p>",
"   <p>",
"    Technically, pregnancy-related eversion of the squamocolumnar junction facilitates the conization procedure in pregnant women. Frequently, a limited wedge biopsy is all that is needed to produce an appropriate diagnostic specimen. Some experts suggest excising a \"coin\"-shaped specimen instead of a \"cone\"- shaped specimen to limit disruption of the endocervical canal and minimize morbidities associated with blood loss and disturbing the fetal membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a true conization is required, one option is to perform a cone cerclage whereby a cerclage is placed immediately after the conization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link\">",
"     \"Transvaginal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate staging is critical for patient counseling and treatment planning. Cervical cancer staging is clinical and follows the guidelines put forth by the International Federation of Gynecology and Obstetrics (FIGO) (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination is a key element of the clinical staging process. If examination in an ambulatory setting is suboptimal, we suggest performing the examination under anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the nongravid population, radiologic studies that can be used for FIGO staging include chest and skeletal radiographs, intravenous pyelogram (IVP), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema. Findings on computed tomographic (CT) studies, magnetic resonance imaging (MRI), positron emission tomography (PET), and lymphangiograms cannot be used for staging purposes, with the exception of the urogram portion. However, these studies can be helpful for treatment planning.",
"   </p>",
"   <p>",
"    In pregnant women, imaging studies should be limited to those associated with the lowest exposure to ionizing radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .) We recommend the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A chest x-ray (with abdominal shielding) is warranted for evaluation of pulmonary metastatic disease in all patients with more than microscopic cervical cancer.",
"     </li>",
"     <li>",
"      For stage IA and",
"      <span class=\"nowrap\">",
"       microscopic/very",
"      </span>",
"      small stage IB (&lt;1 cm) cervical cancer in which extracervical disease is unlikely, routine radiographic imaging of the urinary tract may be omitted.",
"     </li>",
"     <li>",
"      In gravid patients with larger stage IB1, bulky stage IB2, or more advanced disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      higher-risk histology (adenocarcinoma, small cell carcinoma), the urinary tract should be imaged with ultrasonography or MRI to rule out stage IIIB disease.",
"     </li>",
"     <li>",
"      For pregnant patients with larger stage IB1, bulky stage IB2 or more advanced disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      higher-risk histology (adenocarcinoma, small cell carcinoma), additional imaging of the abdomen and pelvis is extremely helpful for patient counseling and formulation of a management plan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrasonography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI can be used to evaluate liver and urinary tract involvement. MRI has the advantage of excellent tissue contrast and depicts pelvic anatomy in three planes; therefore, it can be used to calculate tumor volume and assess spread to adjacent organs and lymph nodes. For the assessment of tumor size in nonpregnant patients, the overall accuracy of MRI is 93 percent and the negative predictive value for parametrial invasion is above 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/28\">",
"     28",
"    </a>",
"    ]. For small nodal metastases, the accuracy of conventional MRI in nonpregnant patients is poor; however, once nodal diameter is greater than 1 cm in short axis, the sensitivity and specificity of MRI are 62 to 89 percent and 88 to 91 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients who desire to continue their pregnancy, but are at significant risk for lymph node metastases, staging lymphadenectomy during pregnancy via extraperitoneal or laparoscopic approach may provide the most definitive information on lymph node status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. This information is important for guiding management, including whether to delay definitive therapy. Case reports on patients with early stage cervical cancer who underwent successful laparoscopic lymphadenectomy during pregnancy suggest the feasibility of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic staging procedures such as cystoscopy or proctosigmoidoscopy are rarely indicated, but if required, experts in this area have concluded that endoscopy during pregnancy is generally safe if performed by an experienced operator [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of cervical cancer in pregnancy poses major challenges to the patient, her family, and her care providers. A careful multidisciplinary team approach is required to address issues such as termination versus continuation of pregnancy, delay of definitive treatment, mode of therapy during pregnancy, timing and route of delivery (",
"    <a class=\"graphic graphic_algorithm graphicRef58797 \" href=\"UTD.htm?1/13/1233\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the fetal lungs are mature at the time of diagnosis, or if the fetus is",
"      <span class=\"nowrap\">",
"       at/near",
"      </span>",
"      the gestational age of expected lung maturity, immediate delivery and definitive treatment of the mother is the preferred approach (antenatal glucocorticoid therapy are given, if indicated).",
"     </li>",
"     <li>",
"      If the pregnancy is previable and the patient decides not to continue the pregnancy, immediate therapy of the mother should be initiated (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Pregnancy termination'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      For all other patients, decisions regarding timing of treatment and delivery require careful consideration of the stage of disease, the trimester in which the diagnosis is made, and the preferences of the affected woman and her family regarding the pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     High grade preinvasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of high grade preinvasive disease should be deferred to the postpartum period because progression to invasive carcinoma during pregnancy is rare (0 to 0.4 percent); regression may occur postpartum, thus obviating the need for excision; and excision during pregnancy is a morbid procedure (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Conization'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. It is unclear whether route of delivery (vaginal versus cesarean) affects the rate of regression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/15,37\">",
"     15,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Microinvasive disease (stage IA1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, conization is performed during pregnancy to exclude invasive disease, and when knowledge of the diagnosis will alter management (timing or mode of delivery, maternal treatment). Patients with confirmed stage IA1 disease (conization specimen showing microinvasion only with margins negative for invasion or dysplasia and no lymphovascular space involvement) are followed by clinical examination and colposcopy each trimester throughout the pregnancy. Cesarean delivery is performed for standard obstetrical indications. Cytology and colposcopy with biopsies and endocervical curettage should be performed six to eight weeks postpartum.",
"   </p>",
"   <p>",
"    The feasibility of this approach was suggested by a report of eight pregnant women with IA1 squamous cell carcinoma (negative margins and no lymphovascular space involvement [LVSI]) who were diagnosed by cervical conization and managed expectantly for 9 to 25 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/38\">",
"     38",
"    </a>",
"    ]. No invasive disease was detected in the postpartum hysterectomy specimens.",
"   </p>",
"   <p>",
"    In addition, a study on the conservative treatment of four patients with stage IA1 adenocarcinoma of the cervix and no LVSI who underwent conization during pregnancy reported excellent maternal and fetal outcomes: all had term deliveries and no invasive carcinoma in the postpartum treatment specimens (hysterectomy in three, repeat conization in one) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/39\">",
"     39",
"    </a>",
"    ]. While the management of stage IA1 adenocarcinoma of the cervix continues to raise controversy, this report and a growing body of evidence in the literature of non-pregnant women with stage IA1 adenocarcinoma of the cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/40\">",
"     40",
"    </a>",
"    ] suggest that stage by stage cervical adenocarcinoma may be treated similar to its squamous counterpart and has a comparable prognosis.",
"   </p>",
"   <p>",
"    If margins of the conization performed during pregnancy are positive for dysplasia, the patient has a 22 percent risk of residual disease in the uterus and about a 10 percent chance of having more than microinvasive disease (based on data from non-pregnant patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/41\">",
"     41",
"    </a>",
"    ]. Based on the evidence summarized below, we feel a reasonable approach is to follow these patients with monthly clinical examinations and colposcopy each trimester, deliver by cesarean, and then repeat the conization postpartum.",
"   </p>",
"   <p>",
"    If there is no evidence of residual disease on follow-up evaluation, then:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who desire future childbearing need no additional treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/42\">",
"       42",
"      </a>",
"      ]. They should be counseled regarding the need for long-term follow-up to detect possible recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H24#H24\">",
"       \"Management of early stage cervical cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women who have completed childbearing should be offered extrafascial hysterectomy without lymph node dissection (unless there is evidence of LVSI) since a small percentage (&lt;0.5 percent) of stage IA1 patients ultimately develop a recurrence and die of metastatic disease. The operative and postoperative morbidity and mortality risks, however, should be weighed against the small risk of disease recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cesarean hysterectomy is an option for women with stage IA1 disease who had a negative conization margin and who are having a cesarean delivery for obstetrical indications. The convenience of performing cesarean delivery and hysterectomy in one setting needs to be weighed against the high morbidity of hysterectomy at the time of cesarean. Otherwise, if the conization margin has been positive, delivery by cesarean and repeat conization postpartum to rule out invasive disease prior to interval hysterectomy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29367?source=see_link\">",
"     \"Peripartum hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Early stage invasive disease (stage IA2, IB, nonbulky IIA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of invasive cervical cancer in pregnancy poses major challenges to the patient, her family, and her care providers. A multidisciplinary team approach facilitates caring for these patients. Relevant issues that need to be addressed include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continuation versus termination of the pregnancy",
"     </li>",
"     <li>",
"      Risks associated with delay of definitive treatment",
"     </li>",
"     <li>",
"      Treatment options in pregnant compared with nonpregnant women",
"     </li>",
"     <li>",
"      Timing and route of delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed above, delivery and definitive treatment of the mother is the preferred approach if the fetus is at or near term, after confirmation of fetal lung maturity. At an early gestational age, termination of the pregnancy and definitive treatment of the mother may be an option. If the mother chooses to continue the pregnancy, decisions regarding timing of treatment and delivery require careful consideration of disease stage and the trimester in which the diagnosis is made (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Delaying treatment to minimize fetal/neonatal risks'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Immediate, definitive treatment regardless of gestational age is generally appropriate in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Locally advanced disease",
"     </li>",
"     <li>",
"      Documented lymph node metastases",
"     </li>",
"     <li>",
"      Patient choice",
"     </li>",
"     <li>",
"      Progression of disease during the pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, for these patients, management needs to be carefully individualized, weighing maternal benefit from immediate local therapy against fetal risks of prematurity. Particularly in the late second and early third trimester, a treatment delay of three weeks may convey significant gains in fetal prognosis, while the delay is unlikely to alter the maternal outcome. Furthermore, patients with documented distant metastases may be able to initiate systemic chemotherapy during pregnancy, thus providing the mother with the appropriate therapy while allowing more time for fetal growth and maturation.",
"   </p>",
"   <p>",
"    In general, treatment guidelines for pregnant patients with invasive cervical cancer are similar to those for nonpregnant patients. Surgery and definitive radiation therapy are similarly effective, but differ in associated morbidity and type of complications. The advantages of definitive surgical treatment are that it avoids the risk of radiation-associated vaginal stricture and the acute and long-term gastrointestinal toxicities of radiation therapy, and it generally preserves ovarian function. The surgical approach also enables the surgeon to thoroughly explore the pelvis and abdomen for metastatic disease not detectable on clinical staging; thus, it can assist in individualizing further management.",
"   </p>",
"   <p>",
"    On the other hand, radiation therapy avoids both immediate and long-term sequelae of surgery, including the risks of blood loss necessitating transfusion, prolonged hospitalization for postoperative recovery, and surgery-related injury to nearby organs. If primary radiation therapy is administered, it should be given with concomitant chemotherapy (chemoradiotherapy) as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    augments tumor response to radiation therapy, adding an absolute 12 percent benefit in five-year survival over radiation therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pregnancy termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a patient with early stage disease who chooses to terminate the pregnancy, we generally recommend radical hysterectomy with the fetus in situ and with preservation of the ovaries whenever possible. Alternatively, radiation therapy can be initiated and will usually lead to pregnancy termination. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medically-induced uterine evacuation is also possible. One report described two cases of FIGO stage IB2 squamous cell carcinoma of the cervix diagnosed in the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/45\">",
"     45",
"    </a>",
"    ]. Following whole pelvic irradiation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    radiosensitization, intrauterine fetal demise occurred without subsequent spontaneous abortion. In both cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was used successfully to evacuate the uterus without an undue delay in therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radical cesarean hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is recommended for patients with stage IA2-IB-IIA disease (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Delivery route'",
"    </a>",
"    below). A radical hysterectomy and",
"    <span class=\"nowrap\">",
"     pelvic/paraaortic",
"    </span>",
"    lymphadenectomy can be performed as soon as the infant has been delivered and the hysterotomy closed. Cesarean-radical hysterectomy is associated with greater blood loss and need for blood transfusion than radical hysterectomy in nongravid women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. However, no significant differences have been noted in the time required for postoperative bladder drainage, mean hospital stay, febrile morbidity, incidence of wound infection, wound separation, pelvic abscess, thromboembolic disease, or urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/48\">",
"     48",
"    </a>",
"    ]. The benefit of one surgical procedure (cesarean-radical hysterectomy) instead of two separate procedures (cesarean and radical hysterectomy) outweighs the disadvantage of increased blood loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Radical trachelectomy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Postpartum",
"      </strong>",
"      &mdash; Radical trachelectomy with lymphadenectomy six to eight weeks postpartum is an alternative to radical hysterectomy for selected women with stage IA2 or small stage IB1 disease for whom fertility preservation is desired [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. This procedure is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=see_link\">",
"       \"Fertility sparing surgery for invasive cervical cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Antepartum",
"      </strong>",
"      &mdash; There are few reports of radical trachelectomy performed during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/51-53\">",
"       51-53",
"      </a>",
"      ]. In the reports, a total of eight women with stage IB1 disease and one woman with IA2 disease underwent radical trachelectomy at 7 to 18 weeks of gestation either abdominally (five patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/51\">",
"       51",
"      </a>",
"      ]) or vaginally (four patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/52,54\">",
"       52,54",
"      </a>",
"      ]). Three pregnancies resulted in fetal loss that occurred 1 to 16 days postoperatively, five pregnancies went on to deliver at &ge;36 weeks of gestation, and one delivered at 29 weeks. No maternal recurrences were observed at follow-up of 9 to 132 months. Given the high rate of fetal loss, antepartum radical trachelectomy should be avoided during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early pregnancy, external-beam radiation therapy can be initiated with the fetus in situ, and usually results in fetal death. Pregnancy loss occurs in 70 percent of cases by completion of 40 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/2,55\">",
"     2,55",
"    </a>",
"    ]. After miscarriage occurs, radiation treatment is completed with intracavitary brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/2,56\">",
"     2,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest evacuating the uterus before radiation treatment if the fetus is more than 20 weeks of gestation. Dilatation and evacuation (D&amp;E) or hysterotomy may be used. This recommendation is based on data from a series of 14 pregnant patients who underwent radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/57\">",
"     57",
"    </a>",
"    ]. Pregnancy loss occurred between 27 and 50 days (average 32.7 days) after the start of therapy in the first trimester and between 33 and 66 days in the second trimester (average 43.9 days). This suggests that fetal tissues are less sensitive to radiation in the second trimester; as a result, pregnancy loss is delayed and occurs less reliably compared with therapy in the first trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary radiation therapy is given with concomitant platinum-based chemotherapy. At least four cases of chemoradiotherapy initiated with the fetus in utero have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/45,58\">",
"     45,58",
"    </a>",
"    ]. In two, stage IB2 squamous cell carcinoma of the cervix diagnosed in the second trimester was treated with whole pelvic irradiation concurrent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    radiosensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/45\">",
"     45",
"    </a>",
"    ]. Intrauterine fetal demise occurred without subsequent miscarriage; in both cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was successful in evacuating the uterus without undue delay in therapy. In the remaining cases, uterine evacuation occurred spontaneously in one and was achieved by curettage in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stage IIB or higher",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoradiotherapy is the standard treatment for stage IIB to IVA disease (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ), while patients with stage IVB disease require a more systemic approach to therapy. Treatment of pregnant patients follows the general principles in nonpregnant patients, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SPECIFIC ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Delaying treatment to minimize fetal/neonatal risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planned delay of treatment to avoid exposing the fetus to cancer therapy or a preterm birth probably does not significantly increase maternal risk in certain settings. These include women with early-stage disease (stage IA to IB1) (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ) who present in the late second and early third trimesters of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/6,59,60\">",
"     6,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several lines of evidence support this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In nonpregnant women, it is common to allow a six-week interval between diagnostic conization and definitive surgery, if definitive surgery is not performed within 72 hours of the diagnostic cone biopsy. This delay has not been associated with adverse effects on outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of 98 pregnancies in which therapy for cervical cancer was deliberately delayed for 3 to 40 weeks to allow fetal maturation also provided reassuring data [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/59\">",
"       59",
"      </a>",
"      ]. At last follow-up, 93 patients (96 percent) were alive with no evidence of disease. All 98 of the patients had stage I-II disease, and most had very early-stage disease (stage IA and small volume IB1), for which there is only a small risk of clinically significant disease progression. An updated summary of these cases is presented in the table (",
"      <a class=\"graphic graphic_table graphicRef53517 \" href=\"UTD.htm?19/48/20238\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A case-control study compared the outcomes of 45 women with stage I cervical cancer diagnosed during pregnancy or within six months postpartum to those of 44 non-pregnant, matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/60\">",
"       60",
"      </a>",
"      ]. The mean gestational age of the 23 pregnant women was 22 weeks (range 8 to 39 weeks). In 10 of these women, primary treatment was delayed for up to eight weeks to improve neonatal outcome. The overall five-year survival rate was 80 percent among subjects and 82 percent among controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on treatment delay during pregnancy for patients with advanced-stage disease is lacking. Some oncologists have suggested that treatment not be postponed for patients with tumors exceeding 4 cm and those with positive lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/63\">",
"     63",
"    </a>",
"    ]. Lymph node status can be determined by laparoscopic lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/30,31,64\">",
"     30,31,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Use of neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulky and locally advanced cervical cancer in nonpregnant women is sometimes treated with neoadjuvant chemotherapy (NACT) because it can lead to clinically significant tumor shrinkage, and thus increase operability. Radical hysterectomy is performed after NACT. Two phase III trials in nonpregnant patients with advanced cervical cancer showed a survival benefit for patients treated by NACT followed by radical surgery compared with surgery only, radiation therapy only, or sequential chemotherapy and radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H10523617#H10523617\">",
"     \"Management of locally advanced cervical cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NACT has been attempted in pregnant women with locally advanced cervical carcinoma who were unwilling to undergo either pregnancy termination or a therapy likely to result in fetal death. The goal of NACT was to achieve disease regression or stabilization until the fetus could be safely delivered. Only 16 such cases have been reported; the patients were diagnosed between 14 and 23 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/59,67-74\">",
"     59,67-74",
"    </a>",
"    ]. All received two to seven cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . Ten patients with stage IB disease have had excellent outcomes with relatively short (7 to 24 months) follow-up, but five of the remaining six patients with stage IIA-IIIB disease died of their disease. Two of these women refused further treatment after cesarean hysterectomy. The 17 offspring (one twin pregnancy was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/74\">",
"     74",
"    </a>",
"    ]) were in good health and had no congenital anomalies at last follow-up (5 to 80 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Chemotherapy in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of chemotherapy on the fetus depend upon the gestational age, agent(s) used, and dose [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/75\">",
"     75",
"    </a>",
"    ]. The most effective cytotoxic drug for treatment of cervical cancer is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . There is a paucity of information on the use of cisplatin either as a single agent or in combination with other drugs during pregnancy.",
"   </p>",
"   <p>",
"    In most animal experiments,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    caused an increase in pregnancy loss, but teratogenic effects were not observed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. A 2013 systematic review of 48 human pregnancy exposures to platinum derivatives for treatment of cervical cancer at 17 to 33 weeks of gestation reported 67.4 percent of neonates were completely healthy at birth and the problems in most of the remainder were associated with prematurity (eg, respiratory distress) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/80\">",
"     80",
"    </a>",
"    ]. These reports do not establish a causal association between cisplatin administration and adverse fetal effects.",
"   </p>",
"   <p>",
"    Transient neutropenia in the newborn has also been reported after intrauterine exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and is a known side effect of this drug. Ideally, there should be three weeks between completion of chemotherapy and delivery so the bone marrow can recover, and to allow the placenta to metabolize and eliminate cytotoxic drugs from the fetus. Since the potential for spontaneous labor increases towards the end of pregnancy, it is prudent to avoid administering chemotherapy in the late third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnant women with stage IVB disease or any stage with proven systemic metastases are candidates for primary systemic chemotherapy, as previously discussed. We also consider chemotherapy for women with stage IB2, IIA, and possibly very early IIB disease if the patient is appropriately counseled, agrees to NACT and strongly desires to continue the pregnancy. As an example, if such a patient presented after approximately 20 weeks and strongly desired to continue the pregnancy, chemotherapy would be a reasonable management option because a 6- to 10-week course of NACT would be well within the duration of NACT studied in non-pregnant patients and would likely provide time for a significant gain in fetal maturity. If such a patient presented much before 20 weeks, counseling would be more difficult because NACT would need to be given for a longer duration of time without a clear benefit and with potentially higher risks to the mother. We would not suggest a planned treatment delay and NACT for patients with stage IIB-IVA disease, but would offer it if the patient was determined not to terminate the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Delivery route",
"    </span>",
"    &nbsp;&mdash;&nbsp;The route of delivery does not influence the outcome of women with stage IA1 carcinoma who had negative margins at conization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, cesarean delivery is generally reserved for conventional obstetrical indications in these cases.",
"   </p>",
"   <p>",
"    No randomized trials evaluating maternal outcome according to mode of delivery are available. Retrospective and case-controlled studies have suggested that vaginal delivery through a cervix with microscopic cervical cancer generally does not alter maternal prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/1,82\">",
"     1,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a general consensus that vaginal delivery should be avoided if gross tumor is present, as maternal cancer outcomes appear to be worse in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/1,83\">",
"     1,83",
"    </a>",
"    ]. Furthermore, patients with bulky or friable gross tumor, and those with barrel-shaped cervical cancer who attempt vaginal delivery, are at risk for significant hemorrhage and obstruction of the birth canal during labor and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, it is prudent to schedule a cesarean delivery once fetal maturity is reached.",
"   </p>",
"   <p>",
"    At least 15 cases of tumor cell implantation in the episiotomy site have been reported after vaginal birth in women with cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/82\">",
"     82",
"    </a>",
"    ]. Five of the 11 patients who had recurrence of cervical cancer in the episiotomy site died of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/7\">",
"     7",
"    </a>",
"    ]. Episiotomy should be avoided when possible; there is good evidence that routine episiotomy is not beneficial in any pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of studies do not suggest a difference in the oncologic prognosis of women with invasive cervical cancer diagnosed during pregnancy compared to nonpregnant women with invasive cervical cancer when adjusted for stage; however, data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/8,9,46,62,84,85\">",
"     8,9,46,62,84,85",
"    </a>",
"    ]. As an example, a retrospective study compared 40 women with pregnancy-associated cervical cancer to 89 nonpregnant women with cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/8\">",
"     8",
"    </a>",
"    ]. Maternal survival was not significantly different in both groups after 30 years of follow-up. Another study evaluated 53 women with stage IB disease diagnosed in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/9\">",
"     9",
"    </a>",
"    ]. Five-year survival was similar to that of nonpregnant controls and was not affected by the time of initiation of therapy during the pregnancy. A large, long-term series of pregnant women with invasive cervical cancer reported 5.5 percent developed a second primary, which is similar to the second primary rate in all women under 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of cervical cancer on pregnancy outcome is less clear. Two retrospective studies (n = 40, n = 21) reported that the diagnosis of a cervical cancer did not adversely affect pregnancy outcome, assuming that the pregnancy was not terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/8,46\">",
"     8,46",
"    </a>",
"    ]. Mean gestational age at delivery and rates of preterm birth, intrauterine growth restriction, and stillbirth rate were similar for pregnant women with and without cervical cancer.",
"   </p>",
"   <p>",
"    In contrast, a large study that linked infant",
"    <span class=\"nowrap\">",
"     birth/death",
"    </span>",
"    certificates, discharge records, and cancer registry files in California identified 434 cases of cervical cancer in pregnant and postpartum women over an eight-year period; 136 cases were diagnosed prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/84\">",
"     84",
"    </a>",
"    ]. Compared to women without cancer, women diagnosed with cervical cancer during pregnancy or postpartum had higher rates of both spontaneous and iatrogenic prematurity, with correspondingly higher rates of low birth weight and very low birth weight infants. These relationships held even in patients diagnosed with cervical cancer up to 12 months following delivery.",
"   </p>",
"   <p>",
"    Of note, only one case of cervical squamous cell carcinoma with placental metastases has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?6/42/6826/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cancer is one of the most common malignancies in pregnancy, with an estimated incidence of 0.8 to 1.5 cases per 10,000 births. Most cases are identified as a result of cervical cancer screening programs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colposcopic evaluation of the cervix in pregnancy with biopsies should be performed by colposcopists with experience in pregnancy-related changes in cervical appearance. Endocervical curettage should not be performed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Abnormal cervical cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic conization is only indicated during pregnancy if confirmation of invasive disease will alter the timing or mode of delivery; otherwise, conization is postponed until the postpartum period to avoid potentially disrupting the pregnancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Conization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staging examinations are modified in pregnant women to limit fetal exposure to ionizing radiation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A chest x-ray (with abdominal shielding) is performed for evaluation of pulmonary metastatic disease in all patients with more than microscopic cervical cancer.",
"     </li>",
"     <li>",
"      For stage IA and",
"      <span class=\"nowrap\">",
"       microscopic/very",
"      </span>",
"      small stage IB (&lt;1 cm) cervical cancer in which extracervical disease is unlikely, routine radiographic imaging of the urinary tract may be omitted. For all other patients, the urinary tract should be imaged with ultrasonography or magnetic resonance to rule out stage IIIB disease. Magnetic resonance imaging has the added advantage of providing information on tumor size, parametrial disease, and lymph node status.",
"     </li>",
"     <li>",
"      When controlled for stage of cervical cancer, the course of disease and prognosis of cervical cancer in pregnant women are similar to those of nonpregnant women. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with stage IA1 disease are followed with clinical examinations and colposcopy each trimester throughout pregnancy. If postpartum evaluation shows no residual disease, we suggest monitoring women who desire future childbearing for possible recurrence and offering extrafascial hysterectomy to women with stage IA1 disease who have completed childbearing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Microinvasive disease (stage IA1)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A multidisciplinary team approach is crucial to address the complex care issues confronting a pregnant patient with cervical cancer, such as termination versus continuation of pregnancy, delay of definitive treatment, mode of therapy during pregnancy, or timing and route of delivery.",
"     </li>",
"     <li>",
"      If the fetus is at or near term, the preferred approach to invasive disease is immediate delivery and definitive treatment of the mother. At early gestational ages, termination of the pregnancy and definitive treatment of the mother is an option. If the mother chooses to continue the pregnancy, decisions regarding timing of treatment and delivery require careful consideration of the stage of disease and the trimester in which the diagnosis is made. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Early stage invasive disease (stage IA2, IB, nonbulky IIA)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest immediate, definitive treatment for patients with locally advanced disease, documented lymph node metastases, progression of disease during the pregnancy, and for those patients who wish to undergo immediate therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Early stage invasive disease (stage IA2, IB, nonbulky IIA)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Planned delay of treatment to avoid exposing the fetus to cancer therapy or preterm birth probably does not significantly increase maternal risk in women with early-stage (stage IA to IB1) disease presenting in the late second and early third trimester of pregnancy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Delaying treatment to minimize fetal/neonatal risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antepartum radical trachelectomy should be avoided during pregnancy because of the high rate of fetal loss. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Radical trachelectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neoadjuvant chemotherapy may be an option for patients with stage IB2, IIA, and early IIB disease if the patient is appropriately counseled, agrees to neoadjuvant chemotherapy, and strongly desires to continue the pregnancy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Use of neoadjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with stage IVB disease or any other stage disease with proven systemic metastases are candidates for primary systemic chemotherapy, which may be initiated during pregnancy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Chemotherapy in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal delivery is acceptable for women with microscopic (stage IA, diagnosed via conization with negative margins) cervical cancer. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Delivery route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cesarean delivery should be performed for women with stage IB and above disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Delivery route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with early stage invasive disease (IB-IIA) who do not plan future childbearing, we suggest radical cesarean hysterectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Early stage invasive disease (stage IA2, IB, nonbulky IIA)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/1\">",
"      Nguyen C, Montz FJ, Bristow RE. Management of stage I cervical cancer in pregnancy. Obstet Gynecol Surv 2000; 55:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/2\">",
"      Creasman WT. Cancer and pregnancy. Ann N Y Acad Sci 2001; 943:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/3\">",
"      Smith LH, Dalrymple JL, Leiserowitz GS, et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001; 184:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/4\">",
"      Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol 2003; 189:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/5\">",
"      Demeter A, Sziller I, Csap&oacute; Z, et al. Outcome of pregnancies after cold-knife conization of the uterine cervix during pregnancy. Eur J Gynaecol Oncol 2002; 23:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/6\">",
"      Duggan B, Muderspach LI, Roman LD, et al. Cervical cancer in pregnancy: reporting on planned delay in therapy. Obstet Gynecol 1993; 82:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/7\">",
"      Van Calsteren K, Vergote I, Amant F. Cervical neoplasia during pregnancy: diagnosis, management and prognosis. Best Pract Res Clin Obstet Gynaecol 2005; 19:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/8\">",
"      Zemlickis D, Lishner M, Degendorfer P, et al. Maternal and fetal outcome after invasive cervical cancer in pregnancy. J Clin Oncol 1991; 9:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/9\">",
"      Hopkins MP, Morley GW. The prognosis and management of cervical cancer associated with pregnancy. Obstet Gynecol 1992; 80:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/10\">",
"      Lee RB, Neglia W, Park RC. Cervical carcinoma in pregnancy. Obstet Gynecol 1981; 58:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/11\">",
"      Hannigan EV. Cervical cancer in pregnancy. Clin Obstet Gynecol 1990; 33:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/12\">",
"      Morimura Y, Fujimori K, Soeda S, et al. Cervical cytology during pregnancy--comparison with non-pregnant women and management of pregnant women with abnormal cytology. Fukushima J Med Sci 2002; 48:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/13\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/14\">",
"      Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/15\">",
"      Kaplan KJ, Dainty LA, Dolinsky B, et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer 2004; 102:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/16\">",
"      Serati M, Uccella S, Laterza RM, et al. Natural history of cervical intraepithelial neoplasia during pregnancy. Acta Obstet Gynecol Scand 2008; 87:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/17\">",
"      Fader AN, Alward EK, Niederhauser A, et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation. Am J Obstet Gynecol 2010; 203:113.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/18\">",
"      Economos K, Perez Veridiano N, Delke I, et al. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol 1993; 81:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/19\">",
"      Baldauf JJ, Dreyfus M, Ritter J, Philippe E. Colposcopy and directed biopsy reliability during pregnancy: a cohort study. Eur J Obstet Gynecol Reprod Biol 1995; 62:31.",
"     </a>",
"    </li>",
"    <li>",
"     Colposcopy-Cervical Pathology: Textbook and Atlas, 3rd, Burghardt E, Pickel H, Girardi F (Eds), Thieme, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/21\">",
"      Robinson WR, Webb S, Tirpack J, et al. Management of cervical intraepithelial neoplasia during pregnancy with LOOP excision. Gynecol Oncol 1997; 64:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/22\">",
"      Douvier S, Filipuzzi L, Sagot P. [Management of cervical intra-epithelial neoplasm during pregnancy]. Gynecol Obstet Fertil 2003; 31:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/23\">",
"      Muller CY, Smith HO. Cervical neoplasia complicating pregnancy. Obstet Gynecol Clin North Am 2005; 32:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/24\">",
"      Palle C, Bangsb&oslash;ll S, Andreasson B. Cervical intraepithelial neoplasia in pregnancy. Acta Obstet Gynecol Scand 2000; 79:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/25\">",
"      Averette HE, Nasser N, Yankow SL, Little WA. Cervical conization in pregnancy. Analysis of 180 operations. Am J Obstet Gynecol 1970; 106:543.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Gynecologic Oncology, 6th, DiSaia PJ, Creasman WT (Eds), Mosby, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/27\">",
"      Goldberg GL, Altaras MM, Block B. Cone cerclage in pregnancy. Obstet Gynecol 1991; 77:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/28\">",
"      Reznek RH, Sahdev A. MR imaging in cervical cancer: seeing is believing. The 2004 Mackenzie Davidson Memorial Lecture. Br J Radiol 2005; 78 Spec No 2:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/29\">",
"      Van Calsteren K, Hanssens M, Moerman P, et al. Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy. Acta Obstet Gynecol Scand 2008; 87:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/30\">",
"      Alouini S, Rida K, Mathevet P. Cervical cancer complicating pregnancy: implications of laparoscopic lymphadenectomy. Gynecol Oncol 2008; 108:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/31\">",
"      Hertel H, Possover M, K&uuml;hne-Heid R, Schneider A. Laparoscopic lymph node staging of cervical cancer in the 19th week of pregnancy. A case report. Surg Endosc 2001; 15:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/32\">",
"      Stan C, Megevand E, Irion O, et al. Cervical cancer in pregnant women: laparoscopic evaluation before delaying treatment. Eur J Gynaecol Oncol 2005; 26:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/33\">",
"      Maikranz P, Lindheimer M, Coe F. Nephrolithiasis in pregnancy. Baillieres Clin Obstet Gynaecol 1994; 8:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/34\">",
"      O'mahony S. Endoscopy in pregnancy. Best Pract Res Clin Gastroenterol 2007; 21:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/35\">",
"      Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999; 93:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/36\">",
"      Paraskevaidis E, Koliopoulos G, Kalantaridou S, et al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum. Eur J Obstet Gynecol Reprod Biol 2002; 104:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/37\">",
"      Ahdoot D, Van Nostrand KM, Nguyen NJ, et al. The effect of route of delivery on regression of abnormal cervical cytologic findings in the postpartum period. Am J Obstet Gynecol 1998; 178:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/38\">",
"      Takushi M, Moromizato H, Sakumoto K, Kanazawa K. Management of invasive carcinoma of the uterine cervix associated with pregnancy: outcome of intentional delay in treatment. Gynecol Oncol 2002; 87:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/39\">",
"      Yahata T, Numata M, Kashima K, et al. Conservative treatment of stage IA1 adenocarcinoma of the cervix during pregnancy. Gynecol Oncol 2008; 109:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/40\">",
"      Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. Gynecol Oncol 2007; 107:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/41\">",
"      Roman LD, Felix JC, Muderspach LI, et al. Risk of residual invasive disease in women with microinvasive squamous cancer in a conization specimen. Obstet Gynecol 1997; 90:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/42\">",
"      Ward RM, Bristow RE. Cancer and pregnancy: recent developments. Curr Opin Obstet Gynecol 2002; 14:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/43\">",
"      Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/44\">",
"      Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/45\">",
"      Ostrom K, Ben-Arie A, Edwards C, et al. Uterine evacuation with misoprostol during radiotherapy for cervical cancer in pregnancy. Int J Gynecol Cancer 2003; 13:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/46\">",
"      Monk BJ, Montz FJ. Invasive cervical cancer complicating intrauterine pregnancy: treatment with radical hysterectomy. Obstet Gynecol 1992; 80:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/47\">",
"      Sivanesaratnam V, Jayalakshmi P, Loo C. Surgical management of early invasive cancer of the cervix associated with pregnancy. Gynecol Oncol 1993; 48:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/48\">",
"      Sood AK, Sorosky JI, Krogman S, et al. Surgical management of cervical cancer complicating pregnancy: a case-control study. Gynecol Oncol 1996; 63:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/49\">",
"      Covens A, Shaw P, Murphy J, et al. Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix? Cancer 1999; 86:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/50\">",
"      Dargent D, Martin X, Sacchetoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000; 88:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/51\">",
"      Ung&aacute;r L, Smith JR, P&aacute;lfalvi L, Del Priore G. Abdominal radical trachelectomy during pregnancy to preserve pregnancy and fertility. Obstet Gynecol 2006; 108:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/52\">",
"      van de Nieuwenhof HP, van Ham MA, Lotgering FK, Massuger LF. First case of vaginal radical trachelectomy in a pregnant patient. Int J Gynecol Cancer 2008; 18:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/53\">",
"      Sioutas A, Schedvins K, Larson B, Gemzell-Danielsson K. Three cases of vaginal radical trachelectomy during pregnancy. Gynecol Oncol 2011; 121:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/54\">",
"      J&auml;rvel&auml; IY, Juutinen J, Koskela P, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 2006; 29:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/55\">",
"      Creasman WT, Rutledge FN, Fletcher GH. Carcinoma of the cervix associated with pregnancy. Obstet Gynecol 1970; 36:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/56\">",
"      Sood AK, Sorosky JI. Invasive cervical cancer complicating pregnancy. How to manage the dilemma. Obstet Gynecol Clin North Am 1998; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/57\">",
"      Prem KA, Makowski EL, McKelvey JL. Carcinoma of the cervix associated with pregnancy. Am J Obstet Gynecol 1966; 95:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/58\">",
"      Benhaim Y, Haie-Meder C, Lhomm&eacute; C, et al. Chemoradiation therapy in pregnant patients treated for advanced-stage cervical carcinoma during the first trimester of pregnancy: report of two cases. Int J Gynecol Cancer 2007; 17:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/59\">",
"      Karam A, Feldman N, Holschneider CH. Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy. Nat Clin Pract Oncol 2007; 4:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/60\">",
"      van der Vange N, Weverling GJ, Ketting BW, et al. The prognosis of cervical cancer associated with pregnancy: a matched cohort study. Obstet Gynecol 1995; 85:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/61\">",
"      Method MW, Brost BC. Management of cervical cancer in pregnancy. Semin Surg Oncol 1999; 16:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/62\">",
"      Lee JM, Lee KB, Kim YT, et al. Cervical cancer associated with pregnancy: results of a multicenter retrospective Korean study (KGOG-1006). Am J Obstet Gynecol 2008; 198:92.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/63\">",
"      Germann N, Haie-Meder C, Morice P, et al. Management and clinical outcomes of pregnant patients with invasive cervical cancer. Ann Oncol 2005; 16:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/64\">",
"      Herod JJ, Decruze SB, Patel RD. A report of two cases of the management of cervical cancer in pregnancy by cone biopsy and laparoscopic pelvic node dissection. BJOG 2010; 117:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/65\">",
"      Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002; 20:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/66\">",
"      Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997; 67:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/67\">",
"      Giacalone PL, Laffargue F, Benos P, et al. Cis-platinum neoadjuvant chemotherapy in a pregnant woman with invasive carcinoma of the uterine cervix. Br J Obstet Gynaecol 1996; 103:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/68\">",
"      Tewari K, Cappuccini F, Gambino A, et al. Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy: a report of two cases and review of issues specific to the management of cervical carcinoma in pregnancy including planned delay of therapy. Cancer 1998; 82:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/69\">",
"      Marana HR, de Andrade JM, da Silva Mathes AC, et al. Chemotherapy in the treatment of locally advanced cervical cancer and pregnancy. Gynecol Oncol 2001; 80:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/70\">",
"      Caluwaerts S, VAN Calsteren K, Mertens L, et al. Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. Int J Gynecol Cancer 2006; 16:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/71\">",
"      Benhaim Y, Pautier P, Bensaid C, et al. Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression. Eur J Obstet Gynecol Reprod Biol 2008; 136:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/72\">",
"      Bader AA, Petru E, Winter R. Long-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy. Gynecol Oncol 2007; 105:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/73\">",
"      Palaia I, Pernice M, Graziano M, et al. Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report. Am J Obstet Gynecol 2007; 197:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/74\">",
"      Marnitz S, K&ouml;hler C, Oppelt P, et al. Cisplatin application in pregnancy: first in vivo analysis of 7 patients. Oncology 2010; 79:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/75\">",
"      Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/76\">",
"      Anabuki K, et al. Reproductive studies on cisplatin. Yakuri to Chiryo 1982; 10:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/77\">",
"      Keller KA, Aggarwal SK. Embryotoxicity of cisplatin in rats and mice. Toxicol Appl Pharmacol 1983; 69:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/78\">",
"      K&ouml;pf-Maier P, Merker HJ. Effects of the cytostatic drug cis-platinum on the developing neocortex of the mouse. Teratology 1983; 28:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/79\">",
"      Nagaoka T, et al. Reproductive studies on cisplatin. Kiso to Rinsho 1981; 15:5769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/80\">",
"      Zagouri F, Sergentanis TN, Chrysikos D, Bartsch R. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol 2013; 121:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/81\">",
"      Weisz B, Meirow D, Schiff E, Lishner M. Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther 2004; 4:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/82\">",
"      Van den Broek NR, Lopes AD, Ansink A, Monaghan JM. \"Microinvasive\" adenocarcinoma of the cervix implanting in an episiotomy scar. Gynecol Oncol 1995; 59:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/83\">",
"      Baloglu A, Uysal D, Aslan N, Yigit S. Advanced stage of cervical carcinoma undiagnosed during antenatal period in term pregnancy and concomitant metastasis on episiotomy scar during delivery: a case report and review of the literature. Int J Gynecol Cancer 2007; 17:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/84\">",
"      Dalrymple JL, Gilbert WM, Leiserowitz GS, et al. Pregnancy-associated cervical cancer: obstetric outcomes. J Matern Fetal Neonatal Med 2005; 17:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/85\">",
"      Stensheim H, M&oslash;ller B, van Dijk T, Foss&aring; SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/86\">",
"      Pettersson BF, Andersson S, Hellman K, Hellstr&ouml;m AC. Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer 2010; 116:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/42/6826/abstract/87\">",
"      Dildy GA 3rd, Moise KJ Jr, Carpenter RJ Jr, Klima T. Maternal malignancy metastatic to the products of conception: a review. Obstet Gynecol Surv 1989; 44:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4805 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6826=[""].join("\n");
var outline_f6_42_6826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abnormal cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENERAL PRINCIPLES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      High grade preinvasive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Microinvasive disease (stage IA1)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Early stage invasive disease (stage IA2, IB, nonbulky IIA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radical cesarean hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Radical trachelectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stage IIB or higher",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SPECIFIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Delaying treatment to minimize fetal/neonatal risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Use of neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Chemotherapy in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Delivery route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4805|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/13/1233\" title=\"algorithm 1\">",
"      Algorithm CA cx preg rx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 1\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/48/20238\" title=\"table 2\">",
"      Outcome delayed rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=related_link\">",
"      Cervical adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=related_link\">",
"      Fertility sparing surgery for invasive cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29367?source=related_link\">",
"      Peripartum hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_42_6827="Treatment results NPC";
var content_f6_42_6827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival rates for nasopharyngeal cancer in an endemic population",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent of patients",
"      </td>",
"      <td class=\"subtitle1\">",
"       Five-year OS, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       90",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II",
"      </td>",
"      <td>",
"       41",
"      </td>",
"      <td>",
"       84",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       75",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IVA-B",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       58",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OS: overall survival.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lee, AW, Sze, WM, Au, JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61:1107.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6827=[""].join("\n");
var outline_f6_42_6827=null;
var title_f6_42_6828="Cleaning lead dust PI";
var content_f6_42_6828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ways to clean to decrease exposure to lead in dust",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cleaning hard surfaces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mop floors once a week with soapy water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clean window sills and the area around the windows once a week with soapy water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use paper towels or set aside a sponge for lead cleaning only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use separate buckets for wash and rinse water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lightly spray floors with water before sweeping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seal wood floors to provide a smooth, easy-to-clean surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put a blanket or rug on bare floors where children play",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep children and their clothes and toys away from windows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open double-hung windows from the top",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cleaning carpeted surfaces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Use a HEPA* vacuum for cleaning if possible, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Use a \"HEPA-type\" or \"allergy\" filter bag, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Lightly coat new vacuum bags by spreading and vacuuming flour or cornstarch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use a vacuum with an agitator head",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be thorough when you vacuum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When steam cleaning carpets, consider adding Calgon&reg; to the cleaning solution. (It has a chemical that can improve cleaning.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be careful when removing older carpets that already have a lot of lead dust trapped in them",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * High-efficiency particulate air.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Environmental Protection Agency. Additional information available at:",
"     <a href=\"file://www.epa.gov/lead/\" target=\"_blank\">",
"      file://www.epa.gov/lead/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6828=[""].join("\n");
var outline_f6_42_6828=null;
var title_f6_42_6829="Chemo met panc endocrine tum";
var content_f6_42_6829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected trials of systemic chemotherapy for metastatic pancreatic neuroendocrine tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor response rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median progression-free survival, months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median overall survival, months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Prospective studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlorozotocin",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        30&bull;",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        18.0",
"       </td>",
"       <td rowspan=\"3\">",
"        Moertel C; 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluorouracil + streptozocin",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        45&bull;",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxorubicin + streptozocin",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        69&bull;",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        26.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dacarbazine (DTIC)",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        19.3",
"       </td>",
"       <td>",
"        Ramanathan R; 2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide + thalidomide",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Kulke M; 2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide + bevacizumab",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        14.3",
"       </td>",
"       <td>",
"        41.7",
"       </td>",
"       <td>",
"        Chan JA; 2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide + everolimus",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Kulke M; 2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Retrospective series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Steptozocin + doxorubicin + fluorouracil",
"       </td>",
"       <td>",
"        84&Delta;",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        Kouvaraki M; 2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide (diverse regimens)",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        13.6",
"       </td>",
"       <td>",
"        35.3",
"       </td>",
"       <td>",
"        Kulke M; 2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide (single agent)",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Ekeblad S; 2007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide + capecitabine",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Strosberg J; 2011",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"     <br>",
"      * Number of patients evaluable for efficacy endpoints.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Combined biochemical and radiologic response rate.",
"       <br>",
"        &Delta; Includes patients with locally advanced disease.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6829=[""].join("\n");
var outline_f6_42_6829=null;
var title_f6_42_6830="Survival of dialysis patients who received ICD devices";
var content_f6_42_6830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Survival of dialysis patients who received ICD devices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival of patients who received an implantable cardioverter-defibrillator (ICD) for secondary prevention compared with matched controls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Charytan DM, Patrick AR, Liu J, et al. Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. Am J Kidney Dis 2011; 58:409. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6830=[""].join("\n");
var outline_f6_42_6830=null;
var title_f6_42_6831="Edema skin";
var content_f6_42_6831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Edema skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Edema of the Skin Edema of the skin is produced by lymphatic blockade. It appears as thickened skin with enlarged pores - the so-called peau d'orange (orange peel) sign. It is often seen first in the lower portion of the breast or areola.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley, LS, Szilagyi, P. Bates' Guide to Physical Examination and History Taking, Eighth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_42_6831=[""].join("\n");
var outline_f6_42_6831=null;
